Tricylic indole compounds having affinity for serotonin receptor

Abstract

Having an affinity against serotonine receptors, compound (I) shown below is useful as a therapeutic agent against various kinds of diseases of central nervous systems. 1

Description

TECHNICAL FIELD

[0001] The present invention is related to tricyclic indole compounds. Having an affinity against serotonin receptors, the present compounds are useful as medicines, for example, a therapeutic agent for diseases of central nervous system thereof and useful as synthetic intermediates thereof.

BACKGROUND ART

[0002] Serotonin (5-hydroxytryptamine) is one of amines, which exists in living body, and has a lot of physiological activities. For example, serotonin is located in granule cell of intestinal basal and promotes the movement of the intestinal tract. And also, on an occasion of bleeding, serotonin is released from platelets into blood and concerned with hemostasis by contracting blood capillary. Apart from this, serotonin works as a neurotransmitter in brain and takes part in modulating mental action, limit of pain, body-temperature and sleep-awakening cycle thereof, through serotonin receptors [Physiol. Rev. 72(1992) 165-229].

[0003] It has been reported that serotonin receptors are classified mainly to seven families and by including their subtypes, at least 14 kinds of receptors have been identified until now. Each receptor is reported to be concerned with various kinds of physiological functions and diseases [Pharmacol. Rev. 46(1994) 157-203]. Displaying to have agonistic or antagonistic activities, an agent having a binding affinity against serotonin receptors, is expected to be a therapeutic or prophylactic medicament. [Pharmacol.Rev. 43(1991) 509-525].

[0004] Among them, 5-HT5A, 5-HT5B, 5-HT6, and 5-HT7 are receptors which have been recently identified and cloned [FEBS Lett. 355(1994) 242-6, FEBS Lett. 333(1993) 25-31, J. Neurochem. 66(1996) 47-56, Neuron, 11(1993) 449-458] and there is few report about the selective agonist and antagonist. Each of these receptors has already been known to be located mainly in central nervous system. For example, it has been reported that 5-HT5A and 5-HT5B receptors are located in hippocampus and cerebral cortex, which are profoundly concerned with learning and memory [FEBS Lett. 355 (1994) 242-6, FEBS Lett. 333 (1993) 25-31], 5-HT6 receptor is located in corpus striatum, which is concerned with motor function [J. Neurochem. 66 (1996) 47-56], and 5-HT7 receptor is located in suprachiasmatic nucleus, which is concerned with mammalian biological clock [Neuron, 11(1993) 449-458]. Therefore, there is a possibility for the selective agonist or antagonist against the receptor to be a therapeutic agent for dementia, Parkinson's disease, psychosis or diseases concerning circannual rhythm thereof. Selective agonists and antagonists against serotonin receptors other than 5-HT5A, 5-HT5B, 5-HT6 and 5-HT7 receptors have already been launched as therapeutic agents for various kinds of diseases.

[0005] Furthermore, indole derivatives having an affinity against serotonin receptors have been disclosed; for example, compounds of a 4-membered ring type are disclosed in WO 96/32944, WO 95/28403, EP 0738513 and so on and compounds of a 3-membered ring type are disclosed in GB 2341549, WO 98/00400, JP 99-189585A and so on. However, these indole derivatives do not contain oxygen as an ring element. Moreover, naturally occurring heterocyclyl type of indole derivatives are described in WO 00/59909.

[0006] Under the situations mentioned above, development of novel compounds having an affinity against serotonin receptors and medicines containing them have been desired.

DISCLOSURE OF INVENTION

[0007] The present inventors have intensively studied to find that tricyclic indole compounds have an affinity against serotonin receptors, and accomplished the present invention shown below.

[0008] (1) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof of the formula: 2

[0009] wherein

[0010] R1 is hydrogen;

[0011] R2 is hydrogen or lower alkyl;

[0012] R3 is hydrogen, —COOR12 (R12 is hydrogen or ester residue) or —CN;

[0013] R4 is hydrogen, lower alkyl, —COOR13 (R13 is hydrogen or ester residue), —CONR14R15 (R14 and R15 are each independently hydrogen, lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl, or R14 and R15 taken together with a neighboring nitrogen atom may form 5- to 7-membered heterocycle), —CN, —NO2, —NR16R17 (R16 and R17 are each independently hydrogen, —CN, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted amino, or R16 and R17 taken together with a neighboring nitrogen atom may form optionally substituted 5- to 7-membered heterocycle), —NR18COR19 (R18 and R19 are each independently hydrogen, optionally substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl), —NR20COOR21 (R20 is hydrogen, lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl; R21 is ester residue), —NR22SO2R23 (R22 is hydrogen, lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl; R23 is lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl, or lower alkylamino), —OH, lower alkoxy, —SH, or lower alkylthio, or R3 and R4 taken together may form ═O, ═S, or lower alkylenedioxy;

[0014] R5 is hydrogen, or R3 and R5 taken together may form a bond;

[0015] R6 is hydrogen, —COOR24 (R24 is hydrogen or ester residue), —CN, or —CH2NR25R26 (R25 and R26 are each independently hydrogen, lower alkyl, cycloalkyl, or lower alkenyl);

[0016] R7 is hydrogen, halogen, —CN, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted amino, —COOR34 (R34 is hydrogen or ester residue), —COR35 (R35 is hydrogen, lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino, optionally substituted aryl, or optionally substituted heteroaryl) or —CHNOH;

[0017] R8 is hydrogen, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl, —COR27 (R27 is hydrogen, lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl, —COOR28 (R28 is ester residue), —SO2R29 (R29 is lower alkyl, cycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl) or tri-lower alkylsilyl;

[0018] R9, R10 and R11 are each independently hydrogen, halogen, optionally substituted lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, optionally substituted lower alkenyl, lower alkoxy, —OH, —CN, —SR30 (R30 is hydrogen or lower alkyl), —CONH2, —CHO, —CHNOH, —COOR31 (R31 is hydrogen or ester residue), —NR32R33 (R32 and R33 are each independently hydrogen or lower alkyl), optionally substituted aryl, or optionally substituted heteroaryl.

[0019] (2) A compound, prodrug, pharmaceutically acceptable salt, or solvate thereof according to the above 1, wherein R2 is hydrogen.

[0020] (3) A compound, prodrug, pharmaceutically acceptable salt, or solvate thereof according to the above 1, wherein R3 is hydrogen.

[0021] (4) A compound, prodrug, pharmaceutically acceptable salt, or solvate thereof according to the above 1, wherein R5 is hydrogen.

[0022] (5) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R3 and R5 taken together may form a bond.

[0023] (6) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R3 and R4 taken together may form ═O, ═S or lower alkylenedioxy.

[0024] (7) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R4 represents —COOR13 (R13 is hydrogen or lower alkyl), —NR16R17 (R16 and R17 are each independently hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino, or R16 and R17 taken together may form an optionally substituted 5 to 7 membered heterocyclyl ring with the neighboring nitrogen atom), —NR18COR19 (R18 and R19 are each independently hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl), —NR20COOR21 (R20 is hydrogen, or lower alkyl; R21 is an ester moiety), —NR22SO2R23 (R22 is hydrogen; R23 is lower alkyl or lower alkylamino), —OH, or lower alkoxy.

[0025] (8) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R4 is —COOR13 (R13 is hydrogen or methyl), —NR16R17 (R16 is hydrogen or lower alkyl, R17 is hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino, optionally substituted amino or R16 and R17 are taken together may form an optionally substituted 5 to 7 membered heterocyclyl ring with the neighboring nitrogen atom), —NR18COR19 (R18 is hydrogen, R19 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl), —NR20COOR21 (R20 is hydrogen or methyl; R21 is methyl), —NR22SO2R23 (R22 is hydrogen; R23 is methyl or methylamino), —OH, or lower alkoxy.

[0026] (9) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R4 is —NH2, —NHCH3 or —N(CH3)2.

[0027] (10) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R6 is hydrogen, COOCH3, COOCH2CH3, CN, or CH2NH2.

[0028] (11) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R6 is hydrogen.

[0029] (12) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R7 is hydrogen, lower alkyl, halogen, phenyl, —COOR34 (R34 is mentioned before), —CHO or —CHNOH.

[0030] (13) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R7 is hydrogen, methyl, ethyl, halogen or phenyl.

[0031] (14) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R8 is hydrogen, optionally substituted lower alkyl, —COR27 (R27 is hydrogen, lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl), —COOR28 (R28 is ester moiety), or —SO2R29 (R29 is lower alkyl, cycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl), or tri-lower alkylsilyl.

[0032] (15) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R8 is hydrogen or —SO2R29 (R20 is mentioned before)

[0033] (16) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein all of R9, R10 and R11 are hydrogen.

[0034] (17) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R2 is hydrogen; R3 and R5 are both hydrogen or taken together may form a bond.

[0035] (18) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 16 and 17, wherein R6 is hydrogen, COOCH3, COOCH2CH3, CN, or CH2NH2; R7 is hydrogen, lower alkyl, halogen or phenyl; R8 is hydrogen, lower alkyl, COPh, or SO2Ph (Ph represents phenyl).

[0036] (19) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R9 is hydrogen or halogen.

[0037] (20) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R9 is hydrogen.

[0038] (21) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R10 is hydrogen.

[0039] (22) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R11 is hydrogen, halogen, lower alkyl, optionally substituted lower alkenyl, —CN, —SR30 (R30 is hydrogen or lower alkyl), —CONH2, —CHO, —CHNOH, —NR32R33 (R32 and R33 are each independently hydrogen or lower alkyl) or aryl.

[0040] (23) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R11 is hydrogen, halogen, methyl, —CN, or —CONH2.

[0041] (24) A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to the above 1, wherein R1, R2, R3, R5, R6, R9, and R10 is hydrogen; R4 is —NH2, —NHCH3, or —N(CH3)2; R7 is hydrogen, halogen, lower alkyl, or phenyl; R8 is hydrogen or —SO2R29 (R29 is mentioned before); R11 is hydrogen, halogen, lower alkyl, —CN, or —CONH2.

[0042] (25) A pharmaceutical composition containing a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of the above 1-24.

[0043] (26) A therapeutic or prophylactic medicament against the serotonin receptors mediated diseases, comprising a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of the above 1-24.

[0044] (27) A therapeutic or prophylactic medicament according to the above 26, wherein the serotonine receptor is a 5-HT6 receptor.

[0045] (28) A therapeutic or prophylactic medicament according to the above 26, wherein the disease is that of central nervous system.

[0046] (29) A therapeutic or prophylactic medicament according to the above 28, wherein the disease of the central nervous system is schizophrenia, Alzheimer's disease, Parkinson's disease, depression, anxiety, pain or migraine.

[0047] (30) A method for treating or preventing the serotonin receptors mediated diseases, which comprises administrating to said mammal an effective amount of a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of the above 1-24.

[0048] (31) Use of a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of the above 1-24, in order to prepare a therapeutic or prophylactic medicament for the serotonin receptors mediated diseases.

BEST MODE FOR CARRYING OUT THE INVENTION

[0049] Each group of compound (I) is explained below. Each term used herein is defined to have meanings described below in either case of a single or a joint use with other terms, unless otherwise noted.

[0050] “Halogen” refers to F, Cl, Br, I.

[0051] “Lower alkyl” includes a straight-chain and branched-chain C1-C6 alkyl group and refers to methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl, i-pentyl, neo-pentyl, tert-pentyl, n-hexyl and the like, preferably a C1-C4 alkyl group and more preferably a C1-C3 alkyl group, such as methyl, ethyl, n-propyl, and i-propyl.

[0052] “Lower alkenyl” includes a straight-chain and branched-chain C2-C6 alkenyl group and refers to vinyl, allyl, 1-propenyl, 2-butenyl, 3-butenyl, 1-pentenyl, prenyl, 2-hexenyl and the like, preferably vinyl, allyl or prenyl and the like.

[0053] “Lower alkoxy” includes oxy groups binding to an above mentioned lower alkyl group, and refers to methoxyl, ethoxyl, n-propoxyl, i-propoxyl, tert-butoxy, pentyloxy, hexyloxy and the like, preferably a C1-C4 alkoxyl group and more preferably a C1-C3 alkoxyl group such as methoxyl, ethoxyl, n-propoxyl, and i-propoxyl.

[0054] “Cycloalkyl” includes C3-C8 cycloalkyl and refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like, preferably a C5-C7 cycloalkyl group such as cyclopentyl, cyclohexyl, and cycloheptyl.

[0055] “Cycloalkyl(lower)alkyl” means an above mentioned lower alkyl group bound with an above mentioned cycloalkyl group and refers to cyclopropylmethyl, 2-cyclopropyl ethyl and the like.

[0056] “Lower alkylthio” includes a thio group bound with an above mentioned lower alkyl group and refers to methylthio, ethylthio, i-propylthio, tert-butylthio, pentylthio, hexylthio and the like, preferably methylthio.

[0057] “Aryl” used herein means a single or fused aromatic hydrocarbon ring system and refers to phenyl, naphthyl (such as α-naphthyl, and β-naphthyl), anthryl, indenyl, phenanthryl and the like, preferably phenyl or naphthyl.

[0058] “Lower alkylenedioxy” includes a straight-chain and branched-chain C1-C6 alkylendioxy group, preferably methylenedioxy, ethylenedioxy, or trimethylenedioxy, more preferably ethylenedioxy.

[0059] “Aralkyl” used herein means a lower alkyl group bound with an above mentioned aryl group, refers to benzyl, phenethyl, phenylpropyl (such as 3-phenylpropyl), naphthylmethyl (such as α-naphthylmethyl), anthrylmethyl such as 9-anthrylmethyl and the like.

[0060] “Heteroaryl” used herein means a single or polycyclic aromatic ring system in which the ring contains the same or different heteroatom selected from the group of O, S and N.

[0061] The single aromatric ring system includes a 5- to 7-membered ring moiety in which the heterocycle contains 1 to 4 heteroatoms and refers to furyl, thienyl, tetrazolyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, thiadiazolyl, pyridinyl, oxazinyl, triazinyl and the like, preferably 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridinyl, 3-pyridinyl, or 4-pyridinyl.

[0062] Polycyclic aromatic ring system includes a di- or tri-heterocyclic moiety in which the heterocycle contains 1 to 5 heteroatoms and refers to benzofuranyl, isobenzofuranyl, benzothienyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzoxazoly, benzothiazolyl, benzotriazolyl and the like.

[0063] 5- to 7-Membered heterocycle formed by “R14 and R15” or “R16 and R17” taken together with the neighboring nitrogen, refers to pyrrolydine, piperidine, azepine, piperazine, morpholine and the like, preferably pyrrolydine, piperazine or morpholine.

[0064] Substituents on the aryl, heteroaryl or heterocyclyl ring refer to halogen, hydroxy, amino, carboxy, cyano, nitro, carbamoyl, sulfamoyl, lower alkyl (such as methyl or ethyl), halo-lower alkyl (such as —CCF3), lower alkyl-carbamoyl (such as methylcarbamoyl), lower alkyl-sulfamoyl (such as methylsulfamoyl), lower alkoxy (such as methoxyl), lower alkoxycarbonyl (such as ethoxylcarbonyl), a 5- to 7-membered heterocyclyl group such as isoxazolyl and the like, preferably halogen, methyl, methoxyl, trihalo-methyl such as trifluoromethyl. preferably 1 to 3 of these groups can be substituted.

[0065] “Ester” residue refers to lower alkyl, optionally substituted aralkyl and the like, preferably, methyl, ethyl, n-propyl, i-propyl, tert-butyl, benzyl and the like.

[0066] “Lower alkyl” or “lower alkenyl” can be optionally substituted, in which a substituent refers to hydroxy, halogen, amino and optionally mono- or di-lower alkyl substituted carbamoyl (such as carbamoyl, and dimethylcarbamoyl), phenyl, phenylamino, cyclohexylamino, lower alkoxy, lower alkoxycarbonyl such as methoxylcarbonyl and the like.

[0067] An optional substitutent on amino groups refers to lower alkyl, lower alkoxycarbonyl and the like.

[0068] Preferred examples are shown below.

[0069] (1) both of R1 and R5 are hydrogen.

[0070] (2) all of R1, R3, and R5 are hydrogen.

[0071] (3) R1 is hydrogen; R3 and R4 are taken together may form a bond.

[0072] (4) R1 is hydrogen; R3 and R4 are taken together may form ═O or ═S.

[0073] Other preferred examples are shown in following tables.

	TABLE 1
	R2	R3	R4	R6
	H	H	H	H
	methyl	COOR12	methyl	COOR24
	ethyl	CN	ethyl	CN
	n-propyl		n-propyl	CH2NR25R26
	i-propyl		i-propyl
			COOR13
			CONR14R15
			CN
			NO2
			NR16R17
			NR18COR19
			NR20COOR21
			NR22SO2R23
			OH
			methoxyl
			ethoxyl
			n-propoxyl
			i-propoxyl
			SH
			methyl thio
			ethyl thio
			n-propylthio
			i-propylthio
		—O(CH2)2O—

[0074]

TABLE 2
R7	R8	R9, R10, R11
H	H	H
F	methyl	F
Cl	ethyl	Cl
Br	n-propyl	Br
I	i-propyl	I
methyl	cyclopropylmethyl	methyl
ethyl	cyclopentyl	ethyl
n-propyl	cyclohexyl	n-propyl
i-propyl	cycloheptyl	i-propyl
cyclopropylmethyl	vinyl	cyclopropylmethyl
cyclopentyl	allyl	cyclopentyl
cyclohexyl	prenyl	cyclohexyl
cycloheptyl	benzyl	cycloheptyl
vinyl	phenethyl	vinyl
allyl	phenyl	allyl
prenyl	2-furyl	prenyl
benzyl	3-furyl	OH
phenethyl	2-pyridinyl	methoxyl
phenyl	3-pyridinyl	ethoxyl
2-furyl	4-pyridinyl	n-propoxyl
3-furyl	2-pyrrolyl	i-propoxyl
2-pyridinyl	3-pyrrolyl	CN
3-pyridinyl	2-thienyl	CHO
4-pridinyl	3-thienyl	SCH3
2-pyrrolyl	COR27	CH═N—OH
3-pyrrolyl	COOR28	CONH2
2-thienyl	SO2R29	phenyl
3-thienyl	Si(iPr)3	CH═CHCO2CH3
CN

[0075]

	TABLE 3
	R12, R13	R14, R16	R15, R17
	H	H	H
	methyl	methyl	methyl
	ethyl	ethyl	ethyl
	n-propyl	n-propyl	n-propyl
	i-propyl	i-propyl	i-propyl
	t-butyl	cyclopropyl methyl	cyclopropylmethyl
	benzyl	cyclopentyl	cyclopentyl
		cyclohexyl	cyclohexyl
		cycloheptyl	cycloheptyl
		allyl	allyl
		prenyl	prenyl
		benzyl	benzyl
		phenethyl	phenethyl
		phenyl	phenyl
		2-furyl	2-furyl
		3-furyl	3-furyl
		2-pyridinyl	2-pyridinyl
		3-pyridinyl	3-pyridinyl
		4-pyridinyl	4-pyridinyl
		2-pyrrolyl	2-pyrrolyl
		3-pyrrolyl	3-pyrrolyl
		2-thienyl	2-thienyl
		3-thienyl	NHBoc
			cyclopropyl
			CH2CF3
		—CH2CH2CH2CH2—
		—CH2CH2CH2CH2CH2—
		—CH2CH2CH2CH2CH2CH2—
		—CH═CH—CH═CH—
		—CH2CH2NHCH2CH2—
		—CH2CH2NCH3CH2CH2—
		—CH2CH2OCH2CH2—

[0076]

	TABLE 4
	R21	R18, R19, R20, R22	R23
	methyl	H	methyl
	ethyl	methyl	ethyl
	n-propyl	ethyl	n-propyl
	i-propyl	n-propyl	i-propyl
	t-butyl	i-propyl	cyclopropylmethyl
	benzyl	cyclopropylmethyl	cyclopentyl
		cyclopentyl	cyclohexyl
		cyclohexyl	cycloheptyl
		cycloheptyl	vinyl
		allyl	allyl
		prenyl	prenyl
		benzyl	benzyl
		phenethyl	phenethyl
		phenyl	phenyl
		2-furyl	2-furyl
		3-furyl	3-furyl
		2-pyridinyl	2-pyridinyl
		3-pyridinyl	3-pyridinyl
		4-pyridinyl	4-pyridinyl
		2-pyrrolyl	2-pyrrolyl
		3-pyrrolyl	3-pyrrolyl
		2-thienyl	2-thienyl
		3-thienyl	3-thienyl
		CH2N(CH3)2	NHCH3
		CF3
		CH2NH-cyclohexyl

[0077]

TABLE 5
R24      R25, R26
H        H
methyl   methyl
ethyl    ethyl
n-propyl n-propyl
i-propyl i-propyl
t-butyl  cyclopropylethyl
benzyl   cyclopentyl
         cyclohexyl
         cycloheptyl
         vinyl
         allyl
         prenyl

[0078]

	TABLE 6
	R27	R28	R29
	H	methyl	methyl
	methyl	ethyl	ethyl
	ethyl	n-propyl	n-propyl
	n-propyl	i-propyl	i-propyl
	i-propyl	t-butyl	cyclopropylmethyl
	cyclopropylmethyl	benzyl	cyclopentyl
	cyclopentyl		cyclohexyl
	cyclohexyl		cycloheptyl
	cycloheptyl		vinyl
	vinyl		allyl
	allyl		prenyl
	prenyl		benzyl
	benzyl		phenethyl
	phenethyl		phenyl
	phenyl		2-furyl
	2-furyl		3-furyl
	3-furyl		2-pyridinyl
	2-pyridinyl		3-pyridinyl
	3-pyridinyl		4-pyridinyl
	4-pyridinyl		2-pyrrolyl
	2-pyrrolyl		3-pyrrolyl
	3-pyrrolyl		2-thienyl
	2-thienyl		3-thienyl
	3-thienyl		α-naphthyl
			mono or diCl-phenyl
			CF3-phenyl
			Br-phenyl
			mono or dimethoxy
			phenyl
			Br-di F-phenyl
			phenyl vinyl
			mono or diF-phenyl
			Cl-thienyl
			isoxyazolylthienyl

[0079] The following cases are more preferable.

[0080] R2 is more preferably hydrogen or methyl and particularly preferable is hydrogen.

[0081] R3 and R5 are more preferably both hydrogen or taken together may form a bond and particularly preferable is hydrogen.

[0082] R4 is preferably —COOR13 (R13 is hydrogen or lower alkyl), —NR16R17 (R16 and R17 is each independently hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino, or R16 and R17 taken together may form optionally substituted 5- to 7-membered heterocyclyl with the neighboring nitrogen atom), —NR18COR19 (R18 and R19 are each independently hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl), —NR20COOR21 (R20 is hydrogen, or lower alkyl; R21 is ester residue), —NR22SO2R23 (R22 is hydrogen; R23 is lower alkyl or lower alkylamino), —OH, lower alkoxy. R4 is preferably —COOR13 (R13 is hydrogen or methyl), —NR16R17 (R16 is hydrogen or lower alkyl, R17 is hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino, or R16 and R17 taken together may form optionally substituted 5- to 7-membered heterocyclyl with the neighboring nitrogen atom), —NR18COR19 (R18 is hydrogen, R19 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl), —NR20COOR21 (R20 is hydrogen or methyl; R21 is methyl), —NR22SO2R23 (R22 is hydrogen; R23 is methyl or methylamino), —OH, lower alkoxy. R4 is preferably —NH2, —NHCH3, or —N(CH3)2.

[0083] R6 is more preferably hydrogen, COOMe (Me is methyl), COOEt (Et is ethyl), CN, or CH2NH2, more preferably hydrogen.

[0084] R7 is preferably hydrogen, lower alkyl, halogen, phenyl, —COOR34 (R34 is hydrogen or ester residue), —CHO or —CHNOH, more preferably hydrogen, methyl, ethyl, halogen, or phenyl.

[0085] R8 is more preferably hydrogen, optionally substituted lower alkyl, —COR27 (R27 is hydrogen, lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl), —COOR28 (R28 is ester residue), or —SO2R29 (R29 is lower alkyl, cycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl), or tri-lower alkyl silyl, more preferably hydrogen or —SO2R29 (R29 is lower alkyl, cycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl). R29 is more preferably mono- or di-Cl-phenyl, CF3-phenyl, Br-phenyl, mono- or di-methoxyphenyl, phenylvinyl, mono- or di-F-phenyl, Cl-thienyl, naphthyl.

[0086] R9 is preferably hydrogen or halogen, more preferably hydrogen.

[0087] R10 is preferably hydrogen.

[0088] R11 is preferably hydrogen, halogen, lower alkyl, optionally substituted lower alkenyl, —CN, —SR30 (R30 is hydrogen or lower alkyl), —CONH2, —CHO, —CHNOH, —NR32R33 (R32 and R33 is each independently hydrogen or lower alkyl) or aryl, more preferably hydrogen, halogen, methyl, —CN, or —CONH2.

[0089] In a preferred compound among compound (I), R1, R2, R3, R5, R6, R9, and R10 are hydrogen; R4 is —NH2, —NHCH3, or —N(CH3)2; R7 is hydrogen, halogen, lower alkyl or phenyl; R8 is hydrogen or —SO2R29 (R29 is mentioned before); R11 is hydrogen, halogen, lower alkyl, —CN, or —CONH2.

[0090] A produg of compound (I) is a derivative of compound (I), which has a chemically or metabolically decomposible group and can get back to a pharmaceutically active present invention compound by the solvolysis or under physiological conditions in vivo. Methods of selection and production of a suitable prodrug derivative has been disclosed, for example in Design of Prodrugs, Elsevier, Amsterdam 1985. Having a carboxylic acid group, the original acidic compound can be exemplified to be reacted with an appropriate alcohol derivative to give the ester derivative or reacted with a suitable amino derivative to give the amide derivative as the prodrug. Having a hydroxyl group, the hydroxyl compound for example can be exemplified to be reacted with appropriate acid halides or acid anhydrides to give the acyloxy derivative as the prodrug. Having an amino group, the amino compound can be exemplified to be reacted with a suitable acid halide or acid anhydride to give the amide compound as the prodrug.

[0091] A pharmaceutically acceptable salt of compound (I) or the prodrug refers to those salts, which are obtained by reacting with inorganic acids, inorganic bases, ammonia, organic bases, inorganic acids, organic acids, basic amino acids, ionic halogen and the like, or the internal salt. The inorganic base refers to alkaline metals (Na, K and the like), alkaline-earth metal (Ca, Mg and the like). Organic base refers to trimethylamine, triethylamine, corrine, procaine, ethanolamine and the like. The inorganic acid refers to hydrochloric acid, hydrogen bromide, sulfuric acid, nitric acid, phosphoric acid, and the like. The organic acid refers to p-toluenesulfonic acid, methanesulfonic acid, formic acid, trifluoroacetic acid, maleic acid and the like. Basic amino acid refers to lysine, arginine, ornithine, histidine and the like.

[0092] A solvate of compound (I) refers to the hydrate or alcholate and the like. The racemic or the optically active compound (I) and the like are all included in the present invention.

[0093] Compound (I) can be prepared from indole derivatives and the like as starting material which are well known or can be obtained easily by the synthesis. General method of preparation is shown below. 3

[0094] (The 1st Process)

[0095] Compound (III) can be obtained by reacting indole derivative (II) with vinyl compound (IV) (X1 is H) in the presence of a base. This reaction can be accomplished fundamentally according to the Baylis-Hillman vinyl alkylation condition. The reaction temperature can be exemplified to be −20-50° C. and the solvent can be illustrated to be tetrahydrofuran (THF), dioxane, dichloromethane, chloroform and the like. Excess vinyl compound can be used as the solvent, also. As the base, 1,4-diazabicyclo[2,2,2]octane (DABCO), tri-n-butylphosphine and the like can be exemplified. The reaction time is ordinarily several hours to several days.

[0096] The preparation of compound (III) is also possible by reacting the acetylene compound R2C≡CR4 (V) with the vinyl compound (III) (X1 is Al(i-Bu)2), obtained from compound R2C≡CR4 (V) and diisopropylaluminumhydride (DIBAL). The reaction to the vinyl aluminum compound can be carried out according to a similar manner of well-known methods (for example: the method is disclosed in J. Org. Chem., 1988, 53, 1037.). The reaction temperature is exemplified to be ordinarily −100 to 50° C. and the solvent is tetrahydrofuran (THF), dioxane, dichloromethane and the like. The reaction temperature is normally several hours to tens of hours.

[0097] (The 2nd Process)

[0098] Compound (III) is cyclized under a Mitsunobu reaction condition to give compound (I-1) of the present invention. The Mitsunobu reaction can be carried out according to the well-known ordinary method (for example, a method disclosed in Synthesis, 1981,1.). The reaction temperature used are exemplified to be −50-50° C. and the solvent used are exemplified to be tetrahydrofuran (THF), dioxane, benzene, toluene, dichloromethane and the like, respectively. Among reagents, 1,1′-(azodicarbonyl )-diethyl ester, 1,1′-(azodicarbonyl)-diisopropyl ester, 1,1′-(azodicarbonyl)-dipiperidine and the like are used in this reaction as diazocarboxylic acid ester derivatives. Further, triphenylphosphine, tri-n-butylphosphine and the like can be exemplified as phosphine derivatives. The reaction time is ordinarily several hours to tens of hours.

[0099] Furthermore, compound (I-1) can be obtained by cyclizing compound (III) in the presence of base. Moreover, in order to increase the yield of the reaction, it is preferable that the secondary hydrokyl group is first changed to the appropriate removable group such as acetoxyl group and the like and then the cyclization reaction is carried out in the presence of base. The reaction temperature can be exemplified to be 0-100° C. and the solvents can be exemplified to be tetrahydrofuran (THF), dioxane, toluene, acetone, acetonitrile, and the like, respectively. Potassium carbonate, NaH, pyridine, triethylamine and the like can be exemplified as the base used. The reaction time is ordinarily several hours to tens of hours.

[0100] Furthermore, it is possible in the 1st process to convert to compound (I-1) through the only one step by reacting compound (II) with compound (IV) (X1 is H) at relatively high temperature (20-50° C.).

[0101] Furthermore, it is possible to convert to compound (I-1) through the only one step by reacting compound (II) and compound (IV) (X1 is —PO(OMe)2) under the presence of base. The reaction temperature is ordinarily −20-50° C. Tetrahydrofuran (THF), dioxane, toluene, dichloromethane and the like can be exemplified as the solvent. Potassium tert-butoxyde and the like can be exemplified as the base. The reaction time is ordinarily several hour to tens of hours.

[0102] According to the above reaction, preferably a compound, in which R4 in compound (I-1) is electron-withdrawing group, is obtained. As the electron-withdrawing group, ester group, carboxylic acid group, cyano group, amide group, aldehyde group, nitro group and the like are exemplified.

[0103] Compound (I-1) is a compound (I) in the present invention, where R1 and R6 are both hydrogen and R3 and R5 taken together may form a bond. Compound (I-1) can be derived to other compounds of the present invention by chemical modifications. For example, compound (I-1), where R4 is carboxylic acid, can be transferred to the various kinds of ester and amide compounds by converting to the acid chloride with thionyl chloride and the like or to the acid anhydride with ethyl chloroacetate and the like under the existence of base such as triethylamine, followed by reacting with the various kinds of alcohol or amino derivatives. Furthermore, compound (I-1) can also be transferred to the various kinds of ester and amide compounds by using appropriate condensing agents such as dicyclohexylxarbodiimide, carbonyldiimidazole and the like. Further, if the reaction is carried out according to Curtius reaction or Hofmann reaction, compound in which R4 is carbamate can be obtained. Moreover, compound in which R4 is hydroxy (or R3 and R4 taken together may form ═O) can be prepared by the hydrolysis of the compound in which R4 is carbamate. Furthermore, by reduction catalytically or with sodium borotriacetoxyhydride under the presence of appropriate base, compound, in which R3 and R4 taken together may form ═O, can be transferred to compounds in which R4 is various kind of N-alkyl groups.

[0104] (The 3rd Process))

[0105] Compound (I-2) of the present invention can be obtained by the reduction of compound (I-1). Compound (I-2) is a compound (I) of the present invention, where all of R1, R3, R5 and R6 are hydrogen. The reduction reaction is carried out preferably by a catalytic reduction (Pd/C, H2) thereof. By further chemical modifications of compound (I-2), another compound of the present invention can be obtained. For example, in the case where R4 is primary or secondary amino group, compound (I-2) can be converted to the various kinds of N-sulfonyl or N-acyl compounds by reacting with various kinds of sulfonyl chloride or acyl chloride in the presence of base such as triethylamine and the like. Furthermore, compound (I-2) can be transferred to various kinds of N-alkyl compounds by reacting with various kinds of alkyl halide under the presence of base such as triethylamine and the like or by reduction catalytically or with sodium triacetoxyborohydride in the presence of various kinds of aldehydes or ketones. 4

[0106] Compound (I-3) of the present invention can be obtained by cyclization of indole derivative (IV) (X2 is a removing group such as lower alkoxy and the like) preferably under the presence of base. Compound (I-3) is a compound in which R3 and R5 taken together may form a bond and R4 is a hydroxy group in compound (I). As the solvent, ether, tetrahydrofuran (THF), dioxane and the like are exemplified. NaH, sodium metal, potassium tert-butoxyde lithium bis(trimethylsilyl)amide and the like are exemplified as the base. The reaction time is ordinarily several hours to tens hours. By this reaction, a preferred compound is obtained, in which R6 is an electron-withdrawing group such as carboxylic acid group, ester group, cyano group.

[0107] Moreover, R1 and R2 are preferably hydrogen in the above preparations. Furthermore, if necessary, the group can be protected before the reaction and de-protected after the reaction by the well-known method. For example, R8 in the intermediate is preferably an amino protecting group such as Boc. Compounds obtained by the above method of preparation of the present invention can be transferred to another compound of this invention by further chemical modifications of well-known reaction such as oxidation, reduction, protection, deprotection, rearrangement reaction, halogenation, hydroxylation, alkylation, alkylthiolation, demethylation, O-alkylation, O-acylation, N-alkylation, N-alkenylation, N-acylation, N-cyanation, N-sulfonylation, coupling reaction using transition metals and the like.

[0108] Having an affinity against various kinds of serotonin receptors, compound (I) has functions as the agonist or antagonist. Therefore, compound (I) is useful as a therapeutic or prophylactic medicine to various serotonin receptor mediated diseases, such as diseases of central nervous systems such as sleep-awakening lesion, circadian rhythm lesion, anxiously mental disorder, schizophrenia, cerebral stroke, dementia, pain, Alzheimer's disease, Parkinson's disease, depression, anxiety, megrim and the like. A specifically preferable compound (I) described above has an affinity against 5HT1A, 5HT6, 5HT7 among serotonin receptors and more preferably has a high selective affinity against 5HT6. Increase of the selectivity against 5HT6 can be achieved preferably by introducing various kinds of substituents to R7 and R11 and so on. Then, compound (I) is useful to the selectively 5HT6 receptor mediated diseases among the diseases of central nervous system (for example, schizophrenia, Alzheimer's disease, Parkinson's disease, depression, anxiety, migraine and the like).

[0109] Compound (I) can be administrated orally or parenterally to mammals including human. Granule, tabula, capsules, injections, suppositorium and the like can be exemplified as an admirable dosage form. In pharmaceutical manufacturing, if necessary, following various additive agents can be used, for example remedium constituens (lactose, mannitol, crystalline cellulose, starch and the like), disintegrators (carmellose, hydroxypropylmethyl cellulose, polyvinylpolypyrrolidone and the like), binding agent (methylcellose, hydroxypropylcellose, cellose, poloyvinylalcohol and the like), lubricant (Magnesium stearate, talc and the like), stabilizing agent, coloring agent, coating material. Dosage varies depending on the examinee's age, body weight, condition of diseases and dosage forms and so on. Generally, dosage is ca. 0.001 mg to 1 g/day to an adult in oral or parenteral administration. Number of administration time is one to several times/day.

[0110] Examples of this invention are described below without limiting the present invention thereto. “Ex” in the Scheme of reaction corresponds to the number of Example, e.g. “Ex 1” means compound (1) obtained by the procedure cited in Example 1.

[0111] (Abbreviated Words)

[0112] Me=methyl; Et=ethyl; tBu=t-butyl; nPr=n-propyl; Ph=phenyl; Ts=p-toluene sulfonyl; Bn=benzyl; Ms=methanesulfonyl

EXAMPLE 1 OF REFERENCE

[0113] 5

4-Hydroxyindole-3-carbaldehyde (1-1) (R7═R11═H)

[0114] Phosphorous oxychloride 7.35 ml was added dropwise to dry dimethylformamide 15 ml under cooling in ice-methanol bath and the mixture was stirred for 15 min. Then, a solution of the 4-hydroxyindole 5.0 g in dry dimethylformamide 10 ml was added dropwise to the mixture under cooling in ice and the mixture was stirred for 2 h at room temperature. Water was added under cooling in ice to the mixture, which was made alkaline with a 30% aqueous sodium hydroxide solution and was stirred for 15 min. Then, the mixture was acidified to pH 4 with 5N-HCl and the precipitate was collected by filtration, washed with water and dried to give the titled compound 4.99 g as crude crystalline materials. Yield 82%. Crude crystalline materials are recrystallized from methanol to give yellow crystals m.p. 190-193° C.

[0115] 1 H-NMR(DMSO-d6): 6.54 (1H, dd, J=8.1, 0.9 Hz), 6.95 (1H, dd, J=8.1, 0.9 Hz), 7.13 (1H, t, J=8.1 Hz), 8.37 (1H, s), 9.64 (1H, s), 10.54 (1H, br s), 12.35 (1H, br s).

[0116] Following compounds were obtained, according to the similar treatment.

Comp			m.p.
No	R7	R11	(° C.)	1H-NMR (DMSO-d6)
1-2	Ph	H	239-247	6.57 (1H, dd, J=8.1, 0.9 Hz), 6.95
			(dec.)	(1H, dd, J=8.1, 0.9 Hz), 7.17 (1H, t,
				J=8.1 Hz), 7.61-7.82 (5H, m), 9.56
				(1H, s), 11.05 (1H, s), 12.67 (1H, br s)
1-3	Me	Me	269-272	2.16 (3H, s), 2.66 (3H, s), 6.72 (1H, d,
			(dec.)	J=8.1 Hz), 6.93 (1H, d, J=8.1 Hz),
				9.64 (1H, br s), 11.05 (1H, s), 12.14
				(1H, br s)

EXAMPLE 2 OF REFERENCE

[0117] 6

3-Formyl-4-hydroxyindole-1-carboxylic Acid tert-butyl Ester (2-1) (R7═R11═H)

[0118] A mixture of the 3-formyl-4-hydroxyindole (1-1) 323 mg, di-tert-butyldicarbonate 458 mg, dimethylaminopyridine 12.5 mg and acetonitrile 25 ml was stirred under cooling in ice for 3 h. The solvent was removed under reduced pressure and the residue obtained was recrystallized from acetone-isopropyl ether to give the titled compound as pale yellow crystals, m.p. 159-161° C.(dec.), 389 mg. Yield 74%.

[0119] 1 H-NMR(CDCl3): 1.71 (9H, s), 6.84 (1H, dd, J=8.1, 0.9 Hz), 7.31 (1H, t, J=8.1 Hz), 7.61 (1H, dd, J=8.1, 0.9 Hz), 8.25 (1H, s), 9.76 (1H, d, J=0.6 Hz), 10.13 (1H, s).

[0120] Following compounds were obtained, according to the similar treatment.

Comp			m.p.
No	R7	R11	(° C.)	1H-NMR (CDCl3)
2-2	Ph	H	154-155	1.26 (9H, s), 6.86 (1H, dd, J=8.4,
			(dec.)	0.9 Hz), 7.33 (1H, t, J=8.4 Hz),
				7.43-7.53 (5H, m), 7.66 (1H, dd,
				J=8.4, 0.9 Hz), 9.36 (1H, s), 10.64
				(1H, s)
2-3	Me	Me	177-179	1.71 (9H, s), 2.30 (3H, s), 2.88 (3H, s),
			(dec.)	7.09 (1H, d, J=8.4 Hz), 7.39 (1H, d,
				J=8.4 Hz), 9.90 (1H, br s), 10.92
				(1H, s)

EXAMPLE 3 OF REFERENCE

[0121] 7

5-Bromo-3-formyl-4-hydroxyindole-1-carboxylic Acid tert-butyl Ester (2-4)

[0122] Compound (2-1) 26.1 g was suspended in dry tetrahydrofuran 260 ml and chloroform 260 ml. Pyridinium bromide perbromide 33.6 g was added to the suspension under cooling in ice and the mixture was stirred at room temperature for 4.5 h. An aqueous sodium hydrogen carbonate 16.77 g solution was added to the reaction mixtures, which were extracted with chloroform. The extracts were washed with water, dried over anhydrous magnesium sulfate, concentrated up to the deposition of crystals and diluted with isopropanol. Appeared crystals were collected by filtration to give the titled compound as yellow crystals. 29.1 g. Yield 86%. m.p. 239-242° C.(dec.)

[0123] 1 H-NMR(CDCl3): 1.71 (9H, s), 7.52 (2H, s), 8.24 (1H, s), 9.75 (1H, s), 10.91 (1H, br s).

[0124] (Scheme of reactions, Examples 1-5) 8

EXAMPLE 1

7H-6-Oxa-2-azabenzo[c,d]azulene-2,8-dicarboxylic Acid 2-tert-butyl Ester 8-methyl Ester (3-1) (R7═R11═H)

Method 1

[0125] 60% Sodium hydride 23.0 mg was suspended in dry tetrahydrofuran 4 ml. Compound (2-1) 123 mg and trimethyl-2-phosphonoacrylate 116 μl were added with cooling in ice under nitrogen atmosphere and the mixture was stirred for 19 h. Water was added to the mixture with cooling in ice and the mixture was extracted with ethyl acetate. The extracts were washed with water, dried over anhydrous magnesium sulfate and chromatographed on silica gel 25 g in ethyl acetate:hexane (1:10) to give the titled compound (3-1) as colorless crystals, 46 mg. Yield 30%.

[0126] 1 H-NMR(CDCl3): 1.69 (9H, s), 3.84 (3H, s), 5.06 (2H, s), 6.85 (1H, dd, J=7.5, 0.6 Hz), 7.24 (1H, t, J=7.5 Hz), 7.74 (1H, s), 7.77 (1H, d, J=7.5 Hz), 8.00 (1H, s).

Method 2

[0127] Compound (2-1) 140 mg, 1,4-diazabicyclo[2.2.2]octane 70 mg was suspended in methyl acrylate 1.4 ml and the suspension was stirred at room temperature for 4 days. Ethyl acetate was added to the reaction mixtures and the insoluble materials were filtered off. The filtrate was concentrated under reduced pressure and chromatographed on silica gel 25 g in ethyl acetate:hexane (1:10) to give titled compound (3-1) as colorless crystals 59 mg. Yield 34%.

Method 3

(a) 4-Hydroxy-3-(1-hydroxy-2-methoxycarbonylallyl)indole-1-carboxylic Acid tert-butyl Ester (4-1) (R7═R11═H)

[0128] Compound (2-1) 140 mg and 1,4-diazabicyclo[2.2.2]octane 70 mg were suspended in methyl acrylate 1.4 ml with cooling in ice and the suspension was stirred at 4° C. for 24 h. The reaction mixtures was chromatographed on silica gel in ethyl acetate:hexane several times to give the titled compound (4-1) as a colorless oil 178 mg. Yield 96%.

[0129] 1 H-NMR (CDCl3): 1.66 (9H, s), 3.86 (3H, s), 5.05 (1H, br s), 5.63 (1H, s), 5.81 (1H, s), 6.39 (1H, s), 6.78 (1H, dd, J=8.1, 0.9 Hz), 7.24 (1H, t, J=8.1 Hz), 7.31 (1H, s), 7.67 (1H, d, J=8.1 Hz), 9.10 (1H, br s).

[0130] Following compounds were obtained, according to the similar treatment.

Comp			m.p.
No	R7	R11	(° C.)	1H-NMR (CDCl3)
4-2	Ph	H	121-122	1.21 (9H, s), 3.82 (3H, s), 5.01 (1H,
				br s), 5.51 (2H, s), 6.35 (1H, s), 6.81
				(1H, dd, J=7.8, 0.6 Hz), 7.28 (1H, t,
				J=8.4 Hz), 7.38-7.40 (5H, m), 7.83
				(1H, dd, J=8.4, 0.6 Hz), 9.14 (1H, s)
4-3	Me	Me	155-156.5	1.68 (9H, s), 2.29 (3H, s), 2.48 (3H, s),
				3.87 (3H, s), 5.14 (1H, br s), 5.37 (1H,
				s), 5.96 (1H, s), 6.30 (1H, s), 7.05 (1H,
				d, J=8.4 Hz), 7.56 (1H, d, J=8.4 Hz),
				9.27 (1H, s)
4-4	H	Br	Colorless	1.66 (9H, s), 3.85 (3H, s), 5.13 (1H, d,
			oil	J=5.4 Hz), 5.62 (1H, s), 5.82 (1H, d,
				J=5.4 Hz), 6.39 (1H, s), 7.32 (1H, s),
				7.44 (1H, d, J=8.7 Hz), 7.57 (1H, d,
				J=8.7 Hz), 9.59 (1H, br s)

(b) 7H-6-Oxa-2-azabenzo[c,d]azulene-2,8-dicarboxylic Acid 2-tert-butyl Ester 8-methyl Ester (3-1)

[0131] Triethylamine 20.1 mg, 1,1′-(azodicarbonyl)-dipiperidine 42.0 mg and triphenylphosphine 43.9 mg were dissolved in dry tetrahydrofuran 1 ml. Compound (4-1) 37 mg was added to the solution with cooling in ice under nitrogen. The mixture was stirred at room temperature for 17 h. Water was added with cooling in ice and the reaction mixture was extracted with ethyl acetate. The extracts were washed with water, dried over anhydrous magnesium sulfate and chromatographed on silica gel 15 g in ethyl acetate:hexane (1:3) to give titled compound (3-1) as colorless crystals, 17. mg. Yield 48%.

(C) 7H-6-Oxa-2-azabenzo[c,d]azulene-2,8-dicarboxylic Acid 2-tert-butyl Ester 8-methyl Ester (3-1) (R7═R11═H)

[0132] Acetic anhydride 0.38 ml was added to a solution of compound (4-1) 1.32 g in pyridine 13.1 ml with cooling in ice under nitrogen. The mixture was stirred at that temperature for 1 h The solvent was removed by distillation under reduced pressure and the residue obtained was chromatographed on silica gel 60 g in ethyl acetate:hexane (1:3) to give a yellow oil 860 mg. The oily compound 747 mg was dissolved in dioxane 7 ml and potassium carbonate 530.5 mg was added. The mixture was stirred at 80° C. for 6 h, filtered through cerite and chromatographed on silica gel 40 g in ethyl acetate:hexane (1:10) to give the titled compound (3-1) as colorless crystals, 501 mg. Yield 40%, m.p. 124-126° C. (recrystallized from isopropanol)

[0133] Following compounds were obtained, according to the similar treatment.

Comp			m.p.
No	R7	R11	(° C.)	1H-NMR (CDCl3)
3-2	Ph	H	151-152	1.26 (9H, s), 3.75 (3H, s), 5.08 (2H, s),
				6.87 (1H, dd, J=8.1, 0.9 Hz), 7.27 (1H,
				t, J=8.1 Hz), 7.35-7.49 (5H, m), 7.65
				(1H, s), 7.87 (1H, dd, J=8.1, 0.9 Hz)
3-3	Me	Me	112-114	1.69 (9H, s), 2.31 (3H, s), 2.70 (3H, s),
				3.84 (3H, s), 5.03 (2H, s), 7.04 (1H, d,
				J=8.4 Hz), 7.61 (1H, d, J=8.4 Hz),
				8.07 (1H, s)
3-4	H	Br	160-161	1.68 (9H, s), 3.84 (3H, s), 5.14 (2H, s),
				7.46 (1H, d, J=9.0 Hz), 7.68 (1H, d,
				J=9.0 Hz), 7.74 (1H, s), 7.99 (1H, s)

Method 4)

4-Hydroxy-3-(1-hydroxy-2-methoxycarbonylallyl)-2,5-dimethylindole-1-carboxylic Acid tert-butyl Ester (4-3) (R7═R11═H)

[0134] Diisobutylaluminumhydride (0.9 mol/l hexane solution) 50 ml was added to a mixture of hexamethylphosphorous triamide (8.96) g and dry tetrahydrofuran 80 ml with cooling in ice under a nitrogen atmosphere. The mixture was stirred for 30 min. Methyl propiorate 3.78 g was added and he mixture was stirred for 1 h with cooling in ice. Compound (2-3) 4.36 g was added to the reaction mixture, which was stirred for 10 min and then at room temperature for 2 h. 1N-HCl 50 ml was added with cooling in ice and the mixture was extracted with ethyl acetate. The extracts were washed with 1N-HCl, water, brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 130 g in ethyl acetate:hexane (1:4) to give colorless crystals which were recrystallized from ethyl acetate-hexane to give the titled compound, 4.47 g. Yield 80%, m.p. 155-156.5° C.

EXAMPLE 2

2,7-Dihydro-6-oxa-2-azabenzo[c,d]azulene-8-carboxylic Acid (5-1) (R7═R11═H)

[0135] The above obtained compound (3-1) 1.01 g was dissolved in tetrahydrofuran 15 ml and 1 N sodium hydroxide 15 ml was added to the solution. The mixture was stirred for 1 h. Methanol 7.5 ml was added. The mixture was stirred at 50° C. for 3 h, acidified with 2N-HCl 7.5 ml to weakly acidic with cooling in ice and extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give a yellow solid, which was recrystallized from methanol to give the titled compound (5-1), m.p. 230° C.(dec.) as yellow crystals, 450 mg. From the mother liquor, the second crop 134 mg was obtained by crystallization from isopropanol. Yield 88%.

[0136] 1 H-NMR (CD3OD): 4.98 (2H, s), 6.60 (1H, m), 7.02-7.08 (2H, m), 7.55 (1H, s), 8.19 (1H, s).

[0137] Following compounds were obtained, according to the similar treatment.

Compd			m.p.
No	R7	R11	(° C).	1H-NMR (DMSO-d6)
5-2	Ph	H	218-220	4.98 (2H, s), 6.59-6.60 (1H, m),
			(dec.)	7.06-7.13 (2H, m), 7.51-7.68 (5H, m),
				8.05 (1H, s), 12.27 (1H, br s)
5-3	Me	ME	203-206	2.20 (3H, s), 2.48 (3H, s), 4.87 (2H, s),
			(dec.)	6.84-6.89 (2H), 8.03 (1H, s), 11.69
				(1H, s), 12.03 (1H, br s)
5-4	H	Br	210-215	4.97 (2H, s), 7.07 (1H, d, J=8.4 Hz),
			(dec.)	7.27 (1H, d, J=8.7 Hz), 7.83 (1H, s),
				8.09 (1H, s), 12.07 (1H, s)

EXAMPLE 3

(2,7-Dihydro-6-oxa-2-azabenzo[c,d]azulen-8-yl)carbamic Acid tert-butyl Ester (6-1) (R7═H)

[0138] Triethylamine 0.38 ml and chloroethyl carbonate 0.26 ml were added to a solution of the compound obtained by Ex. 2 (5-1) 530 mg in dry tetrahydrofuran 5 ml with cooling in ice-methanol bath and the mixture was stirred for 30 min. Then an aqueous solution of sodium azide 320 mg/water 2 ml was added dropwise and the mixture was stirred for 4 h with cooling in ice-methanol bath. Water was added and the reaction mixture was extracted with ethyl acetate. The extracts were washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give a yellow solid. The residue obtained was suspended in toluene 20 ml and heated under reflux at 125° C. for 20 min and concentrated under reduced pressure. The residue obtained was again suspended in t-butanol 20 ml, heated at 100° C. for 2.5 h and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 50 g in ethyl acetate:hexane (1:3) to give brown crystals, which was recrystallized from ether-petrolether to give the titled compound (6-1) m.p. 125-130° C. (dec.) as pale brown crystals, 436 mg. Yield 62%.

[0139] 1 H-NMR (CDCl3): 1.50 (9H, s), 4.76 (2H, s), 6.01 (1H, br s), 6.64 (1H, dd, J=7.2, 1.2 Hz), 6.98-7.12 (3H, m), 8.17 (1H, br s).

[0140] Following compounds were obtained, according to the similar treatment.

Compd		m.p.
No	R7	(° C.)	1H-NMR (CDCl3)
6-2	Ph	201-202	1.49 (9H, s), 4.90 (2H, br s), 6.11 (1H, br s),
		(dec.)	6.67 (1H, m), 6.88-7.41 (5H, m), 7.49 (1H,
			m), 7.59 (1H, d, J=8.4 Hz), 8.24 (1H, br s)

EXAMPLE 4

(2,7,8,9-Tetrahydro-6-oxa-2-azabenzo[c,d]azulen-8-yl)carbamic Acid tert-butyl Ester (7-1) (R7═H)

[0141] 5% Pd/C 100 mg was added to a solution of the compound obtained in Ex. 3 460 mg in methanol 10 ml. The mixture was stirred in a hydrogen atmosphere for 1.5 h. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue obtained was chromatographed on silica gel in ethyl acetate:hexane (1:3) to give the titled compound (7-1) as a reddish oil, 390 mg. Yield 84%.

[0142] 1 H-NMR (CDCl3): 1.41 (9H, s), 2.98-3.10 (1H, m), 3.26-3.38 (1H, m), 4.23 (1H, d, J=12.0 Hz), 4.27-4.40 (1H, m), 4.48-4.58 (1H, m), 6.67 (1H, dd, J=7.2, 0.9 Hz), 6.98 (1H, br s), 7.02 (1H, dd, J=7.2, 0.9 Hz), 7.09 (1H, t, J=7.2 Hz), 8.13 (1H, br s).

[0143] Following compounds were obtained, according to the similar treatment.

Compd		m.p.
No	R7	(° C.)	1H-NMR (CDCl3)
7-2	Ph	188-189	1.38 (9H, s), 3.18 (1H, m), 3.43 (1H, m),
			4.29 (1H, d, J=12.0 Hz), 4.39 (1H, m), 4.56
			(1H, m), 5.08 (1H, br s), 6.70 (1H, m), 7.04
			(1H, m), 7.11 (1H, t, J=7.8 Hz), 7.34-7.55
			(5H, m), 8.28 (1H, br s)

EXAMPLE 5

2,7,8,9-Tetrahydro-6-oxa-2-azabenzo[c,d]azulen-8-ylamine (8-1)

[0144] The compound obtained in Ex 4 (7-1) 262 mg was dissolved in ethyl acetate 3 ml. A solution of 4 N HCl/ethyl acetate 2 ml was added to the solution with cooling in ice and the mixture was stirred at room temperature for 3 h. Furthermore, 4N-HCl/ethyl acetate 1 ml was added and the mixture was stirred at room temperature for 1 h. After the volatile materials were remove by distillation under reduced pressure up to the half volume, the mixture was diluted with ethyl acetate 10 ml. An aqueous saturated sodium hydrogen solution carbonate was added to alkaline with cooling in ice. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give a brown oily residue, which was chromatographed on aluminum oxide 40 g in methanol:chloroform (3:97) to give the titled compound (8-1) as brown crystals, 144 mg. Yield 84%.

[0145] Further, this oil was recrystallized from isopropanol to give the titled compound (8-1) as gray crystals, 60 mg. m.p. 172-173° C.

[0146] 1 H-NMR (CD3OD): 2.84-2.93 (1H, ddd, J=15.6, 8.7, 1.5 Hz), 3.17-3.25 (1H, m), 3.36-3.43 (1H, m), 4.12-4.25 (2H, m), 6.43-6.50 (1H, m), 6.89-7.00 (3H, m).

[0147] Following compounds were obtained, according to the similar treatment.

Compd		m.p.
No	R7	(° C.)	1H-NMR (CDCl3)
8-2	Ph	189-191	3.09 (1H, dd, J=15.6, 8.1 Hz), 3.29 (1H, dd,
			J=15.6, 3.6 Hz), 3.59 (1H, m), 4.27-4.36
			(2H, m), 6.67 (1H, m), 7.01 (1H, m), 7.10
			(1H, t, J=8.1 Hz), 7.34-7.59 (5H, m),
			8.25 (1H, br s)

[0148] Scheme of reactions, Examples 6-10 are shown in below. 9

EXAMPLE 6

8-Hydroxy-2,7-dihydro-6-oxa-2-azabenzo[c,d]azulene-9-carbonitrile (10)

[0149] Compound (9) 200 mg was dissolved in dry tetrahydrofuran 10 ml. 60% Sodium hydride 72 mg was added to the solution with cooling in ice and the mixture was stirred at room temperature for 2.5 h. After excess sodium hydride was decomposed with ethanol with cooling in ice, 2 N-HCl 1.5 ml was added. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 4 g in ether to give an eluent 187 mg which was again chromatographed on silica gel 5 g in ether to give the titled compound (10) as reddish orange crystals, 132 mg. Yield 79.5%.

[0150] 1 H-NMR (CDCl3): 4.80 (2H, s), 6.52 (1H, dd, J=7.5, 0.9 Hz), 6.99 (1H, t, J=7.5 Hz), 7.06 (1H, dd, J=7.5, 0.9 Hz), 7.24 (1H, d, J=2.7 Hz), 11.07 (1H, s), 11.39 (1H, s).

EXAMPLE 7

(1) 3-Ethoxycarbonylmethyl-1H-indol-4-yloxy)acetic Acid Ethyl Ester (11)

[0151] Compound (9) 1.49 g was dissolved in 95% ethanol 45 ml. Concentrated sulfuric acid 4.5 ml was added to the solution. The mixture was heated under reflux for 40 h. After the solvent was removed under reduced pressure, ice-water was added to the mixture, which was extracted with chloroform. The extracts were washed with water dried over anhydrous magnesium sulfate and chromatographed on silica gel 37 g in chloroform. The eluent 1.497 g was recrystallized from acetone-isopropyl ether to give the titled compound (11) as pale gray crystals, 1.304 g, m.p. 90-91.5° C. Yield 70.1%.

[0152] 1 H-NMR (CDCl3): 1.26 (3H, t, J=7.2 Hz), 1.31 (3H, t, J=7.2 Hz), 4.05 (2H, s), 4.18 (2H, q, J=7.2 Hz), 4.28 (2H, q, J=7.2 Hz), 4.69 (2H, s), 6.36 (1H, dd, J=7.2, 0.9 Hz), 6.97-7.07 (3H, m), 8.07(1H, br s).

(2) 8-Hydroxy-2,7-dihydro-6-oxa-2-azabenzo[c,d]azulene-9-carboxylic Acid ethyl-ester (12)

[0153] Compound (11) 754 mg was dissolved in dry tetrahydrofuran 20 ml. 60% Sodium hydride 217 mg was added to the solution of with cooling in ice. The mixture was stirred at room temperature for 1 h. To the ice-cold reaction mixture, ethanol 0.5 ml was added and the 2N HCl 3 ml was added to acidify. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 45 g in chloroform. The eluent 198 mg was recrystallized from ether-isopropyl ether to give the titled compound (12) as colorless crystals 195 mg, m.p. 136-137° C. Yield 30.5%.

[0154] 1 H-NMR (CDCl3): 1.44 (3H, t, J=7.2 Hz), 4.42 (2H, q, J=7.2 Hz), 4.75 (2H, s), 6.56-6.71 (1H, m), 7.02-7.09 (2H, m), 7.50 (1H, d, J=2.7 Hz), 8.20 (1H, br s), 13.02 (1H, s).

EXAMPLE 8

8-Methoxyl-2,7-dihydro-6-oxa-2-azabenzo[c,d]azulene-9-carboxylic Acid Ethyl Ester (13)

[0155] A mixture of the compound obtained in Ex. 7 (12) 100 mg, methyl iodide 0.031 ml and potassium carbonate 9 mg in dimethylformamide 3 ml was stirred at room temperature for 15 h. Water was added and the mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 6 g in chloroform. The eluent 102 mg was recrystallized from acetone-ether to give the titled compound (13) as colorless crystals 67 mg, m.p. 183-184° C. Yield 63.8%.

[0156] 1 H-NMR (CDCl3): 1.24-1.29 (3H, m), 1.82 (3H, s), 4.16-4.35 (2H, m), 4.49 (1H, d, J=17.4 Hz), 5.02 (1H, d, J=17.4 Hz), 6.73-6.79 (1H, m), 6.96-6.97(1H, m), 7.02-7.13 (2H, m), 8.35 (1H, br s).

EXAMPLE 9

(1) 4-Ethoxycarbonylmethoxy-3-ethoxycarbonylmethyl-indole-1-carboxylic Acid tert-butyl Ester (14)

[0157] Compound (11) 1.40 g and di-tert-butyldicarbonate 1.05 g were dissolved in tetrahydrofuran 20 ml and 4-dimethylaminopyridine 28 mg was added. The mixture was allowed to stand at room temperature overnight and concentrated under reduced pressure to remove tetrahydrofurane. The residue obtained was dissolved in toluene and chromatographed on silica gel 10 g in 5% ethyl acetate-toluene to give the titled compound (14) as a colorless oil, 1.789 g. Yield 96.2%.

[0158] 1 H-NMR (CDCl3): 1.26 (3H, t, J=7.2 Hz), 1.30 (3H, t, J=7.2 Hz), 1.65 (9H, s), 3.96 (2H, s), 4.18 (2H, q, J=7.2 Hz), 4.27 (2H, q, J=7.2 Hz), 4.67 (2H, s), 6.52 (1H, d, J=8.1 Hz), 7.18 (1H, t, J=8.1 Hz), 7.42 (1H, s), 7.80 (1H, d, J=8.1 Hz).

(2) 8-Hydroxy-7H-6-oxa-2-azabenzo[c,d]azulene-2,9-dicarboxlic Acid 2-tert-butyl Ester 9-ethyl Ester (15)

[0159] Compound (14) 953 mg was dissolved in dry tetrahydrofuran 15 ml and 1.0 M solution of lithium bistrimethylsilylamide-tetrahydrofuran 3.5 ml was added to the solution with cooling in ice. The mixture was stirred at room temperature for 30 min. A solution of ammonium chloride 375 mg in water 5 ml was added with cooling in ice. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 30 g in chloroform. The eluent 259 mg was recrystallized from ether-isopropyl ether to give the titled compound (15) as colorless crystals, m.p.139.5-140.5° C., 236 mg. Yield 28.0%.

[0160] 1 H-NMR (CDCl3): 1.47 (3H, t, J=7.1 Hz), 1.68 (9H, s), 4.43 (2H, q, J=7.1 Hz), 4.73 (2H, s), 6.80 (1H, d, J=8.1 Hz), 7.18 (1H, t, J=8.1 Hz), 7.83 (1H, d, J=8.1 Hz), 7.87 (1H, s), 13.27 (1H, s).

EXAMPLE 10

(1) [3-Ethoxycarbonylmethyl-1-(toluene-4-sulfonyl)-1H-indol-4-yloxy]acetic Acid Ethyl Ester (16)

[0161] Compound (11) 305 mg was dissolved in dry tetrahydrofuran 20 ml. 1.0 M Solution of lithium bistrimethylsilylamide-tetrahydrofuran 1.1 ml was added to the solution with cooling in dry ice-acetone bath at −70° C. After the mixture was stirred for 10 min, a solution of p-toluenesulfonyl chloride 229 mg in tetrahydrofuran 3 ml was added at that temperature. The mixture was stirred at room temperature for 2 h. A solution of ammonium chloride 59 mg in water 1 ml was added to the mixture, which was concentrated under reduced pressure to remove tetrahydrofuran. Water was added. The mixture was extracted with chloroform. The extracts were washed with water dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 17 g in chloroform to give the titled compound (16) as a colorless oil 231 mg. Yield 50.2%.

[0162] 1 H-NMR (CDCl3): 1.24 (3H, t, J=7.2 Hz), 1.28 (3H, t, J=7.2 Hz), 2.34 (3H, s), 3.94 (2H, s), 4.16 (2H, q, J=7.2 Hz), 4.25 (2H, q, J=7.2 Hz), 4.62 (2H, s), 6.49 (1H, d, J=8.1 Hz), 7.17 (1H, t, J=8.1 Hz), 7.21 (2H, d, J=8.7 Hz), 7.44 (2H, d, J=8.7 Hz), 7.60 (1H, d, J=8.1 Hz), 7.74 (2H, d, J=8.7 Hz).

(2) 8-Hydroxy-2-(toluene-4-sulfonyl)-2,7-dihydro-6-oxa-2-azabenzo[c,d]-azulene-9-carboxlic Acid Ethyl Ester (17)

[0163] Compound (16) 228 mg was dissolved in dry tetrahydrofuran 10 ml and 1.0 M solution of lithium bistrimethylsilylamide tetrahydrofuran 1.05 ml was added to the solution with cooling in ice. The mixture was stirred for 20 min. A solution of ammonium chloride 112 mg in water 1 ml was added to the mixture, which was acidified with dilute hydrochloric acid. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained 279 mg was chromatographed on silica gel 10 g in toluene to give the titled compound (17) as a pale yellow oil 61 mg. Yield 29.8%.

[0164] 1 H-NMR (CDCl3): 1.50 (3H, t, J=7.2 Hz), 2.35 (3H, s), 4.45 (2H, q, J=7.2 Hz), 4.68 (2H, s), 6.78 (1H, dd, J=7.8, 0.9 Hz), 7.17 (1H, t, J=7.8 Hz), 7.23 (2H, d, J=8.1 Hz), 7.67 (1H, dd, J=7.8, 0.9 Hz), 7.77 (2H, d, J=8.7 Hz) 7.80 (1H, s), 13.30 (1H, s).

[0165] (Scheme of reactions, Examples 11-16) 10

EXAMPLE 11

2,9-Dihydro-6-oxa-2-azabenzo[cd]azulen-8-one (18-1) (R7═R11═H)

[0166] Triethylamine 10 ml and ethyl chlorocarbonate 5.6 ml were added to a solution of compound (5-1) 14.85 g in dry tetrahydrofuran 148 ml with cooling in ice-methanol bath. The mixture was stirred at that temperature for 30 min. Then, a solution sodium azide 8.97 g in water 59 ml was added dropwise. The mixture was stirred with cooling in ice for 4 h. To the reaction mixtures water was added. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate, concentrated under reduced pressure to give a yellow solid. The residue obtained was suspended in dioxane 280 ml. After the suspension was heated under reflux for 20 min, 1N HCl 58.3 ml was added with cooling in ice. Again, the mixture was heated under reflux for 20 min and cooled in ice-bath. Water was added. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 150 g in ethyl acetate:hexane (1:4) to give brown crystals, which was recrystallized from ether-petroleum ether to give the titled compound 7.94 g, m.p. 128-129° C. Yield 61%.

[0167] 1 H-NMR(CDCl3): 4.11 (2H, d, J=0.6 Hz), 4.69 (2H, s), 6.72-6.79 (1H, m), 6.92-6.95 (1H, m), 7.07-7.14 (2H, m), 8.12 (1H, br s).

[0168] Following compounds were obtained, according to the similar treatment.

Compd			m.p.
No	R7	R11	(° C).	1H-NMR (CDCl3)
18-2	Me	ME	136-139	2.32 (3H, s), 2.33 (3H, s), 3.99 (2H, s),
				4.66 (2H, s), 6.89 (1H, d, J=8.4 Hz),
				6.92 (1H, d, J=8.4 Hz), 7.77 (1H, br s)
18-3	H	Br	137-138	4.09 (2H, d, J=1.2 Hz), 4.75 (2H, s),
				6.95 (1H, m), 7.01 (1H, d, J=8.7 Hz),
				7.27 (1H, d, J=8.7 Hz), 8.14 1H, br s)

EXAMPLE 12

Dimethyl-(2,7,8,9-tetrahydro-6-oxo-2-azabenzo[cd]azulen-8-yl)amine (19-1) (R7═R11═H; R16═R17═Me)

[0169] Dimethylamine (2 mol/tetrahydrofuran solution), compound (18-1) 690 mg, sodium triacetoxyborohydride 1.17 g and acetic acid 226 mg were dissolved in tetrahydrofuran 28 ml with cooling in ice. The mixture was stirred at room temperature for 1 h and allowed stand overnight. To the reaction mixture, ice-water and an aqueous sodium hydrogen carbonate solution were added. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide 30 g in chloroform:methanol (50:1) to give the titled compound as colorless crystals 689 mg. Yield 86%. This was recrystallized from ethyl acetate-hexane to give colorless crystals, m.p. 131-132.5° C.

[0170] 1 H-NMR(CDCl3): 2.42 (6H, s), 2.93-3.24 (3H, m), 4.15 (1H, dd, J=12.3, 6.6 Hz), 4.55 (1H, dd, J=12.3, 1.5 Hz), 6.62 (1H, dd, J=6.6, 0.9 Hz), 6.95-7.09 (3H, m), 8.14 (1H, br s).

[0171] Following compounds were obtained, according to the similar treatment.

Compd
No	R7	R11	R16	R17	m.p. (° C.)	1H-NMR (CDCl3)
19-2	H	H	H	Me	112-116	2.56 (3H, s), 2.99-3.22 (3H, in),
					oxalate	4.27-4.38 (2H, m), 6.65 (1H, d, J=
						7.5 Hz), 6.96-7.09 (3H, m), 8.24
						(1H, br s)
19-3	H	H	H	nPr	137-139	0.93 (3H, t, J=7.5 Hz), 1.54 (2H,
						sex, J=7.5 Hz), 2.62-2.80 (2H, m),
						2.92-3.02 (1H, m), 3.14-3.25 (2H,
						m), 4.19-4.30 (2H, m), 6.44-6.50
						(1H, m), 6.90-7.02 (3H, m) CD3OD
19-4	H	H	Et	Et	123-124	1.12 (6H, t, J=7.5 Hz), 2.69 (4H,
						q, J=7.5 Hz), 2.90-3.00 (1H, m),
						3.20-3.30 (2H, m), 4.08 (1H, dd, J=
						11.7, 6.3 Hz), 4.53 (1H, dd, J=
						11.7, 2.1 Hz), 6.41-6.48 (1H, m),
						6.88-6.95 (2H, m), 7.01-7.03 (1H,
						m) CD3OD
19-5	H	H	NPr	nPr	60-61	0.90 (6H, t, J=7.5 Hz), 1.40-1.60
						(4H, m), 2.40-2.60 (4H, m), 2.90-
						3.01 (1H, m), 3.15-3.35 (2H, m),
						4.09 (1H, dd, J=12.3, 6.9 Hz),
						4.61 (1H, dd, J=12.3, 1.8 Hz),
						6.61 (1H, d, J=7.5 Hz), 6.95-6.98
						(2H, m), 7.06 (1H, t, J=7.5 Hz),
						8.06 (1H, br s)
19-6	H	H	H	cyclohexyl	141-142	1.00-2.02 (10H, m), 2.64-2.74 (1H,
						m), 2.98 (1H, ddd, J=15.3, 8.4,
						1.2 Hz), 3.14 (1H, dd, J=15.3, 3.6
						Hz), 3.39-3.47 (1H, m), 4.23-4.32
						(2H, m), 6.63 (1H, dd, J=7.5, 0.9
						Hz), 6.95-6.99 (2H, m), 7.07 (1H, t,
						J=7.5 Hz), 8.11 (1H, br s)
19-7	H	H	H	allyl	112-113	3.00-3.18 (2H, m), 3.28-3.49 (1H,
						m), 4.27-4.38 (2H, m), 5.08-5.13
						(1H, m), 5.18-5.26 (1H, m), 5.86-
						5.99 (1H, m), 6.64 (1H, dd, J=
						7.8, 1.2 Hz), 6.95-7.00 (2H, m),
						7.07 (1H, t, J=7.8 Hz), 8.11 (1H,
						br s)
19-8	H	H	H	iPr	133-135	1.10 (3H, d, J=6.0 Hz), 1.11 (3H,
						d, J=6.0 Hz), 2.97-3.17 (3H, m),
						3.35-3.42 (1H, m), 4.25-4.37 (2H,
						m), 6.64 (1H, dd, J=7.5, 0.9
						Hz), 6.95-7.00 (2H, m), 7.07 (1H, t,
						J=7.5 Hz), 8.10 (1H, br s)
19-9	H	H	H	11	104-106	2.83 (2H, t, J=7.5 Hz), 2.95-3.17 (4H, m), 3.26-3.33 (1H, m), 4.29 (2H, d, J=3.6 Hz), 6.62 (1H, d, J=7.5 Hz), 6.93-7.00 (2H, m), 7.07 (1H, t, J=7.8 Hz), 7.18-7.30 (5H, m), 8.08 (1H, br s)
19-10	H	H	12	137-139	1.80-1.89 (4H, m), 2.70-3.04 (6H, m), 3.37(1H, d, J=14.4 Hz), 4.17 (1H, dd, J=12.3, 6.3 Hz), 4.59 (1H, dd, J=12.3, 2.1 Hz), 6.61 (1H, dd, J=7.5, 0.9 Hz), 6.95-6.99 (2H, m), 7.06 (1H, t, J=7.8 Hz), 8.10 (1H, br s)
19-11	H	H	13	115-125 (dec.) oxalate	1.45-1.75 (6H, m), 2.50-2.80 (4H, m), 2.94-3.12 (2H, m), 3.24-3.31 (1H, m), 4.10 (1H, dd, J=12.0, 6.3 Hz), 4.63 (1H, dd, J=12.0, 1.8 Hz), 6.61 (1H, dd, J=7.8, 0.9 Hz), 6.94-6.98 (2H, m), 7.06 (1H, t, J=7.8 Hz), 8.10 (1H, br s)
19-12	H	H	14	183-184 (dec.) oxalate	2.32 (3H, s), 2.40-2.60 (4H, m), 2.62-2.73 (2H, m), 2.80-2.90 (2H, m), 2.95-3.11 (2H, m), 3.22-3.30 (1H, m), 4.12 (1H, dd, J=12.3, 6.3 Hz), 4.60 (1H, dd, J=12.3, 2.1 Hz), 6.61 (1H, dd, J=7.8, 0.9 Hz), 6.95-6.99 (2H, m), 7.06 (1H, t, J=7.8 Hz), 8.12 (1H, br s)
19-13	H	H	15	207-208	2.46-2.56 (2H, m), 2.62-2.72 (2H, m), 2.76-2.98 (2H, m), 3.08-3.18 (1H, m), 3.53-3.62 (4H, m), 4.06 (1H, dd, J=12.3, 6.6 Hz), 4.45 (1H, d, J=12.3 Hz), 6.40 (1H, dd, J=6.6, 2.1 Hz), 6.86-6.94 (2H, m), 7.11 (1H, d, J=1.8 Hz), 10.95 (1H, br s) DMSO-d6
19-14	H	H	H	CH2CH2OH	154-157	2.85-3.11 (4H, m), 3.25-3.30 (2H,
					(dec.)	m), 3.62 (2H, t, J=5.4 Hz), 4.26-
					oxalate	4.42 (2H, m), 6.64 (1H, dd, J=7.5,
						0.9 Hz), 6.96-7.10 (3H, m), 8.16
						(1H, br s)
19-15	H	Br	H	Me		2.58 (3H, s), 2.91-3.22 (3H, m),
						4.34(1H, dd, J=12.6, 6.9 Hz),
						4.44(1H, d, J=12.6 Hz), 6.86 (1H,
						d, J=8.4 Hz), 6.97 (1H, m), 7.28
						(1H, d, J=8.4 Hz), 8.17 (1H, br s)
19-16	H	Br	Me	Me	142-143	2.43 (6H, s), 2.92-3.23 (3H, m),
						4.22 (1H, dd, J=12.3, 6.9 Hz),
						4.67 (1H, dd, J=12.3, 1.8 Hz),
						6.85 (1H, d, J=8.7 Hz), 6.98 (1H,
						m), 7.26 (1H, d, J=8.7 Hz), 8.13
						(1H, br s)
19-17	Me	Me	Me	Me	144-146	2.28 (3H, s), 2.34 (3H, s), 2.47 (6H,
						s), 2.82-3.11 (3H, m), 4.10 (1H,
						dd, J=12.0 Hz, 6.6 Hz), 4.58 (1H,
						d, J=12.0 Hz), 6.79 (1H, d, J=8.1
						Hz), 6.87 (1H, d, J=8.1 Hz), 7.74
						(1H, br s)
19-18	Me	Me	H	Me	173-175	2.29 (3H, s), 2.31 (6H, s), 2.57 (3H,
					(dec.)	s), 2.80-2.87 (1H, m), 2.97-3.03
					oxalate	(1H, m), 3.12-3.20 (1H, m), 4.29-
						4.32 (2H, m), 6.79 (1H, d, J=8.1
						Hz), 6.87 (1H, d, J=8.1 Hz), 7.79
						(1H, br s),
19-19	H	H	H	cyclopropyl	130-131	0.34-0.55 (4H, m), 2.27-2.34 (1H,
						m), 3.02-3.18 (2H, m), 3.38-3.44
						(1H, m), 4.33-4.44 (2H, m), 6.65
						(1H, dd, J=7.5, 0.9 Hz), 6.94-7.07
						(3H, m), 8.27 (1H, br s)
19-20	H	H	H	CH2CF3	108-109	3.13 (2H, d, J=5.1 Hz), 3.27-3.44
						(3H, m), 4.25 (1H, d, J=12.6 Hz),
						4.40 (1H, dd, J=12.6, 6.9 Hz),
						6.64 (1H, dd, J=8.1, 0.9 Hz), 6.98
						(1H, s), 7.00 (1H, dd, J=8.1, 0.9
						Hz), 7.08 (1H, t, J=8.1 Hz), 8.10
						(1H, br s)
19-21	H	H	Me	Et	122-124	1.13 (3H, t, J=7.2 Hz), 2.39 (3H,
						s), 2.54-2.79 (2H, m), 2.97-3.27
						(3H, m), 4.12 (1H, dd, J=12.3, 6.3
						Hz), 4.59 (1H, dd, J=12.3, 1.8
						Hz), 6.62 (1H, dd, J=7.5, 0.9 Hz),
						6.96-7.09 (3H, m), 8.12 (1H, br s)
19-22	H	H	H	Et	139-141	1.14 (3H, t, J=7.2 Hz), 2.73-2.93
						(2H, m), 3.00-3.19 (2H, m), 3.26-
						3.33 (1H, m), 4.27-4.37 (1H, m),
						6.64 (1H, dd, J=7.5, 0.9 Hz),
						6.96-6.99 (2H, m), 7.07 (1H, t, J=
						7.5 Hz), 8.15 (1H, br s)

EXAMPLE 13

Method 1

(2-Benzenesulfonyl-2,7,8,9-tetrahydro-6-oxo-2-azabenzo[cd]azulen-8-yl)dimethylamine Oxalate (20-1) (R7═R11═H)

[0172] 60% Sodium hydride 17 mg was added to a solution of compound (19-1) 75 mg in dry dimethylformamide 2.5 ml with cooling in ice. The mixture was stirred at 45° C. for 1 h. Benzenesulfonyl chloride 1 ml was added with cooling in ice. The mixture was stirred at room temperature for 21 h. Ice-water and an aqueous sodium hydrogen carbonate solution were added to the mixture, which was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:hexane (1:2) to give the titled compound, 46 mg (yield 37%). This compound was treated with 1 eq. of oxalic acid to give the oxalic acid salt, which was recrystallized from ether-ethanol to give colorless crystals. m.p. 106-109° C.(dec.).

[0173] 1 H-NMR(CDCl3): 2.36 (6H, s), 2.80-3.12 (3H, m), 4.13 (1H, dd, J=12.3, 6.6 Hz), 4.42 (1H, dd, J=12.3, 0.6 Hz), 6.75 (1H, d, J=8.1 Hz), 7.14-7.20 (1H, m), 7.34 (1H, s), 7.41-7.61 (4H, m), 7.86-7.89 (2H, m)

[0174] Following compounds were obtained, according to the similar treatment.

Comp
No.	R7	R8	R11	m.p.	1H-NMR (CDCl3)
20-2	H	COPh	H	126-129	2.40 (6H, s), 2.86-3.16 (3H, m), 4.20 (1H,
				(dec.)	dd, J=12.3, 6.3 Hz), 4.50 (1H, d, J=
				oxalate	12.3 Hz), 6.85 (1H, dd, J=7.2, 0.9 Hz),
					7.06 (1H, s), 7.23-7.28 (1H, m), 7.49-7.63
					(3H, m), 7.71 (2H, dd, J=8.4, 1.8 Hz),
					8.04 (1H, dd, J=8.1, 0.9 Hz)
20-3	H	CH2Ph	H	183-186	2.41 (6H, s), 2.88-3.06 (2H, m), 3.15-3.22
				(dec.)	(1H, m), 4.15 (1H, dd, J=12.0, 6.3 Hz),
				oxalate	4.54 (1H, dd, J=12.0, 1.8 Hz), 5.23 (2H,
					s) 6.61 (1H, dd, J=7.8, 0.6 Hz), 6.85-
					6.89 (2H, m), 7.02-7.15 (3H, m), 7.25-
					7.33 (3H, m)
20-4	H	CH2CONMe2	H	119-124	2.40 (6H, s), 2.99 (3H, s), 3.04 (3H, s),
				(dec.)	2.88-3.22 (2H, m), 3.15-3.22 (1H, m),
				oxalate	4.13 (1H, dd, J=12.3, 6.6 Hz), 4.53 (1H,
					dd, J=12.3, 1.8 Hz), 4.82 (2H, s), 6.61
					(1H, dd, J=8.1, 0.9 Hz), 6.79-7.10 (3H,
					m)
20-5	H	16	H	148-149	2.37 (6H, s), 2.89 (1H, m), 3.06-3.16 (2H, m), 4.15 (1H, dd, J=12.9, 6.9 Hz), 4.43 (1H, d, J=12.9 Hz), 6.71 (1H, dd, J=7.8, 0.6 Hz), 7.10 (1H, t, J=8.1 Hz), 7.39-7.67 (5H ,m), 7.86-8.15 (3H, m), 8.76 (1H, d, J=8.7 Hz)
20-6	H	17	H	114-118 (dec.) oxalate	2.36 (6H, s), 2.81-3.11 (3H, m), 4.14 (1H, dd, J=12.6, 6.6 Hz), 4.43 (1H, d, J=12.6 Hz), 6.76 (1H, dd, J=7.8, 0.9 Hz), 7.18 (1H, t, J=8.4 Hz), 7.23 (1H, t, J=1.5 Hz), 7.38-7.42 (2H, m), 7.57 (1H, dd, J=8.4, 0.9 Hz), 7.77-7.82 (2H, m)
20-7	H	SO2Et	H	153-155	1.23 (3H, t, J=7.5), 2.41 (6H, s), 2.87-
				(dec.)	3.14 (3H, m), 3.28 (3H, q, J=7.5 Hz),
				oxalate	4.22 (1H, dd, J=12.3, 6.6 Hz), 4.49 (1H,
					d, J=12.3 Hz), 6.82 (1H, d, J=7.8 Hz),
					7.19-7.27 (2H, m), 7.50 (1H, J=8.4 Hz)
20-8	H	IPr	H	191-194	1.49 (3H, t, J=6.3 Hz), 1.50 (3H, t, J=
				(dec.)	6.3 Hz), 2.42 (6H, s), 2.93-3.24 (3H, m),
				oxalate	4.13 (1H, dd, J=12.3, 6.6 Hz), 4.54 (1H,
					dd, J=12.3, 1.8 Hz), 4.57-4.66 (1H, m),
					6.59 (1H, dd, J=7.8, 1.2 Hz), 6.94 (1H,
					d, J=7.5 Hz), 7.01 (1H, s), 7.07 (1H, d, J=
					7.8 Hz)
20-9	H	18	H	142-144 (dec.) oxalate	2.37 (6H, s), 2.81-3.10 (3H, m), 4.16 (1H, dd, J=12.3, 6.6 Hz), 4.43 (1H, dd, J=12.3 Hz), 6.78 (1H, d, J=8.4 Hz), 7.00 (1H, dd, J=4.8, 3.9 Hz), 7.21 (1H, t, J=8.4 Hz), 7.30 (1H, s), 7.53 (1H, dd, J=5.1, 1.5 Hz), 7.62 (1H, d, J=8.4 Hz), 7.67 (1H, dd, J=4.2, 1.5 Hz)
20-10	H	19	H	119-122 (dec.) oxalate	2.37 (6H, s), 2.82-2.88 (1H, m), 2.96-3.11 (2H, m), 4.16 (1H, dd, J=12.6, 6.6 Hz), 4.43 (1H, d, J=12.6 Hz), 6.78 (1H, dd, J=8.1, 0.9 Hz), 7.17-7.32 (2H, m), 7.59 (1H, dd, J=8.1, 0.6 Hz), 7.71 (2H, d, J=8.4 Hz), 8.00 (2H, d, J=8.1 Hz)
20-11	H	20	H	147-150 (dec.) oxalate	2.37 (6H, s), 2.82-3.12 (3H, m), 4.14 (1H, dd, J=12.6, 6.6 Hz), 4.43 (1H, d, J=12.6 Hz), 6.77 (1H, dd, J=7.8, 0.6 Hz), 7.18 (1H, t, J=8.1 Hz), 7.30 (1H, s), 7.55-7.58 (2H, m), 7.71-7.74 (2H, m)
20-12	H	21	H	168-171 (dec.) oxalate	2.37 (6H, s), 2.81-3.11 (3H, m), 4.16 (1H, dd, J=12.3, 6.6 Hz), 4.42 (1H, d, J=12.3 Hz), 6.77 (1H, dd, J=8.1, 0.3 Hz), 7.20 (1H, t, J=8.1 Hz), 7.30-7.34 (2H, m), 7.57 (1H, d, J=8.1 Hz), 7.64-7.81 (2H, m), 8.01 (1H, t, J=1.8 Hz)
20-13	H	22	H	173-176 (dec.) oxalate	2.40 (6H, s), 2.86-3.11 (3H, m), 4.21 (1H, dd, J=12.3, 6.6 Hz), 4.60 (1H, d, J=12.3 Hz), 6.75 (1H, dd, J=8.1, 0.6 Hz), 7.09 (1H, t, J=8.1 Hz), 7.23-7.26 (1H, m), 7.36-7.50 (2H, m), 7.55 (1H, s), 7.67 (1H, dd, J=7.8, 1.5 Hz), 8.09 (1H, dd, J=7.8, 1.5 Hz)
20-14	H	23	H	140-142 (dec.) oxalate	2.37 (6H, s), 2.81-3.11 (3H, m), 3.80 (3H, s), 4.13 (1H, dd, J=12.3, 6.6 Hz), 4.43 (1H, d, J=12.3 Hz), 6.74 (1H, d, J=8.1 Hz), 6.88 (2H, dd, J=6.9, 2.1 Hz), 7.17 (1H, t, J=8.4 Hz), 7.33 (1H, s), 7.58 (1H, d, J=8.1 Hz), 7.82 (1H, dd, J=6.9, 2.1 Hz)
20-15	H	24	H	123-126 (dec.) oxalate	2.37 (6H, s), 2.82-3.11 (3H, m), 3.85 (3H, s), 3.87 (3H, s), 4.14 (1H, dd, J=12.3, 5.7 Hz), 4.44 (1H, d, J=12.3 Hz), 6.75 (1H, dd, J=7.8, 0.9 Hz), 6.84 (2H, d, J=8.7 Hz), 7.17 (1H, t, J=8.1 Hz), 7.26-7.32 (2H, m), 7.51 (1H, dd, J=8.4, 2.1 Hz), 7.61 (1H, dd, J=8.4, 0.6 Hz)
20-16	H	25	H	169-171 (dec.) oxalate	2.39 (6H, s), 2.85-3.13 (3H, m), 4.19 (1H, dd, J=12.6, 6.3 Hz), 4.46 (1H, d, J=12.6 Hz), 6.74 (1H, d, J=15.3 Hz), 6.80 (1H, dd, J=8.4, 0.6 Hz), 7.20 (1H, t, J=8.4 Hz), 7.27-7.45 (6H, m), 7.52 (1H, dd, J=8.1, 0.9 Hz), 7.70 (1H, d, J=15.5 Hz)
20-17	H	26	H	161-163 (dec.) oxalate	2.39 (6H, s), 2.84-3.09 (3H, m), 4.21 (1H, dd, J=12.3, 5.4 Hz), 4.44 (1H, d, J=12.3 Hz), 6.77 (1H, dd, J=8.4, 0.9 Hz), 7.13 (1H, t, J=8.4 Hz), 7.25 (1H, dd, J=8.1, 0.9 Hz), 7.35 (1H, d, J=8.4 Hz), 7.43-7.48 (2H, m), 8.19 (1H, d, J=2.4 Hz)
20-18	H	SO2Ph	Br	89-90	2.39 (6H, s), 2.85-3.10 (3H, m), 4.24 (1H,
					dd, J=12.3, 6.3 Hz), 4.54 (1H, d, J=
					12.3 Hz), 7.34 (1H, s), 7.39-7.59 (5H, m),
					7.84-7.87 (2H, m)
20-19	H	27	H	143-144 (dec.) oxalate	2.37 (6H, s), 2.82-2.88 (1H, m), 2.96-3.11 (2H, m), 4.15 (1H, dd, J=12.6, 6.6 Hz), 4.42 (1H, d, J=12.6 Hz), 6.76 (1H, d, J=7.8 Hz), 7.08-7.21 (3H, m), 7.25 (1H, dd, J=8.1, 0.9 Hz), 7.31 (1H, s), 7.56 (1H, d, J=8.4 Hz), 7.87-7.92 (2H, m)
20-20	H	28	H	128-131 (dec.) oxalate	2.40 (6H, s), 2.85-2.91 (1H, m), 3.07-3.10 (2H, m), 4.21 (1H, dd, J=12.6, 6.6 Hz), 4.44 (1H, d, J=12.6 Hz), 6.79 (1H, dd, J=8.1, 0.9 Hz), 7.12 (1H, t, J=8.1 Hz), 7.33-7.42 (3H, m), 7.78 (1H, dd, J=7.2, 6.0 Hz)
20-21	H	29	H	154-154 (dec.) oxalate	2.38 (6H, s), 2.83-3.13 (3H, m), 4.18 (1H, dd, J=12.6, 6.6 Hz), 4.44 (1H, d, J=12.6 Hz), 6.80 (1H, dd, J=8.1, 0.6 Hz), 6.83 (1H, d, J=4.2 Hz), 7.19-7.25 (2H, m), 7.46 (1H, d, J=4.1 Hz), 7.56 (1H, dd, J=8.1, 0.6 Hz)
20-22	H	30	H	163-164 (dec.) oxalate	2.38 (6H, s), 2.82-3.09 (3H, m), 4.19 (1H, dd, J=12.3, 6.3 Hz), 4.44 (1H, d, J=12.3 Hz), 6.75-7.03 (3H, m), 7.13 (1H, t, J=8.1 Hz), 7.38-7.41 (2H, m), 8.02-8.11 (1H, m)
20-23	H	31	H	147-150 (dec.) oxalate	2.39 (6H, s), 2.84-3.10 (3H, m), 3.66 (3H, s), 3.82 (3H, s), 4.18 (1H, dd, J=12.3, 6.6 Hz), 4.44 (1H, d, J=12.3 Hz), 6.72 (1H, dd, J=8.1, 0.9 Hz), 6.81 (1H, d, J=9.0 Hz), 7.04 (1H, dd, J=9.0, 3.3 Hz), 7.09 (1H, t, J=8.1 Hz), 7.36 (1H, d, J=8.1 Hz), 7.43 (1H, s), 7.60 (1H, d, J=3.3 Hz)
20-24	H	32	H	103-104	2.37 (6H, s), 2.82-3.12 (3H, m), 3.79 (3H, s), 3.82 (3H, s), 4.15 (1H, dd, J=12.6, 6.6 Hz), 4.43 (1H, d, J=12.6 Hz), 6.75 (1H, dd, J=8.1, 0.6 Hz), 7.03-7.07 (1H, m), 7.17 (1H, t, J=8.1 Hz), 7.31-7.46 (4H, m), 7.60 (1H, dd, J=8.1, 0.6 Hz)
20-25	H	33	H	113-115 (dec.) oxalate	2.32 (6H, s), 2.81-3.12 (3H, m), 4.17 (1H, dd, J=12.6, 6.3 Hz), 4.44 (1H, d, J=12.6 Hz), 6.46 (1H, d, J=1.8 Hz), 6.80 (1H, d, J=7.8 Hz), 7.24 (1H, t, J=8.1 Hz), 7.29 (1H, d, J=3.9 Hz), 7.33 (1H, d, J=3.9 Hz), 7.61 (1H, d, J=7.8 Hz), 7.64 (1H, d, J=3.9 Hz), 8.27 (1H, d, J =1.8 Hz)
20-26(*)	H	SO2Ph	H	98-98	1.09 (3H, t, J=7.2 Hz), 2.34 (3H, s),
				(dec.)	2.50-2.74 (2H, m), 2.91-3.16 (3H, m),
				oxalate	4.05 (1H, dd, J=12.0, 6.6 Hz), 4.51 (1H,
					dd, J=12.0, 0.9 Hz), 6.74 (1H, dd, J=
					8.1, 0.6 Hz), 7.17 (1H, t, J=8.1 Hz),
					7.34 (1H, s), 7.41-7.61 (5H, m), 7.86-
					7.89 (2H, m)
20-27	Me	SO2Ph	Me	155-158	2.24 (3H, s), 2.39 (6H, s), 2.52 (3H, s),
				(dec.)	4.05 (1H, dd, J=12.6, 5.7 Hz), 4.46 (1H,
				oxalate	d, J=12.6 Hz), 7.01 (1H, d, J=8.7 Hz),
					7.38-7.43 (2H, m), 7.49-7.55 (1H, m),
					7.71-7.77 (3H, m)
(*)20-26; R4=N(Me)Et

Method 2)

(2-Benzenesulfonyl-2,7,8,9-tetrahydro-6-oxo-2-aza-benzo[cd]azulen-8-yl)dimethylamine (20-1)

[0175] n-BuLi (1.56 mol/l hexane solution) 1.39 ml was added to a solution of compound (19-1) 432 mg in dry tetrahydrofuran 10 ml at −70° C. under nitrogen atmosphere. The solution was stirred at that temperature for 1 h and at −30° C. for 1 h. Then, the temperature was again lowered to −70° C. and benezenesulofonyl chloride 396 mg was added dropwise. The reaction temperature was allowed to raise gradually to the room temperature. The mixture was stirred at room temperature, poured to ice and an aqueous ammonium chloride solution and extracted with chloroform. The chloroform layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was choromatographed on aluminum oxide 12 g in chloroform:hexane (8:1) to give the titled compound as crystals. Yield 83%. The product was recrystallized from ethyl acetate isopropyl ether to give colorless crystals. m.p. 114-116° C.

[0176] 1 H-NMR(CDCl3): 2.36 (6H, s), 2.80-3.12 (3H, m), 4.13 (1H, dd, J=12.3, 6.6 Hz), 4.42 (1H, dd, J=12.3, 0.6 Hz), 6.75 (1H, d, J=8.1 Hz), 7.14-7.20 (1H, m), 7.34 (1H, s), 7.41-7.61 (4H, m), 7.86-7.89 (2H, m)

EXAMPLE 14

(1-Bromo-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (21),

(1,5-Dibromo-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethyl-amine (22) and

(1,3-Dibromo-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethyl-amine (23)

[0177] N-Bromosuccinimide 214 mg was added to a warm solution of compound (19-1) 216 mg in carbon tetrachloride 33 ml and the mixture was heated under reflux for 2 h. After the reaction ceased, the insoluble materials were removed by filtration and washed with chloroform. The filtrate was concentrated under reduced pressure. The residue obtained was chromatographed on silica gel in chloroform:methanol (30:1). The eluent was chromatographed on thin silica gel plates in chloroform:methanol (30:1) to give the titled compound (21) 51 mg. Yield 17%. This was recrystallized from ethyl acetate-ether to give crystals, m.p. 170-172° C.

[0178] 1 H-NMR(CDCl3): 2.43 (6H, s), 2.88-3.08 (3H, m), 4.15 (1H, dd, J=12.3, 6.0 Hz), 4.52 (1H, d, J=12.3 Hz), 6.62 (1H, dd, J=7.8, 0.9 Hz), 6.89 (1H, dd, J=8.1, 0.9 Hz), 7.04 (1H, t, J=7.8 Hz), 8.07 (1H, br s)

[0179] 1,5-Dibromo compound (22) 15 mg was isolated from another fraction. Yield 4% Purifying from ether gave crystals, m.p. 123-126° C.

[0180] 1 H-NMR(CDCl3): 2.44 (6H, s), 2.84-3.08 (3H, m), 4.21 (1H, dd, J=12.0, 6.9 Hz), 4.66 (1H, d, J=12.0 Hz), 6.78 (1H, d, J=8.7 Hz), 7.25 (1H, d, J=8.7 Hz), 8.49 (1H, br s)

[0181] The mother liquor of the above mentioned 1,5-dibromo compound (22) was concentrated under reduced pressure and again chromatographed on thin silica gel plates in chloroform:methanol (30:1) to give the 1,3-dibromo compound (23) 8 mg (yield 2%). This was treated with 1 eq. oxalic acid to give the salt, m.p. 147-152° C. (dec.).

[0182] 1 H-NMR(CDCl3): 2.42 (6H, s), 2.90-3.05 (3H, m), 4.09-4.16 (1H, m), 4.50 (1H, d, J=12.0 Hz), 6.53 (1H, d, J=8.1 Hz), 7.15 (1H, d, J=8.1 Hz), 8.22 (1H, br s)

EXAMPLE 15

2-Chloro-N-(2,7,8,9-tetrahydro-6-oxo-2-azabenzo[cd]azulen-8-yl)acetamide (24-1) (R═COCH2Cl)

[0183] Compound (8-1) 535 mg was dissolved in dry tetrahydrofuran 15 ml. Triethylamine 345 mg and chloroacetyl chloride 0.25 ml were added to the solution with cooling in ice. The mixture was stirred for 1 h and at room temperature for 30 min. Ice-water was added to the mixture with cooling in ice. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel 25 g in ethyl acetate:hexane (2:1) to give the titled compound 706 mg (94%) as a colorless oil.

[0184] 1 H-NMR(CDCl3): 3.06-3.14 (1H, m), 3.36-3.43 (1H, m), 3.95-4.06 (2H, m), 4.08-4.16 (1H, m), 4.27 (1H, d, J=11.4 Hz), 4.54-4.64 (2H, m), 6.70 (1H, dd, J=7.5, 1.2 Hz), 6.99 (1H, s), 7.03-7.13 (2H, m), 8.18 (1H, br s)

[0185] Following compounds were obtained, according to the similar treatment.

Compd
No	R	m.p.	1H-NMR (CDCl3)
24-2	COOMe	Colorless	3.02-3.07 (1H, m), 3.33-3.39 (1H,
		oil	m), 3.63 (3H, s), 4.23 (1H, d, J=9.3
			Hz), 4.34-4.41 (1H, m), 4.53-4.60
			(1H, m), 5.25 (1H, br d), 6.67 (1H, d,
			J=7.8 Hz), 6.97 (1H, s), 7.00-7.11
			(2H, m), 8.14 (1H, br s)
24-3	Ms	Colorless	3.02 (3H, s), 3.07-3-14 (1H, m),
		oil	3.35-3.42 (1H, m), 4.19-4.27 (2H,
			m), 4.54-4.61 (1H, m), 4.84 (1H, d,
			J=8.7 Hz), 6.68 (1H, d, J=7.5 Hz),
			7.00-7.12 (3H, m), 8.22 (1H, br s)
24-4	SO2NHMe	Yellow	2.70 (3H, d, J=5.4 Hz), 3.04-3.11
		oil	(1H, m), 3.35-3.42 (1H, m), 4.03-
			4.28 (3H, m), 4.53-4.60 (1H, m),
			4.81 (1H, d, J=8.4 Hz), 6.67 (1H,
			dd, J=7.2, 1.2 Hz), 6.98-7.11 (3H,
			m), 8.24 (1H, br s)
24-5	COMe	174-176	1.92 (3H, s), 2.99-3.06 (1H, m),
			3.35-3.41 (1H, m), 4.21-4.25 (1H,
			m), 4.53-4.68 (2H, m), 6.03 (1H, br
			s), 6.69 (1H, d, J=7.2 Hz), 6.98 (1H,
			s), 7.03-7.13 (2H, m), 8.21 (1H, br s)

EXAMPLE 16

2-Cyclohexylamino-N-(2,7,8,9-tetrahydro-6-oxo-2-azabenzo[cd]azulen-8-yl)acetamide (25-1)

[0186] A solution of compound (24-1) 160 mg and cyclohexylamine 360 mg in benzene 4 ml and methanol 4 ml was heated at 60° C. for 21 h and concentrated under reduced pressure. Water was added to the residue obtained. The mixture was extracted with chloroform. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel in ethyl acetate:methanol (30:1) to give the titled compound 161 mg as crystals. Yield 81%. The crude crystalline materials were recrystallized from methanol-ethyl acetate to give colorless crystals, m.p. 184-186° C.

[0187] 1 H-NMR(CDCl3): 0.43-1.04 (4H, m), 1.22-1.57 (6H, m), 1.98-2.07 (1H, m), 3.02-3.46 (4H, m), 4.24-4.29 (1H, m), 4.54-4.59 (2H, m), 6.69 (1H, dd, J=7.5, 0.9 Hz), 6.96-7.11 (3H, m), 7.96 (1H, br s), 8.13 (1H, br s)

[0188] Following compounds were obtained, according to the similar treatment.

Compd
No	R	m.p.	1H-NMR (CDCl3)
25-2	NMe2	161-	2.06 (6H, s), 2.84-2.96 (2H, m), 3.06-3.13
		162.5	(1H, m), 3.31-3.39 (1H, m), 4.26 (1H, d,
			J=11.4 Hz), 4.52-4.62 (2H, m), 6.68 (1H, dd,
			J=7.5, 0.9 Hz), 6.97-7.11 (3H, m), 7.53 (1H,
			br s), 8.21 (1H, br s)

[0189] (Scheme of reactions, Examples 17-25) 34

EXAMPLE 17

((R)-1-Phenylethyl)-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylamine (26)

[0190] Sodium triacetoxyborohydride 318 mg and acetic acid 57 μl were added to a solution of compound (18-1) 187.6 mg and (R)-(+)-α-methylbenzylamine 13.7 mg in dry tetrahydrofuran 8 ml at room temperature and the mixture was stirred for 18 h. Water was added. The reaction mixture was made alkaline with an aqueous saturated sodium hydrogencarabonate solution and extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide 40 g in ethyl acetate:hexane (1:2) to give the titled compound 250 mg as a colorless oil. Yield 86%. The 1H-NMR shows the titled compound is a mixture of their diastereomers.

[0191] 1 H-NMR(CDCl3): 1.33 (total 6H, d, J=6.6 Hz), 2.98-3.22 (total 6H, m), 4.04-4.41 (total 6H, m), 6.61-6.65 (total 2H, m), 6.91-7.41 (total 16H, m), 8.07 (total 2H, br s).

EXAMPLE 18

2,2,2-Trifluoro-N-((R)-1-phenylethyl)-N-(S)-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylacetamide (27) and 2,2,2-Trifluoro-N-((R)-1-phenylethyl)-N-(R)-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylacetamide (28)

[0192] Compound (26) 2.548 g was dissolved in dry tetrahydrofuran 8 ml. A solution of triethylamine 1.34 ml and trifluoroacetic anhydride 2.014 g in dry tetrahydrofuran 1 ml was added to the solution with cooling in ice. The mixture was stirred for 1 h. Furthermore, triethylamine 177 mg, trifluoroacetic anhydride 366 mg were added and the mixture was stirred for 1 h with cooling in ice. The solvents were removed by distillation under reduced pressure. Water was added to the residue. The mixture was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel in ethyl acetate:hexane (1:5) repeatedly to give the titled compound (27) as a colorless oil, 990 mg (yield 29%) and the titled compound (28) as a colorless oil 1.672 g (yield 49%).

[0193] Compound (27)

[0194] 1 H-NMR(CDCl3): 1.82 (3H, d, J=6.9 Hz), 2.07-2.19 (1H, m), 3.54-3.66 (2H, m), 4.43 (1H, dd, J=12.9, 2.4 Hz), 4.81 (1H, dd, J=12.9, 6.0 Hz), 5.40 (1H, q, J=6.9 Hz), 6.61 (1H, dd, J=7.5, 0.9 Hz), 6.64 (1H, m), 6.94 (1H, dd, J=7.5, 0.9 Hz), 7.04 (1H, t, J=7.5 Hz), 7.27-7.40 (5H, m), 7.96 (1H, br s).

[0195] Compound (28)

[0196] 1 H-NMR(CDCl3): 1.72 (3H, d, J=6.9 Hz), 3.00-3.08 (1H, m), 3.55-3.63 (1H, m), 3.85-3.96 (1H, m), 4.10(1H, dd, J=12.6, 2.4Hz), 4.63 (1H, dd, J=12.6, 6.3Hz), 5.39 (1H, q, J=6.9 Hz), 6.43 (1H, dd, J=7.5, 1.2 Hz), 6.91-7.01 (3H, m), 7.34-7.44 (5H, m), 8.08 (1H, br s).

EXAMPLE 19

((R)-1-Phenylethyl)-(S)-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylamine (29)

[0197] Compound (27) 934 mg was dissolved in ethanol 19 ml and sodium borohydride 364 mg was added to the solution at room temperature. The mixture was stirred for 17 h. Water was added with cooling in ice. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel in ethyl acetate:hexane (1:1) to give the titled compound (29) 695 mg. Yield 99.9%. Furthermore, the titled compound (29) was treated with a solution of hydrogen chloride in methanol to give the HCl salt, which was recrystallized from methanol-isopropanol to give colorless crystals, m.p. 233-240° C. (dec.). The absolute configuration was determined by an X-ray crystal structure analysis on a single crystal.

[0198] 1 H-NMR(CDCl3): 1.33 (3H, d, J=6.3 Hz), 3.00-3.22 (3H, m), 4.03 (1H, q, J=6.3 Hz), 4.21 (1H, d, J=11.7 Hz), 4.29-4.36 (1H, m), 6.63 (1H, dd, J=7.8, 0.9 Hz), 6.95-6.99 (2H, m), 7.06 (1H, t, J=7.8 Hz), 7.20-7.42 (5H, m), 8.07 (1H, br s).

[0199] According to the similar manner, ((R)-1-Phenylethyl)-(R)-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylamine (30) was obtained.

[0200] 1 H-NMR(CDCl3): 1.33 (3H, d, J=6.6 Hz), 2.80-3.15 (3H, m), 4.11 (1H, q, J=6.3 Hz), 4.26 (1H, d, J=12.0 Hz), 4.37 (1H, dd, J=12.0, 6.3 Hz), 6.64 (1H, dd, J=7.8, 0.9 Hz), 6.91-6.93 (1H, m), 6.96 (1H, dd, J=7.8, 0.9 Hz), 7.06 (1H, t, J=7.8 Hz), 7.20-7.41 (5H, m), 8.06 (1H, br s).

EXAMPLE 20

(S)-2,7,8,9-Tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylamine (31)

[0201] Compound (29) 609 mg was dissolved in tetrahydrofuran 20 ml. 20% Palladium(II)hydroxide 200 mg was added. A mixture was stirred in a hydrogen atomosphere for 22 h. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform to give the titled compound (31) as pale brown crystals, 337 mg. Yield 86%. Furthermore, this was recrystallized from methanol-isopropanol to give the titled compound (31) as pale brown crystals, m.p. 202-203° C.

[0202] [α]D+38.7±1.6° (C=0.509, methanol, 25° C.)

[0203] According to the similar manner, (R)-2,7,8,9-Tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ylamine (32) was obtained.

[0204] m.p. 202-203° C. [α]D−38.8±1.6° (C=0.508, methanol, 25° C.)

EXAMPLE 21

2,9-Dihydro-6-oxa-2-azabenzo[cd]azulen-8-one Ethylene Ketal (33)

[0205] Ethylene glycol 2.56 g and pyridinium p-toluenesulfonate 250 mg were added to a solution of compound (18-1) 1.877 g in benzene 50 ml. The mixture was heated under reflux for 14 h by use of a Dean-Stark apparatus. The reaction mixture separated into two layers. The upper layer was separated by decantation. Water and dioxane were added to the remained black oily part. The insoluble materials were removed by filtration and the filtrate was extracted with toluene. The extracts were washed with brine, treated with char coal, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give brown crystals. The above obtaied upper layer was washed with water, an aqueous saturated sodium hydrogen carbonate solution and brine successively, treated with char-coal and dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give colorless crystals. The combined crystals were recrystallized from tetrahydrofuran to give the titled compound (33) as colorless crystals, m.p. 200-202° C., 925 mg. Yield 40%.

[0206] 1 H-NMR(DMSO-d6): 3.16 (2H, s), 3.97 (4H, s), 4.13 (2H, s), 6.41 (1H, dd, J=6.6, 1.8 Hz), 6.88-6.96 (2H, m), 7.07 (1H, m), 10.94 (1H, br s).

EXAMPLE 22

2-Benzenesulfonyl-2,9-dihydro-6-oxa-2-azabenzo[cd]azulen-8-one Ethylene Ketal (34)

[0207] 60% Sodium hydride 33 mg was added to a solution of compound (33) in dry dimethylformamide 2 ml with cooling in ice and the mixture was stirred for 10 min. Then, benzenesulfonyl chloride 152 mg was added. The mixture was heated at 60° C. for 14 h. Ice-water was added to the reaction mixtures, which was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was choromatographed on aluminum oxide in chloroform:hexane (1:1) to give the titled compound (34) as a pale yellow oil, 187 mg. Yield 69%.

[0208] 1 H-NMR(CDCl3): 3.22 (2H, s), 4.07 (4H, s), 4.16 (2H, s), 6.80 (1H, dd, J=8.1, 0.9 Hz), 7.18 (1H, t, J=8.1 Hz), 7.33 (1H, m), 7.42-7.58 (3H, m), 7.62 (1H, dd, J=8.4, 0.9 Hz), 7.88-7.92 (2H, m).

EXAMPLE 23

2-Benzenesulfonyl-2,9-dihydro-6-oxa-2-azabenzo[cd]azulen-8-one (35)

[0209] Trifluoroacetic acid 1 ml and water 0.1 ml were added to compound (34) 48.4 mg. The mixture was heated at 80° C. for 15 min and concentrated under reduced pressure. Ice-water was added to the residue, which was made alkaline with an aqueous saturated sodium hydrogen carbonate solution and extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on silica gel in ethyl acetate:hexane (1:2) to give the titled compound (35) as a colorless oil, 33.2 mg. Yield 78%.

[0210] 1 H-NMR(CDCl3): 4.03 (2H, d, J=1.2 Hz), 4.62 (2H, s), 6.90 (1H, dd, J=7.8, 0.6 Hz), 7.25 (1H, t, J=7.8 Hz), 7.30 (1H, m), 7.44-7.61 (3H, m), 7.73 (1H, dd, J=7.8, 0.6 Hz), 7.88-7.93 (2H, m).

EXAMPLE 24

2-Benzenesulfonyl-8-pyrrolidin-1-yl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulene (36-1) (R4=pyrrolidinyl)

[0211] A solution of pyrrolidine 35.4 mg in dry tetrahydrofuran 0.5 ml, sodium triacetoxyborohydride 133.7 mg and acetic acid 26 μl were added to a solution of compound (35) 135.9 mg in dry tetrahydrofuran 3.5 ml at room temperature and the mixture was stirred for 24 h. Water was added to the reaction mixture, which was made alkaline with an aqueous saturated sodium hydrogencarbonate solution and extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide 20 g in chloroform to give the titled compound (36-1) as a brown oil, 97.7 mg. Yield 62%. This was treated with 1 eq. oxalic acid to give the salt which was recrystallized from ether-methanol to give colorless crystals, m.p. 170-173° C.(dec.).

[0212] 1 H-NMR(CDCl3): 1.76-1.84 (4H, m), 2.60-3.26 (7H, m), 4.12 (1H, dd, J=12.9, 6.3 Hz), 4.47 (1H, d, J=12.9 Hz), 6.73 (1H, dd, J=8.1, 0.9 Hz), 7.17 (1H, t, J=8.1 Hz), 7.33 (1H, s), 7.41-7.61 (4H, m), 7.86-7.90 (2H, m).

[0213] Following compounds were obtained, according to the similar treatment.

Compd		m.p.
No	R7	(° C.)	1H-NMR (CDCl3)
36-2	NHMe	208-213	2.52 (3H, s), 2.91-3.15 (3H, m),
		(dec.)	4.22-4.27 (2H, m), 6.76 (1H, dd, J=8.1,
		oxalate	0.9 Hz), 7.18 (1H, t, J=8.1 Hz), 7.32-7.34
			(1H, m), 7.41-7.58 (3H, m), 7.61 (1H, dd,
			J=8.1, 0.9 Hz), 7.86-7.90 (2H, m)
36-3	NEt2	106-108	1.07 (6H, t, J=6.9 Hz), 2.50-3-30 (7H,
			m), 3.98-4.05 (1H, m), 4.52 (1H, d,
			J=11.7 Hz), 6.74 (1H, dd, J=7.8, 0.9 Hz),
			7.17 (1H, t, J=7.8 Hz), 7.33 (1H, s),
			7.42-7.62 (4H, m), 7.86-7.90 (2H, m)
36-4	NHBn	208-209	2.94-3.11 (2H, m), 3.20-3.27 (1H, m),
		(dec.)	3.86 (1H, d, J=13.2 Hz), 3.95 (1H, d,
		oxalate	J=13.2 Hz), 4.27 (2H, d, J=3.9 Hz), 6.77
			(1H, d, J=7.8 Hz), 7.15-7.62 (11H, m),
			7.86-7.90 (2H, m)

EXAMPLE 25

2,7,8,9-Tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-ol(37)

[0214] Compound (18-1) 374.4 mg was suspended in methanol 5 ml and sodium borohydride 75.7 mg was added to the suspension with cooling in ice. The mixture was stirred for 1 h. Water was added with cooling in ice. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was recrystallized from acetone-isopropanol to give the titled compound (37) as colorless crystals m.p. 169-170° C., 356.5 mg. Yield 94%.

[0215] 1 H-NMR(CD3OD): 2.83-2.93 (1H, m), 3.29-3.38 (1H, m), 4.03-4.17 (2H, m), 4.32 (1H, dd, J=5.4, 2.1 Hz), 6.42-6.48 (1H, m), 6.88-6.95 (1H, m), 6.99 (1H, br s).

[0216] (Scheme of reactions, Examples 26-34) 35

EXAMPLE 26

Dimethyl-(5-phenyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)amine (38)

[0217] Phenylboronic acid 190.1 mg, palladium acetate 13.0 mg, tris(2-methylphenyl)phosphine 30.9 mg and potassium carbonate 691.0 mg were added to a solution of compound (19-16) 296 mg in dry dimethylformamide 6 ml under nitrogen atmosphere. The mixture was heated at 120° C. for 2 h. After cooling, water was added. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:toluene (1:2) to give the titled compound (38) as colorless crystals, 33.0 mg. Yield 11%. Furthermore, the titled compound was recrystallized from acetone-isopropyl ether to give colorless crystals, m.p. 168-170° C.

[0218] 1 H-NMR(CDCl3): 2.42 (6H, s), 2.96-3.28 (3H, m), 4.17 (1H, dd, J=12.3, 6.3 Hz), 4.53 (1H, d, J=12.3 Hz), 7.02 (1H, s), 7.03 (1H, d, J=8.4 Hz), 7.15 (1H, d, J=8.4 Hz), 7.27-7.60 (5H, m).

EXAMPLE 27

(E)-3-(8-Dimethylamino-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-5-yl)acrylic Acid Methyl Ester (39)

[0219] Methyl acrylate 140 μl, triethylamine 217 μl and bis(triphenylphosphine)palladium dichloride 0.2 mg were added to a solution of compound (19-16) 306 mg in dry dimethylformamide 5 ml under nitrogen atmosphere. The mixture was heated at 100° C. for 19 h. Water was added with cooling in ice. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:1) to give the titled compound as yellow crystals 146.5 mg. Yield 47%. The titled compound was recrystallized from acetone-isopropyl ether to give pale yellow crystals, m.p. 168-170° C.

[0220] 1 H-NMR(CDCl3): 2.43 (6H, s), 2.90-3.22 (3H, m), 3.80 (3H, s), 4.24 (1H, dd, J=12.0, 6.6 Hz), 4.63 (1H, dd, J=12.6, 0.9 Hz), 6.39 (1H, d, J=16.2 Hz), 6.94 (1H, d, J=8.7 Hz), 6.97 (1H, m), 7.34 (1H, d, J=8.7 Hz), 8.22 (1H, br s), 8.25 (1H, d, J=16.2 Hz).

EXAMPLE 28

Dimethyl-(5-vinyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)amine (40)

[0221] Tri-n-butylvinyltin 952.0 mg, tetrakistriphenylphosphinepalladium 116.1 mg and lithium chloride 254.0 mg were added to a solution of compound (19-16) 592.2 mg in dry dimethylformamide 30 ml under a nitrogen atmosphere. The mixture was heated at 120° C. for 4 h and diluted with ethyl acetate, after cooling. The insoluble materials were removed by filtration through cerite. The filtrate was washed with an aqueous saturated sodium hydrogencarbonate solution and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:toluene (1:2) to give a colorless oil 602.2 mg. This was chromatographed on silica gel in chloroform:methanol:aq. ammonia (46:10:1) to give a yellow oil 500 mg, which was crystallized from hexane giving the titled compound as colorless crystals, 324 mg. Yield 67%. Furthermore, the titled compound was recrystallized from ether-petroleumether to give colorless crystals, m.p.119-120° C.

[0222] 1 H-NMR(CDCl3): 2.43 (6H, s), 2.93-3.23 (3H, m), 4.12-4.19 (1H, m), 4.61 (1H, dd, J=12.6, 1.5 Hz), 5.13 (1H, dd, J=11.4, 1.5 Hz), 5.62 (1H, dd, J=18.0, 1.5 Hz), 6.91-6.96 (2H, m), 7.22 (1H, dd, J=18.0, 11.4 Hz), 7.34 (1H, d, J=8.4 Hz), 8.08 (1H, br s).

EXAMPLE 29

(5-Ethyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd](azulen-8-yl)dimethylamine (41)

[0223] Compound (40) 242 mg was dissolved in methanol 4 ml and 5% palladium/C 60 mg was added. A mixture was stirred in hydrogen atmosphere at room temperature for 3 h. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:2) to give the titled compound as colorless crystals 241.6 mg. Yield 99%. This was recrystallized from acetone-hexane to give the titled compound as colorless crystals, m.p. 91-92° C.

[0224] 1 H-NMR(CDCl3): 1.21 (3H, t, J=7.5 Hz), 2.44 (6H, s), 2.65-2.78 (2H, m), 2.94-3.23 (3H, m), 4.12-4.18 (1H, m), 4.54-4.59 (1H, m), 6.90 (1H, d, J=8.4 Hz), 6.94-6.96 (1H, m), 6.97 (1H, d, J=8.4 Hz), 7.96 (1H, br s).

EXAMPLE 30

(5-Bromo-2-triisopropylsilanyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (42)

[0225] Compound (19-16) 2.00 g was added to a suspension of 60% sodium hydride 300.8 mg in tetrahydrofuran 30 ml with cooling in ice. The mixture was stirred for 1 h. Then, triisopropylsilyl chloride (TIPSCl) 1.6 ml was added with cooling in ice. The mixture was stirred for 4 h with cooling in ice. Water was added to reaction mixture with cooling in ice. The mixture was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:4) to give a pale brown oil 2.67 g. This was recrystallized from isopropyl ether to give colorless crystals, m.p. 119-121° C. 1.85 g. Yield 60%.

[0226] 1 H-NMR(CDCl3): 1.13 (18H, dd, J=7.5, 0.9 Hz), 1.58-1.72 (3H, m), 2.45 (6H, s), 3.03-3.26 (3H, m), 4.18-4.24 (1H, m), 4.66 (1H, dd, J=12.3, 1.5 Hz), 6.96 (1H, d, J=8.7 Hz), 7.00 (1H, s), 7.20 (1H, d, J=8.7 Hz).

EXAMPLE 31

(5-Fluoro-2-triisopropylsilanyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (43)

[0227] A solution of compound (42) 451 mg in dry tetrahydrofuran 5 ml was cooled at −70° C. n-BuLi (1.56 mol/l hexane solution) 1.3 ml was added dropwise to the mixture, which was stirred for 1 h. Then, N-fluorobenzenesulfonimide 694 mg was added and the mixture was stirred for 3.5 h. The reaction mixtures was diluted with an aqueous ammonium chloride solution, extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:5) to give a yellow oil. This was chromatographed on thin aluminum oxide plates (Merck precoated TLC plate alumina 60F254 in ethyl acetate:hexane (1:5)) to give the titled compound as a pale yellow oil, 100 mg.

[0228] 1 H-NMR(CDCl3): 1.28 (18H, dd, J=7.5, 0.9 Hz), 1.58-1.70 (3H, m), 2.45 (6H, s), 2.95-3.28 (3H, m), 4.20-4.26 (1H, m), 4.62 (1H, dd, J=11.7, 1.2 Hz), 6.86-6.97 (2H, m), 7.03 (1H, s).

EXAMPLE 32

Dimethyl-(5-methylsulfanyl-2-triisopropylsilanyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]-azulen-8-yl)amine (44)

[0229] A solution of compound (42) 451 mg in dry tetrahydrofuran 5 ml was cooled at −70° C. n-BuLi (1.56 mol/l hexane solution) 1.3 ml was added dropwise to the solution and the mixture was stirred for 1 h. Then, dimethyldisulfide 185 μl was added and the mixture was stirred for 2 h. The reaction mixtures was diluted with an aqueous ammonium chloride solution and extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:5) to give the titled compound as colorless crystals, 289.8 mg. Yield 69%. This was recrystallized from hexane to give the titled compound as colorless crystals, m.p. 77-79° C.

[0230] 1 H-NMR(CDCl3): 1.13 (18H, d, J=7.5 Hz), 1.58-1.74 (3H, m), 2.45 (total 9H, each s), 2.97-3.30 (3H, m), 4.22 (1H, d, J=12.0, 6.3 Hz), 4.68 (1H, dd, J 12.0, 1.2 Hz), 6.99 (1H, s), 7.04 (1H, d, J=8.4 Hz), 7.10 (1H, d, J=8.7 Hz).

EXAMPLE 33

8-Dimethylamino-2-triisopropylsilanyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]-azulene-5-carbaldehyde (45)

[0231] A solution of compound (42) 750 mg in dry tetrahydrofuran 7 ml was cooled at −70° C. and n-BuLi (1.56 mol/l hexane solution) 2.2 ml was added dropwise to the solution. The mixture was stirred for 1 h. Dimethylformamide 257 μl was added and the mixture was stirred for 2 h. The reaction mixtures was diluted with an aqueous ammonium chloride solution and extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:4) to give the titled compound as yellow oil, 556 mg. This was recrystallized from hexane to give the titled compound as colorless crystals, m.p. 104-106° C., 395 mg. Yield 59%

[0232] 1 H-NMR(CDCl3): 1.14 (18H, d, J=7.5 Hz), 1.55-1.72 (3H, m), 2.45 (6H, s), 2.97-3.30 (3H, m), 4.29 (1H, dd, J=12.6, 6.3 Hz), 4.65 (1H, d, J=12.6 Hz), 7.04 (1H, s), 7.07 (1H, d, J=9.0 Hz), 7.60 (1H, d, J=8.7 Hz), 10.50 (1H, s).

EXAMPLE 34

8-Dimethylamino-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]-azulene-5-carbaldehyde (46-1) (R11═CHO)

[0233] Tetra-n-butylammoniumfluoride (1 mol/l tetrahydrofuran solution) 2.2 ml was added to compound (45) 496 mg in tetrahydrofuran 10 ml with cooling in ice. The mixture was stirred for 3 h, diluted with water and ethyl acetate and, extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (2:1) to give colorless crystals, 273.2 mg. This was recrystallized from acetone-isopropyl ether to give the titled compound as colorless crystals, m.p.175-176° C., 2654 m g. Yield 88%.

[0234] 1 H-NMR(DMSO-d6): 2.29 (6H, s), 2.78-3.13 (3H, m), 4.31 (1H, dd, J=12.3, 6.6 Hz), 4.58 (1H, d, J=12.3 Hz), 6.99 (1H, dd, J=8.4, 0.9 Hz), 7.23 (1H, s), 7.40 (1H, d, J=8.4 Hz), 10.36 (1H, d, J=0.9 Hz), 11.48 (1H, br s).

[0235] Following compounds were obtained, according to the similar treatment.

Compd		m.p.
No	R11	(° C.)	1H-NMR (CDCl3)
46-2	F	148-150	2.44 (6H, s), 2.93-3.25 (3H, m), 4.24 (1H,
			dd, J=12.3, 6.6 Hz), 4.63 (1H, dd, J=12.3,
			1.2 Hz), 6.83 (1H, dd, J=8.7, 3.6 Hz), 6.97
			(1H, dd, J=11.4, 8.7 Hz), 7.01 (1H, m), 8.04
			(1H, br s)
46-3	SMe	112-113	2.44 (3H, s), 2.44 (6H, s), 2.97-3.24 (3H,
			m), 4.24 (1H, dd, J=12.3, 6.3 Hz), 4.69 (1H,
			dd, J=12.3, 2.1 Hz), 6.94 (1H, d, J=8.4 Hz),
			6.97-6.99 (1H, m), 7.19 (1H, d, J=8.7 Hz),
			8.09 (1H, br s)

[0236] (Scheme of reactions, Examples 35-37) 36

EXAMPLE 35

8-Dimethylamino-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]-azulene-5-carbaldehyde Oxime (47)

[0237] Hydroxylamine hydrogenchloride 83.4 mg and sodium acetate 98.4 mg were added to a suspension of compound (46-1) 244 mg in 95% ethanol 10 ml. The mixture was stirred at room temperature for 2 h and concentrated under reduced pressure. Water was added to the residue, which was made alkaline with an aqueous saturated sodium hydrogencarbonate solution. Colorless precipitates appeared and were collected by filtration, washed with methanol-ethyl acetate to give the titled compound as colorless crystals, m.p. 230-235° C.(dec.), 228 mg. Yield 88%.

[0238] 1 H-NMR(DMSO-d6): 2.28 (6H, s), 2.73-3.12 (3H, m), 4.15 (1H, dd, J=12.0, 6.6 Hz), 4.49 (1H, d, J=12.3 Hz), 6.93 (1H, d, J=7.8 Hz), 7.13 (1H, br d, J=2.7 Hz), 7.38 (1H, d, J=8.7 Hz), 8.39 (1H, s), 10.66 (1H, s), 11.12 (1H, br s).

EXAMPLE 36

8-Dimethylamino-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]-azulene-5-carbonitrile (48)

[0239] Triethylamine 33 μl and trichloroacetyl chloride 13 μl were added to a solution of compound (47) 28.9 mg in dichloromethane 2 ml with cooling ice and the mixture was stirred with cooling in ice and at room temperature for 18 h. A saturated sodium hydrogencarbonate solution was added thereto for alkalinization. The mixture was extracted with chloroform. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:methanol (97:3) to give the titled compound 26.3 mg as colorless crystals. Yield 98%. Furthermore, the titled compound was recrystallized from methanol-isopropyl ether to give colorless crystals, m.p. 205-207° C.

[0240] 1 H-NMR(CD3OD): 2.41 (6H, s), 2.89-3.23 (3H, m), 4.39 (1H, dd, J=12.6, 6.9 Hz), 4.64 (1H, d, J=12.6 Hz), 7.03 (1H, d, J=8.7 Hz), 7.17 (1H, d, J=8.7 Hz), 7.18 (1H, m).

EXAMPLE 37

8-Dimethylamino-2,7,8,9-tetrahydro-6-oxa-2-azabenzo [cd]azulene-5-carboxylic Acid Amide (49)

[0241] Polyphophoric acid 420 mg was added to compound (48) 31.6 mg under an argon atmosphere and the mixture was heated at 90° C. for 6 h. Ice-water was added to the reaction mixture, which was made alkaline with an aqueous 5 N-sodium hydroxide solution and extracted with chloroform. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:methanol (97:3) to give the titled compound as colorless crystals, 20.9 mg. Yield 62%. Furthermore, the titled compound was recrystallized from acetone-isopropyl ether to give colorless crystals, m.p. 182-183° C.

[0242] 1 H-NMR(DMSO-d6): 2.29 (6H, s), 2.76-3.13 (3H, m), 4.24 (1H, dd, J=12.0, 6.0 Hz), 4.64 (1H, d, J=12.3 Hz), 6.97 (1H, d, J=8.7 Hz), 7.18 (1H, d, J=2.1 Hz), 7.22 (1H, br s), 7.66 (1H, d, J=8.7Hz), 7.68(1H, br s), 11.20 (1H, br s)

[0243] (Scheme of reactions, Examples 38-40) 37

EXAMPLE 38

N-Cyclopropyl-2,2,2-trifluoromethyl-N-(2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)acetamide (50)

[0244] Compound (19-19) 355 mg was dissolved in dry tetrahydrofuran 11 ml. A solution of triethylamine 178 mg and trifluoroacetic anhydride 344 mg in dry tetrahydrofuran 0.5 ml was added to the solution with cooling in ice. The mixture was stirred with cooling in ice for 2 h. Triethylamine 78 mg and trifluoroacetic anhydride 156 mg in dry tetrahydrofuran 0.2 ml were again added. The mixture was stirred with cooling in ice for 2 h and concentrated under reduced pressure. Water was added to the residue, which was extracted with ether. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide 15 g in chloroform:hexane (4:1) to give the titled compound as pale yellow crystals, 415 mg (yield 82%), m.p. 49-53° C.

[0245] 1 H-NMR(CDCl3): 0.94-1.06 (4H, m), 3.04-3.14 (2H, m), 3.64-3.74 (1H, m), 4.10-4.15 (1H, m), 4.46 (1H, dd, J=12.6, 1.8 Hz), 4.70 (1H, dd, J=12.6, 6.6 Hz), 6.64 (1H, dd, J=7.5, 1.2 Hz), 6.97 (1H, s), 7.00 (1H, dd, J=8.1, 1.2 Hz), 7.08 (1H, d, J=8.1 Hz), 8.17 (1H, br s)

EXAMPLE 39

N-(2-Benzenesulfonyl-2,7,8,9-tetrahydro-6-oxo-2-aza-benzo[cd]azulen-8-yl)-N-cyclopropyl-2,2,2,-trifluoroacetamide (51)

[0246] 60% Sodium hydride 56 mg was added to a solution of compound (50) 324 mg in dimethylformamide 12 ml with cooling in ice and the mixture was stirred at room for 1 h. Benzenesulfonyl chloride 238 mg was added dropwise with cooling in ice and then, the mixture was stirred at 40° C. for 21 h. Ice-water and then an aqueous sodium hydrogencarbonate solution were added to the reaction mixture, which was extracted with ethyl acetate. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:hexane (1:2) to give the titled compound as a colorless oil, 130 mg (yield 28%).

[0247] 1 H-NMR(CDCl3): 0.88-1.05 (4H, m), 3.03-3.09 (2H, m), 3.58-3.68 (1H, m), 3.99-4.06 (1H, m), 4.40 (1H, dd, J=12.9, 1.5 Hz), 4.59 (1H, dd, J=12.9, 6.3 Hz), 6.77 (1H, dd, J=7.8, 0.6 Hz), 7.20 (1H, t, J=8.1 Hz), 7.34 (1H, s), 7.44-7.66 (4H, m), 7.86-7.90 (2H, m)

EXAMPLE 40

(2-Benzenesulfonyl-2,7,8,9-tetrahydro-6-oxo-2-aza-benzo[cd]azulen-8-yl)cyclopropylamine (52)

[0248] Compound (51) 129 mg was dissolved in ethanol 3 ml. Sodium hydrogenborohydride 42 mg was added to the solution at room temperature and the mixture was stirred for 23 h. Water was added with cooling in ice to the reaction mixture, which was extracted with chloroform. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:hexane (1:1) to give the titled compound as a colorless oil, 98 mg. Yield 96%. The titled compound was treated with 1 eq. of oxalic acid to give the salt, which was recrystallized from isopropanol-ether to give colorless crystals, m.p. 119-122° C. (dec.).

[0249] 1 H-NMR(CDCl3): 0.30-0.49 (4H, m), 2.21-2.27 (1H, m), 2.94-3.12 (2H, m), 3.31-3.37 (1H, m), 4.29-4.31 (2H, m), 6.77 (1H, d, J=7.8 Hz), 7.19 (1H, t, J=8.1 Hz), 7.33 (1H, s), 7.42-7.63 (4H, m), 7.86-7.90 (2H, m)

[0250] (Scheme of reactions, Examples 41-44) 38

EXAMPLE 41

(2-Benzenesulfonyl-1-iodo-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (53)

[0251] LDA was prepared by addition of n-BuLi (1.56 mol/l hexane solution) 1.08 ml to a solution of diisopropylamine 255 μl in dry tetrahydrofuran 3 ml at −70° C. Then, a solution of compound (20-1) 500 mg in dry tetrahydrofuran 2 ml was added at that temperature to the mixture, which was stirred for 2 h. Then, a solution of iodine 426 mg in dry tetrahydrofuran 2 ml was added and the mixture was stirred for 2 h. Ice was added to the reaction mixtures, which was extracted with chloroform. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in ethyl acetate:hexane (1:5) to give the titled compound as colorless crystals 514 mg. Yield 76%. This was recrystallized from from acetone-isopropyl ether to give colorless crystals, m.p. 136-137° C.

[0252] 1 H-NMR(CDCl3): 2.36 (6H, s), 2.87-2.97 (3H, m), 4.08-4.14 (1H, m), 4.41 (1H, d, J=12.6 Hz), 6.75 (1H, d, J=7.5 Hz), 7.40-7.45 (2H, m), 7.53-7.58 (1H, m), 7.86-7.90 (2H, m), 7.96 (1H, d, J=7.8 Hz).

EXAMPLE 42

(2-Benzenesulfonyl-1-vinyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (54)

[0253] Tri-n-butyl(vinyl)tin 484.4 mg, tetrakis(triphenylphosphine)palladium 690 mg and lithium chloride 127.7 mg were added to a solution of compound (53) 491 mg in dry dimethylformamide 10 ml under nitrogen atmosphere. The mixture was heated at 100° C. for 3 h, diluted with ethyl acetate after cooling and filtered through cerite to remove the insoluble materials. The filtrate was washed with an aqueous saturated sodium hydrogencarbonate solution and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was pulverized in hexane, collected by filtration and chromatographed on aluminum oxide in chloroform:hexane (1:1) to give the titled compound as colorless crystals 602.2 mg. Yield 79%. Furthermore, the titled compound was recrystallized from acetone-isopropyl ether to give colorless crystals, m.p. 133-134° C.

[0254] 1 H-NMR(CDCl3): 2.53 (6H, s), 2.78-3.10 (3H, m), 4.11 (1H, dd, J=12.6, 6.6 Hz), 4.41 (1H, d, J=12.6 Hz), 5.36 (1H, dd, J=17.7, 1.5 Hz), 5.69 (1H, dd, J=11.4, 1.5 Hz), 6.77 (1H, dd, J=8.1, 0.9 Hz), 7.18 (1H, dd, J=18.0, 11.4 Hz), 7.19 (1H, t, J=8.1 Hz), 7.34-7.53 (3H, m), 7.73-7.76 (2H, m), 7.87 (1H, dd, J=8.4, 0.9 Hz).

EXAMPLE 43

(2-Benzenesulfonyl-1-ethyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (55)

[0255] Compound (54) 200.1 mg was dissolved in a mixture of methanol 8 ml and tetrahydrofuran 4 ml. 10% Pd/C 49.8 mg was added. The mixture was stirred under hydrogen atmosphere for 18 h at room temperature. The catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:hexane (1:1) to give the titled compound as a colorless oil 198 mg. Yield 98%. This was treated with 1 eq. of oxalic acid to give the salt, which was recrystallized from ether-methanol to give colorless crystals, m.p. 193-194° C.(dec.).

[0256] 1 H-NMR(CDCl3): 1.28 (3H, t, J=7.5 Hz), 2.41 (6H, s), 2.89-3.07 (5H, m), 4.07-4.13 (1H, m), 4.43 (1H, d, J=12.6 Hz), 6.75 (1H, dd, J=7.8, 0.9 Hz), 7.13 (1H, t, J=8.1 Hz), 7.37-7.43 (2H, m), 7.49-7.54 (1H, m), 7.71-7.75 (2H, m), 7.83 (1H, dd, J=8.1, 0.9 Hz).

EXAMPLE 44

(1-Ethyl-2,7,8,9-tetrahydro-6-oxa-2-azabenzo[cd]azulen-8-yl)dimethylamine (56-1)

[0257] Magnesium (turning) 246 mg was added to compound (55) in methanol 9 ml and the mixture was stirred at room temperature for 3 h. Ice was added to the reaction mixture which was diluted with chloroform. The insoluble materials were filtered off through cerite and the filtrate was extracted with chloroform. The extracts were washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:hexane (2:1) to give the titled compound as a pale yellow oil 97.8 mg. Yield 79%. This was treated with 1 eq. oxalic acid to give the salt, which was recrystallized from ether-methanol to give colorless crystals, m.p. 236-237° C. (dec.).

[0258] 1 H-NMR(CDCl3): 1.29 (3H, t, J=7.5 Hz), 2.45 (6H, s), 2.75 (2H, q, J=7.5 Hz), 2.86-3.13 (3H, m), 4.12 (1H, dd, J=12.3, 6.3 Hz), 4.54 (1H, d, J=12.3 Hz), 6.59 (1H, dd, J=7.5, 0.9 Hz), 6.91 (1H, dd, J=8.1, 0.9 Hz), 6.99 (1H, t, J=7.8 Hz), 7.90 (1H, br s).

[0259] Following compounds were obtained, according to the similar treatment.

Compd
No	R7	m.p.	1H-NMR (CDCl3)
56-2	vinyl	195-198	2.43 (6H, s), 2.64-3.25 (3H, m), 4.12
		(dec.)	(1H, dd, J=12.0, 6.3 Hz), 4.54 (1H,
		oxalate	dd, J=12.0, 2.1 Hz), 5.27 (1H, d,
			J=11.4 Hz), 5.43 (1H, d, J=11.4 Hz),
			6.58 (1H, dd, J=7.8, 0.9 Hz), 6.79
			(1H, dd, J=17.7, 11.4 Hz), 6.91 (1H,
			dd, J=8.1, 0.9 Hz), 7.06 (1H, t,
			J=8.1 Hz), 8.11 (1H, br s),

EXAMPLE 45

[0260] 39

N-(2,7,8,9-Tetrahydro-6-oxo-2-azabenzo[cd]azulen-8-yl)hydrazinecarboxylic Acid tert-butyl Ester (57)

[0261] t-Butylbuthoxycarbonyl hydrazide 139 mg was added to a solution of compound (18-1) 170 mg in dry tetrahydrofuran 6 ml. The mixture was stirred at room temperature for 4 h and concentrated under reduced pressure. Trifluoroacetic acid 0.7 ml and triethylsilane 212 mg were added to the residue. The mixture was stirred for 80 min. 1N-HCl and then potassium hydroxide pellets were added to the reaction mixture with cooling in ice to alkaline. The mixture was extracted with chloroform. The organic layer was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue obtained was chromatographed on aluminum oxide in chloroform:hexane (4:1) to give the titled compound as crystals, 158 mg (yield 58%). The crude crystalline materials were recrystallized from hexane-ethyl acetate to give pale yellow crystals, m.p. 171-173° C.(dec.).

[0262] 1 H-NMR(CDCl3): 1.46 (9H, s), 2.84-2.93 (1H, m), 3.17-3.24 (2H, m), 3.59-3.66 (1H, m), 4.23 (1H, dd, J=12.3, 7.2 Hz), 4.37 (1H, d, J=12.3 Hz), 6.21 (1H, br s), 6.61 (1H, d, J=7.5 Hz), 6.96-7.08 (3H, m), 8.11 (1H, br s)

EXAMPLE A

[0263] As examples of a compound (I), compounds (I-a) and compounds (I-b) shown in Table 7-28 and Table 29-42, respectively.

TABLE 7
	(I-a)
40
Compd
No	R4	R7	R8
1	COOH	H	H
2	COOMe	H	H
3	COOEt	H	H
4	COO-tBu	H	H
5	CONH2	H	H
6	CONHMe	H	H
7	CONHEt	H	H
8	CONH-nPr	H	H
9	CONMe2	H	H
10	CONEt2	H	H
11	CON(nPr)2	H	H
12	CONHPh	H	H
13	41	H	H
14	42	H	H
15	43	H	H
16	NH2	H	H
17	NHMe	H	H
18	NHEt	H	H
19	NH-nPr	H	H
20	NMe2	H	H
21	NEt2	H	H
22	N(nPr)2	H	H
23	44	H	H
24	45	H	H
25	46	H	H
26	NHCOMe	H	H
27	NHCOEt	H	H

[0264]

TABLE 8
Compd
No	R4	R7	R8
1	NHCO-nPr	H	H
2	NHCOPh	H	H
3	NMeCOMe	H	H
4	N(nPr)COMe	H	H
5	NMeCOPh	H	H
6	N(nPr)COPh	H	H
7	NHCOOMe	H	H
8	NHCOOEt	H	H
9	NHCOO-tBu	H	H
10	NHCOOCH2Ph	H	H
11	NMeCOOMe	H	H
12	N(nPr)COOMe	H	H
13	NMeCOOOH2Ph	H	H
14	N(nPr)COOCH2Ph	H	H
15	NHSO2Me	H	H
16	NHSO2Et	H	H
17	NHSO2Ph	H	H
18	NHTs	H	H
19	NMeSO2Me	H	H
20	N(nPr)SO2Me	H	H
21	NMeSO2Ph	H	H
22	N(nPr)SO2Ph	H	H
23	COOH	Me	H
24	COOMe	Me	H
25	COOEt	Et	H
26	COO-tBu	nPr	H
27	CONH2	Me	H
28	CONHMe	Me	H
29	CONHEt	Et	H
30	CONH-nPr	nPr	H
31	CONMe2	Me	H
32	CONEt2	Et	H
33	CON(nPr)2	nPr	H
34	CONHPh	Me	H
35	47	Me	H
36	48	Et	H
37	49	nPr	H
38	NH2	Me	H
39	NHMe	Me	H
40	NHEt	Et	H

[0265]

TABLE 9
Compd
No	R4	R7	R8
1	NH-nPr	nPr	H
2	NMe2	Me	H
3	NEt2	Et	H
4	N(nPr)2	nPr	H
5	50	Me	H
6	51	Et	H
7	52	nPr	H
8	NHCOMe	Me	H
9	NHCOEt	Et	H
10	NHCO-nPr	nPr	H
11	NHCOPh	Me	H
12	NMeCOMe	Me	H
13	N(nPr)COMe	Et	H
14	NMeOOPh	nPr	H
15	N(nPr)COPh	Me	H
16	NHCOOMe	Me	H
17	NHCOOEt	Et	H
18	NHCOO-tBu	nPr	H
19	NHCOOOH2Ph	Me	H
20	NMeCOOMe	nPr	H
21	N(nPr)COOMe	nPr	H
22	NMeCOOCH2Ph	Me	H
23	N(nPr)COOCH2Ph	nPr	H
24	NHSO2Me	Me	H
25	NHSO2Et	Et	H
26	NHSO2Ph	nPr	H
27	NHTs	Et	H
28	NMeSO2Me	Me	H
29	N(nPr)SO2Me	nPr	H
30	NMeSO2Ph	Me	H
31	N(nPr)SO2Ph	Me	H
32	COOH	Br	H
33	COOMe	Br	H
34	COOEt	CN	H
35	COO-tBu	Br	H
36	CONH2	Br	H
37	CONHMe	Br	H
38	CONHEt	CN	H
39	CONHnPr	Br	H
40	CONMe2	Br	H
41	CONEt2	ON	H
42	CON(nPr)2	Br	H

[0266]

TABLE 10
Compd
No	R4	R7	R8
1	CONHPh	CN	H
2	53	Br	H
3	54	Br	H
4	55	CN	H
5	NH2	Br	H
6	NHMe	Br	H
7	NHEt	CN	H
8	NH-nPr	Br	H
9	NMe2	Br	H
10	NEt2	CN	H
11	N(nPr)2	Br	H
12	56	Br	H
13	57	CN	H
14	58	Br	H
15	NHCOMe	Br	H
16	NHCOEt	Br	H
17	NHCO-nPr	CN	H
18	NHCOPh	Br	H
19	NMeCOMe	Br	H
20	N(nPr)COMe	Br	H
21	NMeCOPh	CN	H
22	N(nPr)COPh	Br	H
23	NHCOOMe	Br	H
24	NHCOOEt	CN	H
25	NHCOO-tBu	Br	H
26	NHCOOCH2Ph	Br	H
27	NMeCOOMe	CN	H
28	N(nPr)COOMe	Br	H
29	NMeCOOCH2Ph	Br	H
30	N(nPr)COOCH2Ph	CN	H
31	NHSO2Me	Br	H
32	NHSO2Et	Br	H
33	NHSO2Ph	Br	H
34	NHTs	CN	H
35	NMeSO2Me	Br	H
36	N(nPr)SO2Me	Br	H
37	NMeSO2Ph	Br	H
38	N(nPr)SO2Ph	CN	H
39	COOH	Ph	H

[0267]

TABLE 11
Compd
No	R4	R7	R8
1	COOMe	Ph	H
2	COOEt	Ph	H
3	COO-tBu	Ph	H
4	CONH2	Ph	H
5	CONHMe	Ph	H
6	CONHEt	Ph	H
7	CONH-nPr	Ph	H
8	CONMe2	Ph	H
9	CONEt2	Ph	H
10	CON(nPr)2	Ph	H
11	CONHPh	Ph	H
12	59	Ph	H
13	60	Ph	H
14	61	Ph	H
15	NH2	Ph	H
16	NHMe	Ph	H
17	NHEt	Ph	H
18	NH-nPr	Ph	H
19	NMe2	Ph	H
20	NEt2	Ph	H
21	N(nPr)2	Ph	H
22	62	Ph	H
23	63	Ph	H
24	64	Ph	H
25	NHCOMe	Ph	H
26	NHCOEt	Ph	H
27	NHCO-nPr	Ph	H
28	NHCOPh	Ph	H
29	NMeCOMe	Ph	H
30	N(nPr)COMe	Ph	H
31	NMeCOPh	Ph	H
32	N(nPr)COPh	Ph	H
33	NHCOOMe	Ph	H
34	NHCOOEt	Ph	H
35	NHCOO-tBu	Ph	H
36	NHCOOCH2Ph	Ph	H
37	NMeCOOMe	Ph	H
38	N(nPr)COOMe	Ph	H

[0268]

TABLE 12
Compd
No	R4	R7	R8
1	NMeCOOCH2Ph	Ph	H
2	N(nPr)COOCH2Ph	Ph	H
3	NHSO2Me	Ph	H
4	NHSO2Et	Ph	H
5	NHSO2Ph	Ph	H
6	NHTs	Ph	H
7	NMeSO2Me	Ph	H
8	N(nPr)SO2Me	Ph	H
9	NMeSO2Ph	Ph	H
10	N(nPr)SO2Ph	Ph	H
11	COOH	H	Me
12	COOMe	H	Me
13	COOEt	H	Me
14	COO-tBu	H	Me
15	CONH2	H	Me
16	CONHMe	H	Me
17	CONHEt	H	Me
18	CONHnPr	H	Me
19	CONMe2	H	Me
20	CONEt2	H	Me
21	CON(nPr)2	H	Me
22	CONHPh	H	Me
23	65	H	Me
24	66	H	Me
25	67	H	Me
26	NH2	H	Me
27	NHMe	H	Me
28	NHEt	H	Me
29	NH-nPr	H	Me
30	NMe2	H	Me
31	NEt2	H	Me
32	N(nPr)2	H	Me
33	68	H	Me
34	69	H	Me
35	70	H	Me
36	NHCOMe	H	Me
37	NHCOEt	H	Me

[0269]

TABLE 13
Compd
No	R4	R7	R8
1	NHCO-nPr	H	Me
2	NHCOPh	H	Me
3	NMeCOMe	H	Me
4	N(nPr)COMe	H	Me
5	NMeCOPh	H	Me
6	N(nPr)COPh	H	Me
7	NHCOOMe	H	Me
8	NHCOOEt	H	Me
9	NHCOO-tBu	H	Me
10	NHCOOCH2Ph	H	Me
11	NMeCOOMe	H	Me
12	N(nPr)COOMe	H	Me
13	NMeCOOCH2Ph	H	Me
14	N(nPr)COOCH2Ph	H	Me
15	NHSO2Me	H	Me
16	NHSO2Et	H	Me
17	NHSO2Ph	H	Me
18	NHTs	H	Me
19	NMeSO2Me	H	Me
20	N(nPr)SO2Me	H	Me
21	NMeSO2Ph	H	Me
22	N(nPr)SO2Ph	H	Me
23	COOH	Me	Me
24	COOMe	Me	Me
25	COOEt	Et	Me
26	COO-tBu	Me	Me
27	CONH2	nPr	Me
28	CONHMe	Me	Me
29	CONHEt	Et	Me
30	CONH-nPr	nPr	Me
31	CONMe2	Me	Me
32	CONEt2	Et	Me
33	CON(nPr)2	nPr	Me
34	CONHPh	Me	Me
35	71	Me	Me
36	72	Et	Me
37	73	nPr	Me

[0270]

TABLE 14
Compd
No	R4	R7	R8
1	NH2	Me	Me
2	NHMe	Me	Me
3	NHEt	Me	Me
4	NH-nPr	Et	Me
5	NMe2	Me	Me
6	NEt2	nPr	Me
7	N(nPr)2	nPr	Me
8	74	Me	Me
9	75	Et	Me
10	76	Me	Me
11	NHCOMe	nPr	Me
12	NHCOEt	Me	Me
13	NHCO-nPr	Et	Me
14	NHCOPh	Me	Me
15	NMeCOMe	nPr	Me
16	N(nPr)COMe	Me	Me
17	NMeCOPh	Et	Me
18	N(nPr)COPh	Me	Me
19	NHCOOMe	nPr	Me
20	NHCOOEt	Me	Me
21	NHCOO-tBu	Et	Me
22	NHCOOCH2Ph	Me	Me
23	NMeCOOMe	nPr	Me
24	N(nPr)COOMe	Me	Me
25	NMeCOOCH2Ph	nPr	Me
26	N(nPr)COOCH2Ph	Me	Me
27	NHSO2Me	Et	Me
28	NHSO2Et	nPr	Me
29	NHSO2Ph	Me	Me
30	NHTs	nPr	Me
31	NMeSO2Me	Me	Me
32	N(nPr)SO2Me	Et	Me
33	NMeSO2Ph	Me	Me
34	N(nPr)SO2Ph	Et	Me
35	COOH	Br	Me
36	COOMe	Br	Me
37	COOEt	CN	Me
38	COO-tBu	CN	Me

[0271]

	TABLE 15
	Compd
	No	R4	R7	R8
	1	CONH2	Br	Me
	2	CONHMe	Br	Me
	3	CONHEt	CN	Me
	4	CONH-nPr	Br	Me
	5	CONMe2	Br	Me
	6	CONEt2	CN	Me
	7	CON(nPr)2	Br	Me
	8	CONHPh	CN	Me
	9	77	Br	Me
	10	78	CN	Me
	11	79	Br	Me
	12	NH2	Br	Me
	13	NHMe	CN	Me
	14	NHEt	CN	Me
	15	NH-nPr	Br	Me
	16	NMe2	Br	Me
	17	NEt2	CN	Me
	18	N(nPr)2	Br	Me
	19	80	Br	Me
	20	81	CN	Me
	21	82	Br	Me
	22	NHCOMe	Br	Me
	23	NHCOEt	Br	Me
	24	NHCO-nPr	CN	Me
	25	NHCOPh	Br	Me
	26	NMeCOMe	Br	Me
	27	N(nPr)COMe	CN	Me
	28	NMeCOPh	Br	Me
	29	N(nPr)COPh	Br	Me
	30	NHCOOMe	CN	Me
	31	NHCOOEt	Br	Me
	32	NHCOO-tBu	Br	Me
	33	NHCOOCH2Ph	Br	Me
	34	NMeCOOMe	CN	Me
	35	N(nPr)COOMe	Br	Me

[0272]

	TABLE 16
	Compd
	No	R4	R7	R8
	1	NMeCOOCH2Ph	Br	Me
	2	N(nPr)COOCH2Ph	CN	Me
	3	NHSO2Me	Br	Me
	4	NHSO2Et	Br	Me
	5	NHSO2Ph	CN	Me
	6	NHTs	Br	Me
	7	NMeSO2Me	Br	Me
	8	N(nPr)SO2Me	CN	Me
	9	NMeSO2Ph	Br	Me
	10	N(nPr)SO2Ph	Br	Me
	11	COOH	Ph	Me
	12	COOMe	Ph	Me
	13	COOEt	Ph	Me
	14	COO-tBu	Ph	Me
	15	CONH2	Ph	Me
	16	CONHMe	Ph	Me
	17	CONHEt	Ph	Me
	18	CONH-nPr	Ph	Me
	19	CONMe2	Ph	Me
	20	CONEt2	Ph	Me
	21	CON(nPr)2	Ph	Me
	22	CONHPh	Ph	Me
	23	83	Ph	Me
	24	84	Ph	Me
	25	85	Ph	Me
	26	NH2	Ph	Me
	27	NHMe	Ph	Me
	28	NHEt	Ph	Me
	29	NH-nPr	Ph	Me
	30	NMe2	Ph	Me
	31	NEt2	Ph	Me
	32	N(nPr)2	Ph	Me
	33	86	Ph	Me
	34	87	Ph	Me
	35	88	Ph	Me

[0273]

	TABLE 17
	Compd
	No	R4	R7	R8
	1	NHCOMe	Ph	Me
	2	NHCOEt	Ph	Me
	3	NHCO-nPr	Ph	Me
	4	NHCOPh	Ph	Me
	5	NMeCOMe	Ph	Me
	6	N(nPr)COMe	Ph	Me
	7	NMeCOPh	Ph	Me
	8	N(nPr)COPh	Ph	Me
	9	NHCOOMe	Ph	Me
	10	NHCOOEt	Ph	Me
	11	NHCOO-tBu	Ph	Me
	12	NHCOOCH2Ph	Ph	Me
	13	NMeCOOMe	Ph	Me
	14	N(nPr)COOMe	Ph	Me
	15	NMeCOOCH2Ph	Ph	Me
	16	N(nPr)COOCH2Ph	Ph	Me
	17	NHSO2Me	Ph	Me
	18	NHSO2Et	Ph	Me
	19	NHSO2Ph	Ph	Me
	20	NHTs	Ph	Me
	21	NMeSO2Me	Ph	Me
	22	N(nPr)SO2Me	Ph	Me
	23	NMeSO2Ph	Ph	Me
	24	N(nPr)SO2Ph	Ph	Me
	25	COOH	H	COPh
	26	COOMe	H	COPh
	27	COOEt	H	COPh
	28	COO-tBu	H	COPh
	29	CONH2	H	COPh
	30	CONHMe	H	COPh
	31	CONHEt	H	COPh
	32	CONH-nPr	H	COPh
	33	CONMe2	H	COPh
	34	CONEt2	H	COPh
	35	CON(nPr)2	H	COPh
	36	CONHPh	H	COPh
	37	89	H	COPh
	38	90	H	COPh
	39	91	H	COPh

[0274]

	TABLE 18
	Compd
	No	R4	R7	R8
	1	NH2	H	COPh
	2	NHMe	H	COPh
	3	NHEt	H	COPh
	4	NH-nPr	H	COPh
	5	NMe2	H	COPh
	6	NEt2	H	COPh
	7	N(nPr)2	H	COPh
	8	92	H	COPh
	9	93	H	COPh
	10	94	H	COPh
	11	NHCOMe	H	COPh
	12	NHCOEt	H	COPh
	13	NHCO-nPr	H	COPh
	14	NHCOPh	H	COPh
	15	NMeCOMe	H	COPh
	16	N(nPr)COMe	H	COPh
	17	NMeCOPh	H	COPh
	18	N(nPr)COPh	H	COPh
	19	NHCOOMe	H	COPh
	20	NHCOOEt	H	COPh
	21	NHCOO-tBu	H	COPh
	22	NHCOOCH2Ph	H	COPh
	23	NMeCOOMe	H	COPh
	24	N(nPr)COOMe	H	COPh
	25	NMeCOOCH2Ph	H	COPh
	26	N(nPr)COOCH2Ph	H	COPh
	27	NHSO2Me	H	COPh
	28	NHSO2Et	H	COPh
	29	NHSO2Ph	H	COPh
	30	NHTs	H	COPh
	31	NMeSO2Me	H	COPh
	32	N(nPr)SO2Me	H	COPh
	33	NMeSO2Ph	H	COPh
	34	N(nPr)SO2Ph	H	COPh
	35	COOH	Me	COPh
	36	COOMe	Me	COPh
	37	COOEt	Et	COPh
	38	COO-tBu	nPr	COPh
	39	CONH2	Me	COPh

[0275]

	TABLE 19
	Compd
	No	R4	R7	R8
	1	CONHMe	Et	COPh
	2	CONHEt	nPr	COPh
	3	CONH-nPr	Me	COPh
	4	CONMe2	Et	COPh
	5	CONEt2	nPr	COPh
	6	CON(nPr)2	nPr	COPh
	7	CONHPh	Me	COPh
	8	95	nPr	COPh
	9	96	Et	COPh
	10	97	Me	COPh
	11	NH2	Et	COPh
	12	NHMe	Me	COPh
	13	NHEt	Et	COPh
	14	NH-nPr	nPr	COPh
	15	NMe2	Me	COPh
	16	NEt2	Et	COPh
	17	N(nPr)2	nPr	COPh
	18	98	Me	COPh
	19	99	Me	COPh
	20	100	Me	COPh
	21	NHCOMe	Et	COPh
	22	NHCOEt	Et	COPh
	23	NHCO-nPr	Et	COPh
	24	NHCOPh	nPr	COPh
	25	NMeCOMe	nPr	COPh
	26	N(nPr)COMe	nPr	COPh
	27	NMeCOPh	Et	COPh
	28	N(nPr)COPh	Et	COPh
	29	NHCOOMe	Et	COPh
	30	NHCOOEt	Me	COPh
	31	NHCOO-tBu	Me	COPh
	32	NHCOOCH2Ph	Me	COPh
	33	NMeCOOMe	Et	COPh
	34	N(nPr)COOMe	nPr	COPh
	35	NMeCOOCH2Ph	nPr	COPh
	36	N(nPr)COOCH2Ph	nPr	COPh
	37	NHSO2Me	Me	COPh
	38	NHSO2Et	Et	COPh

[0276]

	TABLE 20
	Compd
	No	R4	R7	R8
	1	NHSO2Ph	nPr	COPh
	2	NHTs	Me	COPh
	3	NMeSO2Me	Et	COPh
	4	N(nPr)SO2Me	nPr	COPh
	5	NMeSO2Ph	Me	COPh
	6	N(nPr)SO2Ph	Me	COPh
	7	COOH	Br	COPh
	8	COOMe	Br	COPh
	9	COOEt	CN	COPh
	10	COO-tBu	Br	COPh
	11	CONH2	CN	COPh
	12	CONHMe	Br	COPh
	13	CONHEt	CN	COPh
	14	CONH-nPr	Br	COPh
	15	CONMe2	Br	COPh
	16	CONEt2	CN	COPh
	17	CON(nPr)2	Br	COPh
	18	CONHPh	Br	COPh
	19	101	CN	COPh
	20	102	Br	COPh
	21	103	Br	COPh
	22	NH2	CN	COPh
	23	NHMe	Br	COPh
	24	NHEt	CN	COPh
	25	NH-nPr	Br	COPh
	26	NMe2	Br	COPh
	27	NEt2	Br	COPh
	28	N(nPr)2	CN	COPh
	29	104	Br	COPh
	30	105	Br	COPh
	31	106	CN	COPh
	32	NHCOMe	Br	COPh
	33	NHCOEt	CN	COPh
	34	NHCO-nPr	Br	COPh
	35	NHCOPh	CN	COPh
	36	NMeCOMe	Br	COPh
	37	N(nPr)COMe	CN	COPh

[0277]

	TABLE 21
	Compd
	No	R4	R7	R8
	1	NMeCOPh	CN	COPh
	2	N(nPr)COPh	Br	COPh
	3	NHCOOMe	Br	COPh
	4	NHCOOEt	CN	COPh
	5	NHCOO-tBu	Br	COPh
	6	NHCOOCH2Ph	Br	COPh
	7	NMeCOOMe	CN	COPh
	8	N(nPr)COOMe	Br	COPh
	9	NMeCOOCH2Ph	Br	COPh
	10	N(nPr)COOCH2Ph	CN	COPh
	11	NHSO2Me	Br	COPh
	12	NHSO2Et	Br	COPh
	13	NHSO2Ph	CN	COPh
	14	NHTs	Br	COPh
	15	NMeSO2Me	Br	COPh
	16	N(nPr)SO2Me	CN	COPh
	17	NMeSO2Ph	CN	COPh
	18	N(nPr)SO2Ph	CN	COPh
	19	COOH	Ph	COPh
	20	COOMe	Ph	COPh
	21	COOEt	Ph	COPh
	22	COO-tBu	Ph	COPh
	23	CONH2	Ph	COPh
	24	CONHMe	Ph	COPh
	25	CONHEt	Ph	COPh
	26	CONH-nPr	Ph	COPh
	27	CONMe2	Ph	COPh
	28	CONEt2	Ph	COPh
	29	CON(nPr)2	Ph	COPh
	30	CONHPh	Ph	COPh
	31	107	Ph	COPh
	32	108	Ph	COPh
	33	109	Ph	COPh
	34	NH2	Ph	COPh
	35	NHMe	Ph	COPh
	36	NHEt	Ph	COPh

[0278]

	TABLE 22
	Compd
	No	R4	R7	R8
	1	NH-nPr	Ph	COPh
	2	NMe2	Ph	COPh
	3	NEt2	Ph	COPh
	4	N(nPr)2	Ph	COPh
	5	110	Ph	COPh
	6	111	Ph	COPh
	7	112	Ph	COPh
	8	NHCOMe	Ph	COPh
	9	NHCOEt	Ph	COPh
	10	NHCO-nPr	Ph	COPh
	11	NHCOPh	Ph	COPh
	12	NMeCOMe	Ph	COPh
	13	N(nPr)COMe	Ph	COPh
	14	NMeCOPh	Ph	COPh
	15	N(nPr)COPh	Ph	COPh
	16	NHCOOMe	Ph	COPh
	17	NHCOOEt	Ph	COPh
	18	NHCOO-tBu	Ph	COPh
	19	NHCOOCH2Ph	Ph	COPh
	20	NMeCOOMe	Ph	COPh
	21	N(nPr)COOMe	Ph	COPh
	22	NMeCOOCH2Ph	Ph	COPh
	23	N(nPr)COOCH2Ph	Ph	COPh
	24	NHSO2Me	Ph	COPh
	25	NHSO2Et	Ph	COPh
	26	NHSO2Ph	Ph	COPh
	27	NHTs	Ph	COPh
	28	NMeSO2Me	Ph	COPh
	29	N(nPr)SO2Me	Ph	COPh
	30	NMeSO2Ph	Ph	COPh
	31	N(nPr)SO2Ph	Ph	COPh
	32	COOH	H	SO2Ph
	33	COOMe	H	SO2Ph
	34	COOEt	H	SO2Ph
	35	COO-tBu	H	SO2Ph
	36	CONH2	H	SO2Ph
	37	CONHMe	H	SO2Ph

[0279]

	TABLE 23
	Compd
	No	R4	R7	R8
	1	CONHEt	H	SO2Ph
	2	CONH-nPr	H	SO2Ph
	3	CONMe2	H	SO2Ph
	4	CONEt2	H	SO2Ph
	5	CON(nPr)2	H	SO2Ph
	6	CONHPh	H	SO2Ph
	7	113	H	SO2Ph
	8	114	H	SO2Ph
	9	115	H	SO2Ph
	10	NH2	H	SO2Ph
	11	NHMe	H	SO2Ph
	12	NHEt	H	SO2Ph
	13	NH-nPr	H	SO2Ph
	14	NMe2	H	SO2Ph
	15	NEt2	H	SO2Ph
	16	N(nPr)2	H	SO2Ph
	17	116	H	SO2Ph
	18	117	H	SO2Ph
	19	118	H	SO2Ph
	20	NHCOMe	H	SO2Ph
	21	NHCOEt	H	SO2Ph
	22	NHCO-nPr	H	SO2Ph
	23	NHCOPh	H	SO2Ph
	24	NMeCOMe	H	SO2Ph
	25	N(nPr)COMe	H	SO2Ph
	26	NMeCOPh	H	SO2Ph
	27	N(nPr)COPh	H	SO2Ph
	28	NHCOOMe	H	SO2Ph
	29	NHCOOEt	H	SO2Ph
	30	NHCOO-tBu	H	SO2Ph
	31	NHCOOCH2Ph	H	SO2Ph
	32	NMeCOOMe	H	SO2Ph
	33	N(nPr)COOMe	H	SO2Ph
	34	NMeCOOCH2Ph	H	SO2Ph
	35	N(nPr)COOCH2Ph	H	SO2Ph
	36	NHSO2Me	H	SO2Ph
	37	NHSO2Et	H	SO2Ph

[0280]

	TABLE 24
	Compd
	No	R4	R7	R8
	1	NHSO2Ph	H	SO2Ph
	2	NHTs	H	SO2Ph
	3	NMeSO2Me	H	SO2Ph
	4	N(nPr)SO2Me	H	SO2Ph
	5	NMeSO2Ph	H	SO2Ph
	6	N(nPr)SO2Ph	H	SO2Ph
	7	COOH	Me	SO2Ph
	8	COOMe	Me	SO2Ph
	9	COOEt	Et	SO2Ph
	10	COO-tBu	nPr	SO2Ph
	11	CONH2	Me	SO2Ph
	12	CONHMe	Me	SO2Ph
	13	CONHEt	Et	SO2Ph
	14	CONH-nPr	nPr	SO2Ph
	15	CONMe2	Me	SO2Ph
	16	CONEt2	Me	SO2Ph
	17	CON(nPr)2	Me	SO2Ph
	18	CONHPh	Et	SO2Ph
	19	119	Et	SO2Ph
	20	120	Et	SO2Ph
	21	121	nPr	SO2Ph
	22	NH2	nPr	SO2Ph
	23	NHMe	nPr	SO2Ph
	24	NHEt	Et	SO2Ph
	25	NH-nPr	Me	SO2Ph
	26	NMe2	nPr	SO2Ph
	27	NEt2	Et	SO2Ph
	28	N(nPr)2	Et	SO2Ph
	29	122	Me	SO2Ph
	30	123	Me	SO2Ph
	31	124	Me	SO2Ph
	32	NHCOMe	Et	SO2Ph
	33	NHCOEt	Et	SO2Ph
	34	NHCO-nPr	Et	SO2Ph
	35	NHCOPh	Me	SO2Ph
	36	NMeCOMe	Me	SO2Ph

[0281]

	TABLE 25
	Compd
	No	R4	R7	R8
	1	N(nPr)COMe	Me	SO2Ph
	2	NMeCOPh	nPr	SO2Ph
	3	N(nPr)COPh	nPr	SO2Ph
	4	NHCOOMe	nPr	SO2Ph
	5	NHCOOEt	Me	SO2Ph
	6	NHCOO-tBu	Et	SO2Ph
	7	NHCOOCH2Ph	nPr	SO2Ph
	8	NMeCOOMe	Me	SO2Ph
	9	N(nPr)COOMe	Et	SO2Ph
	10	NMeCOOCH2Ph	nPr	SO2Ph
	11	N(nPr)COOCH2Ph	Me	SO2Ph
	12	NHSO2Me	Et	SO2Ph
	13	NHSO2Et	nPr	SO2Ph
	14	NHSO2Ph	Me	SO2Ph
	15	NHTs	Me	SO2Ph
	16	NMeSO2Me	Me	SO2Ph
	17	N(nPr)SO2Me	nPr	SO2Ph
	18	NMeSO2Ph	nPr	SO2Ph
	19	N(nPr)SO2Ph	nPr	SO2Ph
	20	COOH	Br	SO2Ph
	21	COOMe	CN	SO2Ph
	22	COOEt	Br	SO2Ph
	23	COO-tBu	CN	SO2Ph
	24	CONH2	Br	SO2Ph
	25	CONHMe	Br	SO2Ph
	26	CONHEt	Br	SO2Ph
	27	CONH-nPr	Br	SO2Ph
	28	CONMe2	CN	SO2Ph
	29	CONEt2	CN	SO2Ph
	30	CON(nPr)2	CN	SO2Ph
	31	CONHPh	Br	SO2Ph
	32	125	Br	SO2Ph
	33	126	Br	SO2Ph
	34	127	CN	SO2Ph
	35	NH2	Br	SO2Ph
	36	NHMe	CN	SO2Ph

[0282]

	TABLE 26
	Compd
	No	R4	R7	R8
	1	NHEt	Br	SO2Ph
	2	NH-nPr	CN	SO2Ph
	3	NMe2	Br	SO2Ph
	4	NEt2	Br	SO2Ph
	5	N(nPr)2	CN	SO2Ph
	6	128	Br	SO2Ph
	7	129	Br	SO2Ph
	8	130	Br	SO2Ph
	9	NHCOMe	CN	SO2Ph
	10	NHCOEt	Br	SO2Ph
	11	NHCO-nPr	CN	SO2Ph
	12	NHCOPh	Br	SO2Ph
	13	NMeCOMe	Br	SO2Ph
	14	N(nPr)COMe	CN	SO2Ph
	15	NMeCOPh	Br	SO2Ph
	16	N(nPr)COPh	Br	SO2Ph
	17	NHCOOMe	CN	SO2Ph
	18	NHCOOEt	Br	SO2Ph
	19	NHCOO-tBu	Br	SO2Ph
	20	NHCOOCH2Ph	Br	SO2Ph
	21	NMeCOOMe	CN	SO2Ph
	22	N(nPr)COOMe	Br	SO2Ph
	23	NMeCOOCH2Ph	Br	SO2Ph
	24	N(nPr)COOCH2Ph	Br	SO2Ph
	25	NHSO2Me	CN	SO2Ph
	26	NHSO2Et	Br	SO2Ph
	27	NHSO2Ph	Br	SO2Ph
	28	NHTs	CN	SO2Ph
	29	NMeSO2Me	Br	SO2Ph
	30	N(nPr)SO2Me	Br	SO2Ph
	31	NMeSO2Ph	CN	SO2Ph
	32	N(nPr)SO2Ph	Br	SO2Ph
	33	COOH	Ph	SO2Ph
	34	COOMe	Ph	SO2Ph
	35	COOEt	Ph	SO2Ph
	36	COO-tBu	Ph	SO2Ph
	37	CONH2	Ph	SO2Ph

[0283]

	TABLE 27
	Compd
	No	R4	R7	R8
	1	CONHMe	Ph	SO2Ph
	2	CONHEt	Ph	SO2Ph
	3	CONH-nPr	Ph	SO2Ph
	4	CONMe2	Ph	SO2Ph
	5	CONEt2	Ph	SO2Ph
	6	CON(nPr)2	Ph	SO2Ph
	7	CONHPh	Ph	SO2Ph
	8	131	Ph	SO2Ph
	9	132	Ph	SO2Ph
	10	133	Ph	SO2Ph
	11	NH2	Ph	SO2Ph
	12	NHMe	Ph	SO2Ph
	13	NHEt	Ph	SO2Ph
	14	NH-nPr	Ph	SO2Ph
	15	NMe2	Ph	SO2Ph
	16	NEt2	Ph	SO2Ph
	17	N(nPr)2	Ph	SO2Ph
	18	134	Ph	SO2Ph
	19	135	Ph	SO2Ph
	20	136	Ph	SO2Ph
	21	NHCOMe	Ph	SO2Ph
	22	NHCOEt	Ph	SO2Ph
	23	NHCO-nPr	Ph	SO2Ph
	24	NHCOPh	Ph	SO2Ph
	25	NMeCOMe	Ph	SO2Ph
	26	N(nPr)COMe	Ph	SO2Ph
	27	NMeCOPh	Ph	SO2Ph
	28	N(nPr)COPh	Ph	SO2Ph
	29	NHCOOMe	Ph	SO2Ph
	30	NHCOOEt	Ph	SO2Ph
	31	NHCOO-tBu	Ph	SO2Ph
	32	NHCOOCH2Ph	Ph	SO2Ph
	33	NMeCOOMe	Ph	SO2Ph
	34	N(nPr)COOMe	Ph	SO2Ph
	35	NMeCOOCH2Ph	Ph	SO2Ph
	36	N(nPr)COOCH2Ph	Ph	SO2Ph

[0284]

TABLE 28
Compd
No	R4	R7	R8
1	NHSO2Me	Ph	SO2Ph
2	NHSO2Et	Ph	SO2Ph
3	NHSO2Ph	Ph	SO2Ph
4	NHTs	Ph	SO2Ph
5	NMeSO2Me	Ph	SO2Ph
6	N(nPr)SO2Me	Ph	SO2Ph
7	NMeSO2Ph	Ph	SO2Ph
8	N(nPr)SO2Ph	Ph	SO2Ph

[0285]

TABLE 29
	(I-b)
137
Compd
No	R4	R6	R7	R8
1	COOH	H	H	H
2	COOMe	H	H	H
3	COOEt	H	H	H
4	COO-tBu	H	H	H
5	CONH2	H	H	H
6	CONHMe	H	H	H
7	CONHEt	H	H	H
8	CONH-nPr	H	H	H
9	CONMe2	H	H	H
10	CONEt2	H	H	H
11	CON(nPr)2	H	H	H
12	CONHPh	H	H	H
13	138	H	H	H
14	139	H	H	H
15	140	H	H	H
16	NHCOOMe	H	H	H
17	NHCOOEt	H	H	H
18	NHCOO-tBu	H	H	H
19	NHCOOCH2Ph	H	H	H
20	NMeCOOMe	H	H	H
21	N(nPr)COOMe	H	H	H
22	NMeCOOCH2Ph	H	H	H
23	N(nPr)COOCH2Ph	H	H	H
24	COOH	H	Me	H
25	COOMe	H	Me	H
26	COOEt	H	Et	H

[0286]

TABLE 30
Compd
No	R4	R6	R7	R8
1	COO-tBu	H	nPr	H
2	CONH2	H	Me	H
3	CONHMe	H	Me	H
4	CONHEt	H	Et	H
5	CONH-nPr	H	nPr	H
6	CONMe2	H	Me	H
7	CONEt2	H	Me	H
8	CON(nPr)2	H	Me	H
9	CONHPh	H	Et	H
10	141	H	Et	H
11	142	H	Et	H
12	143	H	Et	H
13	NHCOOMe	H	nPr	H
14	NHCOOEt	H	nPr	H
15	NHCOO-tBu	H	nPr	H
16	NHCOOCH2Ph	H	Me	H
17	NMeCOOMe	H	Et	H
18	N(nPr)COOMe	H	nPr	H
19	NMeCOOCH2Ph	H	Me	H
20	N(nPr)COOCH2Ph	H	nPr	H
21	COOH	H	Br	H
22	COOMe	H	Br	H
23	COOEt	H	CN	H
24	COO-tBu	H	Br	H
25	CONH2	H	Br	H
26	CONHMe	H	CN	H
27	CONHEt	H	Br	H
28	CONH-nPr	H	CN	H
29	CONMe2	H	Br	H
30	CONEt2	H	Br	H
31	CON(nPr)2	H	CN	H
32	CONHPh	H	Br	H
33	144	H	Br	H
34	145	H	CN	H
35	146	H	Br	H

[0287]

TABLE 31
Compd
No.	R4	R6	R7	R8
1	NHCOOMe	H	Br	H
2	NHCOOEt	H	CN	H
3	NHCOO-tBu	H	Br	H
4	NHCOOCH2Ph	H	CN	H
5	NMeCOOMe	H	Br	H
6	N(nPr)COOMe	H	CN	H
7	NMeCOOCH2Ph	H	Br	H
8	N(nPr)COOCH2Ph	H	CN	H
9	COOH	H	Ph	H
10	COOMe	H	Ph	H
11	COOEt	H	Ph	H
12	COO-tBu	H	Ph	H
13	CONH2	H	Ph	H
14	CONHMe	H	Ph	H
15	CONHEt	H	Ph	H
16	CONH-nPr	H	Ph	H
17	CONMe2	H	Ph	H
18	CONEt2	H	Ph	H
19	CON(nPr)2	H	Ph	H
20	CONHPh	H	Ph	H
21	147	H	Ph	H
22	148	H	Ph	H
23	149	H	Ph	H
24	NHCOOMe	H	Ph	H
25	NHCOOEt	H	Ph	H
26	NHCOO-tBu	H	Ph	H
27	NHCOOCH2Ph	H	Ph	H
28	NMeCOOMe	H	Ph	H
29	N(nPr)COOMe	H	Ph	H
30	NMeCOOCH2Ph	H	Ph	H
31	N(nPr)COOCH2Ph	H	Ph	H
32	COOH	H	H	Me
33	COOMe	H	H	Me
34	COOEt	H	H	Me
35	COO-tBu	H	H	Me
36	CONH2	H	H	Me
37	CONHMe	H	H	Me

[0288]

TABLE 32
Compd
No	R4	R6	R7	R8
1	CONHEt	H	H	Me
2	CONH-nPr	H	H	Me
3	CONMe2	H	H	Me
4	CONEt2	H	H	Me
5	CON(nPr)2	H	H	Me
6	CONHPh	H	H	Me
7	150	H	H	Me
8	151	H	H	Me
9	152	H	H	Me
10	NHCOOMe	H	H	Me
11	NHCOOEt	H	H	Me
12	NHCOO-tBu	H	H	Me
13	NHCOOCH2Ph	H	H	Me
14	NMeCOOMe	H	H	Me
15	N(nPr)COOMe	H	H	Me
16	NMeCOOCH2Ph	H	H	Me
17	N(nPr)COOCH2Ph	H	H	Me
18	COOH	H	Me	Me
19	COOMe	H	Me	Me
20	COOEt	H	Et	Me
21	COO-tBu	H	nPr	Me
22	CONH2	H	Me	Me
23	CONHMe	H	Me	Me
24	CONHEt	H	Me	Me
25	CONH-nPr	H	Et	Me
26	CONMe2	H	Et	Me
27	CONEt2	H	Et	Me
28	CON(nPr)2	H	nPr	Me
29	CONHPh	H	nPr	Me
30	153	H	nPr	Me
31	154	H	Me	Me
32	155	H	Et	Me
33	NHCOOMe	H	nPr	Me
34	NHCOOEt	H	Me	Me

[0289]

TABLE 33
Compd
No	R4	R6	R7	R8
1	NHCOO-tBu	H	Et	Me
2	NHCOOCH2Ph	H	nPr	Me
3	NMeCOOMe	H	Me	Me
4	N(nPr)COOMe	H	Me	Me
5	NMeCOOCH2Ph	H	Et	Me
6	N(nPr)COOCH2Ph	H	nPr	Me
7	COOH	H	Br	Me
8	COOMe	H	CN	Me
9	COOEt	H	Br	Me
10	COO-tBu	H	CN	Me
11	CONH2	H	Br	Me
12	CONHMe	H	CN	Me
13	CONHEt	H	Br	Me
14	CONH-nPr	H	CN	Me
15	CONMe2	H	Br	Me
16	CONEt2	H	CN	Me
17	CON(nPr)2	H	Br	Me
18	CONHPh	H	CN	Me
19	156	H	Br	Me
20	157	H	Br	Me
21	158	H	CN	Me
22	NHCOOMe	H	CN	Me
23	NHCOOEt	H	Br	Me
24	NHCOO-tBu	H	CN	Me
25	NHCOOCH2Ph	H	Br	Me
26	NMeCOOMe	H	Br	Me
27	N(nPr)COOMe	H	CN	Me
28	NMeCOOCH2Ph	H	Br	Me
29	N(nPr)COOCH2Ph	H	Br	Me
30	COOH	H	Ph	Me
31	COOMe	H	Ph	Me
32	COOEt	H	Ph	Me
33	COO-tBu	H	Ph	Me
34	CONH2	H	Ph	Me
35	CONHMe	H	Ph	Me
36	CONHEt	H	Ph	Me
37	CONH-nPr	H	Ph	Me

[0290]

TABLE 34
Compd
No	R4	R6	R7	R8
1	CONMe2	H	Ph	Me
2	CONEt2	H	Ph	Me
3	CON(nPr)2	H	Ph	Me
4	CONHPh	H	Ph	Me
5	159	H	Ph	Me
6	160	H	Ph	Me
7	161	H	Ph	Me
8	NHCOOMe	H	Ph	Me
9	NHCOOEt	H	Ph	Me
10	NHCOO-tBu	H	Ph	Me
11	NHCOOCH2Ph	H	Ph	Me
12	NMeCOOMe	H	Ph	Me
13	N(nPr)COOMe	H	Ph	Me
14	NMeCOOCH2Ph	H	Ph	Me
15	N(nPr)COOCH2Ph	H	Ph	Me
16	COOH	H	H	COPh
17	COOMe	H	H	COPh
18	COOEt	H	H	COPh
19	COO-tBu	H	H	COPh
20	CONH2	H	H	COPh
21	CONHMe	H	H	COPh
22	CONHEt	H	H	COPh
23	CONH-nPr	H	H	COPh
24	CONMe2	H	H	COPh
25	CONEt2	H	H	COPh
26	CON(nPr)2	H	H	COPh
27	CONHPh	H	H	COPh
28	162	H	H	COPh
29	163	H	H	COPh
30	164	H	H	COPh
31	NHCOOMe	H	H	COPh
32	NHCOOEt	H	H	COPh
33	NHCOO-tBu	H	H	COPh
34	NHCOOCH2Ph	H	H	COPh

[0291]

TABLE 35
Compd
No	R4	R6	R7	R8
1	NMeCOOMe	H	H	COPh
2	N(nPr)COOMe	H	H	COPh
3	NMeCOOCH2Ph	H	H	COPh
4	N(nPr)COOCH2Ph	H	H	COPh
5	COOH	H	Me	COPh
6	COOMe	H	nPr	COPh
7	COOEt	H	Et	COPh
8	COO-tBu	H	Et	COPh
9	CONH2	H	Et	COPh
10	CONHMe	H	Me	COPh
11	CONHEt	H	Me	COPh
12	CONH-nPr	H	Me	COPh
13	CONMe2	H	nPr	COPh
14	CONEt2	H	nPr	COPh
15	CON(nPr)2	H	nPr	COPh
16	CONHPh	H	Me	COPh
17	165	H	Et	COPh
18	166	H	nPr	COPh
19	167	H	Me	COPh
20	NHCOOMe	H	Me	COPh
21	NHCOOEt	H	Me	COPh
22	NHCOO-tBu	H	Et	COPh
23	NHCOOCH2Ph	H	nPr	COPh
24	NMeCOOMe	H	Et	COPh
25	N(nPr)COOMe	H	nPr	COPh
26	NMeCOOCH2Ph	H	Me	COPh
27	N(nPr)COOCH2Ph	H	Me	COPh
28	COOH	H	Br	COPh
29	COOMe	H	CN	COPh
30	COOEt	H	Br	COPh
31	COO-tBu	H	CN	COPh
32	CONH2	H	Br	COPh
33	CONHMe	H	Br	COPh
34	CONHEt	H	CN	COPh
35	CONH-nPr	H	CN	COPh
36	CONMe2	H	Br	COPh

[0292]

TABLE 36
Compd
No	R4	R6	R7	R8
1	CONEt2	H	Br	COPh
2	CON(nPr)2	H	Br	COPh
3	CONHPh	H	Br	COPh
4	168	H	CN	COPh
5	169	H	CN	COPh
6	170	H	Br	COPh
7	NHCOOMe	H	CN	COPh
8	NHCOOEt	H	Br	COPh
9	NHCOO-tBu	H	CN	COPh
10	NHOCOCH2Ph	H	Br	COPh
11	NMeCOOMe	H	CN	COPh
12	N(nPr)COOMe	H	Br	COPh
13	NMeOCOCH2Ph	H	Br	COPh
14	N(nPr)OCOCH2Ph	H	Br	COPh
15	COOH	H	Ph	COPh
16	COOMe	H	Ph	COPh
17	COOEt	H	Ph	COPh
18	COO-tBu	H	Ph	COPh
19	CONH2	H	Ph	COPh
20	CONHMe	H	Ph	COPh
21	CONHEt	H	Ph	COPh
22	CONH-nPr	H	Ph	COPh
23	CONMe2	H	Ph	COPh
24	CONEt2	H	Ph	COPh
25	CON(nPr)2	H	Ph	COPh
26	CONHPh	H	Ph	COPh
27	171	H	Ph	COPh
28	172	H	Ph	COPh
29	173	H	Ph	COPh
30	NHCOOMe	H	Ph	COPh
31	NHCOOEt	H	Ph	COPh
32	NHCOO-tBu	H	Ph	COPh

[0293]

TABLE 37
Compd
No	R4	R6	R7	R8
1	NHCOOCH2Ph	H	Ph	COPh
2	NMeCOOMe	H	Ph	COPh
3	N(nPr)COOMe	H	Ph	COPh
4	NMeCOOCH2Ph	H	Ph	COPh
5	N(nPr)COOCH2Ph	H	Ph	COPh
6	COOH	H	H	SO2Ph
7	COOMe	H	H	SO2Ph
8	COOEt	H	H	SO2Ph
9	COO-tBu	H	H	SO2Ph
10	CONH2	H	H	SO2Ph
11	CONHMe	H	H	SO2Ph
12	CONHEt	H	H	SO2Ph
13	CONHnPr	H	H	SO2Ph
14	CONMe2	H	H	SO2Ph
15	CONEt2	H	H	SO2Ph
16	CON(nPr)2	H	H	SO2Ph
17	CONHPh	H	H	SO2Ph
18	174	H	H	SO2Ph
19	175	H	H	SO2Ph
20	176	H	H	SO2Ph
21	NHCOOMe	H	H	SO2Ph
22	NHCOOEt	H	H	SO2Ph
23	NHCOO-tBu	H	H	SO2Ph
24	NHCOOCH2Ph	H	H	SO2Ph
25	NMeCOOMe	H	H	SO2Ph
26	N(nPr)COOMe	H	H	SO2Ph
27	NMeCOOCH2Ph	H	H	SO2Ph
28	N(nPr)COOCH2Ph	H	H	SO2Ph
29	COOH	H	Me	SO2Ph
30	COOMe	H	Et	SO2Ph
31	COOEt	H	nPr	SO2Ph
32	COO-tBu	H	Ft	SO2Ph
33	CONH2	H	nPr	SO2Ph
34	CONHMe	H	Me	SO2Ph
35	CONHEt	H	Me	SO2Ph
36	CONH-nPr	H	nPr	SO2Ph

[0294]

TABLE 38
Compd
No	R4	R6	R7	R8
1	CONMe2	H	nPr	SO2Ph
2	CONEt2	H	Et	SO2PII
3	CON(nPr)2	H	Et	SO2Ph
4	CONHPh	H	nPr	SO2Ph
5	177	H	nPr	SO2Ph
6	178	H	nPr	SO2Ph
7	179	H	Me	SO2Ph
8	NHCOOMe	H	Me	SO2Ph
9	NHCOOEt	H	Me	SO2Ph
10	NHCOO-tBu	H	Et	SO2Ph
11	NHCOOCH2Ph	H	Et	SO2Ph
12	NMeCOOMe	H	Et	SO2Ph
13	N(nPr)COOMe	H	Me	SO2Ph
14	NMeOCOCH2Ph	H	Me	SO2Ph
15	N(nPr)COOCH2Ph	H	Me	SO2PIi
16	COOH	H	Br	SO2Ph
17	COOMe	H	Br	SO2Ph
18	COOEt	H	Br	SO2Ph
19	COO-tBu	H	CN	SO2Ph
20	CONH2	H	Br	SO2Ph
21	CONHMe	H	Br	SO2PIi
22	CONHEt	H	Br	SO2Ph
23	CONH-nPr	H	CN	SO2Ph
24	CONMe2	H	Br	SO2Ph
25	CONEt2	H	Br	SO2Ph
26	CON(nPr)2	H	Br	SO2Ph
27	CONHPh	H	CN	SO2Ph
28	180	H	Br	SO2Ph
29	181	H	Br	SO2Ph
30	182	H	Br	SO2Ph
31	NHCOOMe	H	Br	SO2Ph
32	NHCOOEt	H	CN	SO2Ph
33	NHCOO-tBu	H	Br	SO2Ph

[0295]

TABLE 39
Compd
No	R4	R6	R7	R8
1	NHCOOCH2Ph	H	Br	SO2Ph
2	NMeCOOMe	H	Br	SO2Ph
3	N(nPr)COOMe	H	CN	SO2Ph
4	NMeCOOCH2Ph	H	Br	SO2Ph
5	N(nPr)COOCH2Ph	H	Br	SO2Ph
6	COOH	H	Ph	SO2Ph
7	COOMe	H	Ph	SO2Ph
8	COOEt	H	Ph	SO2Ph
9	COO-tBu	H	Ph	SO2Ph
10	CONH2	H	Ph	SO2Ph
11	CONHMe	H	Ph	SO2Ph
12	CONHEt	H	Ph	SO2Ph
13	CONH-nPr	H	Ph	SO2Ph
14	CONMe2	H	Ph	SO2Ph
15	CONEt2	H	Ph	SO2Ph
16	CON(nPr)2	H	Ph	SO2Ph
17	CONHPh	H	Ph	SO2Ph
18	183	H	Ph	SO2Ph
19	184	H	Ph	SO2Ph
20	185	H	Ph	SO2Ph
21	NHCOOMe	H	Ph	SO2Ph
22	NHCOOEt	H	Ph	SO2Ph
23	NHCOO-tBu	H	Ph	SO2Ph
24	NHCOOCH2Ph	H	Ph	SO2Ph
25	NMeCOOMe	H	Ph	SO2Ph
26	N(nPr)COOMe	H	Ph	SO2Ph
27	NMeCOOCH2Ph	H	Ph	SO2Ph
28	N(nPr)COOCH2Ph	H	Ph	SO2Ph
29	OH	COOMe	H	H
30	OMe	COOMe	H	H
31	OH	COOMe	Me	H
32	OMe	COOMe	Me	H
33	OH	COOMe	Br	H
34	OMe	COOMe	Br	H
35	OH	COOMe	Ph	H
36	OMe	COOMe	Ph	H
37	OH	COOMe	H	Me
38	OMe	COOMe	H	Me

[0296]

TABLE 40
Comp
No	R4	R6	R7	R8
1	OH	COOMe	Me	Me
2	OMe	COOMe	Et	Me
3	OH	COOMe	Br	Me
4	OMe	COOMe	Br	Me
5	OH	COOMe	Ph	Me
6	OMe	COOMe	Ph	Me
7	OH	COOMe	H	COPh
8	OMe	COOMe	H	COPh
9	OH	COOMe	Me	COPh
10	OMe	COOMe	nPr	COPh
11	OH	COOMe	Br	COPh
12	OMe	COOMe	CN	COPh
13	OH	COOMe	CN	COPh
14	OMe	COOMe	Ph	COPh
15	OH	COOMe	H	SO2Ph
16	OMe	COOMe	CN	SO2Ph
17	OH	COOMe	Et	SO2Ph
18	OMe	COOMe	Me	SO2Ph
19	OH	COOMe	CN	SO2Ph
20	OMe	COOMe	Br	SO2Ph
21	OH	COOMe	Ph	SO2Ph
22	OMe	COOMe	CN	SO2Ph
23	OH	COOEt	H	H
24	OMe	COOEt	H	H
25	OH	COOEt	nPr	H
26	OMe	COOEt	Et	H
27	OH	COOEt	Br	H
28	OMe	COOEt	CN	H
29	OH	COOEt	Ph	H
30	OMe	COOEt	CN	H
31	OH	COOEt	H	Me
32	OMe	COOEt	H	Me
33	OH	COOEt	nPr	Me
34	OMe	COOEt	CN	Me
35	OH	COOEt	Br	Me
36	OMe	COOEt	CN	Me
37	OH	COOEt	Ph	Me
38	OMe	COOEt	Ph	Me
39	OH	COOEt	H	COPh
40	OMe	COOEt	CN	COPh
41	OH	COOEt	Me	COPh

[0297]

TABLE 41
Comp
No	R4	R6	R7	R8
1	OMe	COOEt	Et	COPh
2	OH	COOEt	Br	COPh
3	OMe	COOEt	CN	COPh
4	OH	COOEt	Ph	COPh
5	OMe	COOEt	CN	COPh
6	OH	OQOEt	H	SO2Ph
7	OMe	OQOEt	H	SO2Ph
8	OH	COOEt	Me	SO2Ph
9	OMe	COOEt	nPr	SO2Ph
10	OH	COOEt	CN	SO2Ph
11	OMe	COOEt	Br	SO2Ph
12	OH	COOEt	Ph	SO2Ph
13	OMe	COOEt	Ph	SO2Ph
14	OH	CN	H	H
15	OMe	CN	CN	H
16	OH	CN	Me	H
17	OMe	CN	Et	H
18	OH	CN	Br	H
19	OMe	CN	CN	H
20	OH	CN	Ph	H
21	OMe	CN	Ph	H
22	OH	CN	H	Me
23	OMe	CN	H	Me
24	OH	CN	CN	Me
25	OMe	CN	Me	Me
26	OH	CN	Br	Me
27	OMe	CN	Br	Me
28	OH	CN	Ph	Me
29	OMe	CN	CN	Me
30	OH	CN	H	COPh
31	OMe	CN	H	COPh
32	OH	CN	CN	COPh
33	OMe	CN	Et	COPh
34	OH	CN	Br	COPh
35	OMe	CN	Br	COPh
36	OH	CN	Ph	COPh
37	OMe	CN	CN	COPh
38	OH	CN	H	SO2Ph
39	OMe	CN	H	SO2Ph
40	OH	CN	nPr	SO2Ph
41	OMe	CN	nPr	SO2Ph

[0298]

TABLE 42
Comp
No	R4	R6	R7	R8
1	OH	CN	Br	SO2Ph
2	OMe	CN	Br	SO2Ph
3	OH	CN	CN	SO2Ph
4	OMe	CN	Ph	SO2Ph
5	OH	CH2NH2	H	H
6	OMe	CH2NH2	H	H
7	OH	CH2NH2	nPr	H
8	OMe	CH2NH2	Me	H
9	OH	CH2NH2	Br	H
10	OMe	CH2NH2	CN	H
11	OH	CH2NH2	Ph	H
12	OMe	CH2NH2	Ph	H
13	OH	CH2NH2	CN	Me
14	OMe	CH2NH2	H	Me
15	OH	CH2NH2	Et	Me
16	OMe	CH2NH2	CN	Me
17	OH	CH2NH2	Br	Me
18	OMe	CH2NH2	Br	Me
19	OH	CH2NH2	Ph	Me
20	OMe	CH2NH2	CN	Me
21	OH	CH2NH2	H	COPh
22	OMe	CH2NH2	H	COPh
23	OH	CH2NH2	nPr	COPh
24	OMe	CH2NH2	nPr	COPh
25	OH	CH2NH2	Br	COPh
26	OMe	CH2NH2	Br	COPh
27	OH	CH2NH2	Ph	COPh
28	OMe	CH2NH2	Ph	COPh
29	OH	CH2NH2	H	SO2Ph
30	OMe	CH2NH2	H	SO2Ph
31	OH	CH2NH2	Me	SO2Ph
32	OMe	CH2NH2	Me	SO2Ph
33	OH	CH2NH2	CN	SO2Ph
34	OMe	CH2NH2	Br	SO2Ph
35	OH	CH2NH2	CN	SO2Ph
36	OMe	CH2NH2	Ph	SO2Ph

[0299] Experimentals

[0300] A mixture of radioactive ligands and some cardinal numbers of test compounds was incubated with a sample of cell membrane, which was prepared from brain of rats or HEK293 cells, which expressed the receptor, under the following conditions. Then, the sample was filtered by suction on a Whatman GF/C. Radioactivity on the filter was encountered by the use of a liquid scintillation counter. 50% Inhibitory concentration values (IC50 values) of each selective binding were calculated for test compounds and the Ki value was obtained by applying an equation of Cheng-Prusoff [Biochem. Pharmacol. 22 (1973) 3099-3108] Ki=IC50/(1+[L]/Kd). [L] represents a concentration of the radio ligand used and Kd shows dissociation constant.

TABLE 43
			Condition of
Receptor	Origin	Radioactive Ligand	Incubation
5-HT1A	Rat	1 nM [3H] 8-OH-	25° C. 30 min
	hippocampus	DPAT
5-HT2	Rat cerebral	1 nM [3H] Ketanserin	37° C. 30 min
	cortex
5-HT6	rat5-HT6	8 nM [3H] 5HT	25° C. 120 min
	(HEK293)	4 nM [3H] LSD	37° C. 60 min
5-HT7	Human 5-HT7	0.5 nM [3H] 5CT	25° C. 120 min
	(HEK293)

[0301]

TABLE 44
		Ki value (nM) ±SE
Example	Compd. No.	5-HT1A	5-HT6	5-HT7
5	8-1	36
12	19-1	81
12	19-2	23	97
12	19-3	5.7		46
12	19-5	10
12	19-7	19
12	19-10	2.5
12	19-15	7.7	4.6	16
12	19-16	58	62	86
12	19-18		2.7
12	19-19	3.8
13	20-1		1.7
13	20-5		0.49
13	20-6		2.7
13	20-9	86	78
13	20-10	95	45
13	20-11		5.7
13	20-12		2.7
13	20-13		3.9
13	20-14		22
13	20-15		29
13	20-16		22
13	20-17		29
13	20-18		22
13	20-19		12
13	20-20		11
13	20-21		2.7
13	20-22		26
13	20-23		9.9
13	20-24		3.2
13	20-25		36
14	21	14
24	36-1	29	65
24	36-2		8.5
24	36-3	58	4.2
24	36-4
26	38	83		22
27	39	27		73
28	40	15	32	74
29	41	57
34	46-2
34	46-3	18
34	46-1		28
35	47		78
36	48		1

[0302] Industrial Applicability

[0303] Having an affinity against serotonin receptors, compounds described in this invention are useful as medicines such as therapeutic agents of diseases for central nervous systems thereof. Furthermore, these compounds are useful as synthetic intermediates thereof.

Claims

1. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof of the formula:

2. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R2 is hydrogen

3. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R3 is hydrogen.

4. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R5 is hydrogen.

5. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R3 and R5 taken together may form a bond.

6. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R3 and R4 taken together may form ═O, ═S or lower alkylenedioxy.

7. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R4 represents —COOR13 (R13 is hydrogen or lower alkyl), —NR16R17 (R16 and R17 are each independently hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino, or R16 and R17 taken together may form an optionally substituted 5- to 7-membered heterocyclyl ring with the neighboring nitrogen atom), —NR18COR19 (R18 and R19 are each independently hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl), —NR20COOR21 (R20 is hydrogen, or lower alkyl; R21 is an ester moiety), —NR22SO2R23 (R22 is hydrogen; R23 is lower alkyl or lower alkylamino), —OH, or lower alkoxy.

8. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R4 is —COOR13 (R13 is hydrogen or methyl), —NR16R17 (R16 is hydrogen or lower alkyl, R17 is hydrogen, optionally substituted lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted amino or R16 and R17 are taken together may form a optionally substituted 5- to 7-membered heterocyclyl ring with the neighboring nitrogen atom), —NR18COR19 (R18 is hydrogen, R19 is hydrogen, optionally substituted lower alkyl or optionally substituted aralkyl), —NR20COOR21 (R20 is hydrogen or methyl; R21 is methyl), —NR22SO2R23 (R22 is hydrogen; R23 is methyl or methylamino), —OH, or lower alkoxy.

9. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, described in claim 1, wherein R4 is —NH2, —NHCH3 or —N(CH3)2.

10. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, described in claim 1, wherein R6 is hydrogen, COOCH3, COOCH2CH3, CN, or CH2NH2.

11. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, described in claim 1, wherein R6 is hydrogen.

12. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, described in claim 1, wherein R7 is hydrogen, lower alkyl, halogen, phenyl, —COOR34 (R34 is mentioned before), —CHO or —CHNOH.

13. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, described in claim 1, wherein R7 is hydrogen, methyl, ethyl, halogen, or phenyl.

14. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R8 is hydrogen, optionally substituted lower alkyl, —COR27 (R27 is hydrogen, lower alkyl, cycloalkyl, lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, or optionally substituted heteroaryl), —COOR28 (R28 is ester moiety), or —SO2R29 (R29 is lower alkyl, cycloalkyl, optionally substituted lower alkenyl, optionally substituted aralkyl, optionally substituted aryl, optionally substituted heteroaryl), or tri-lower alkyl silyl.

15. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R8 is hydrogen or —SO2R29 (R20 is mentioned before).

16. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein all of R9, R10 and R11 are hydrogen.

17. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R2 is hydrogen; R3 and R5 are hydrogen or taken together may form a bond.

18. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 16 and claim 17, wherein R6 is hydrogen, COOCH3, COOCH2CH3, CN, or CH2NH2; R7 is hydrogen, lower alkyl, halogen or phenyl R8 is hydrogen, lower alkyl, COPh, or SO2Ph (Ph represents phenyl).

19. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R9 is hydrogen or halogen.

20. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R9 is hydrogen.

21. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, described in claim 1, wherein R10 is hydrogen.

22. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R11 is hydrogen, halogen, lower alkyl, optionally substituted lower alkenyl, —CN, —SR30 (R30 is hydrogen or lower alkyl), —CONH2, —CHO, —CHNOH, —NR32R33 (R32 and R33 are each independently hydrogen or lower alkyl) or aryl.

23. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R11 is hydrogen, halogen, methyl, —CN, or —CONH2.

24. A compound, prodrug, pharmaceutically acceptable salt or solvate thereof, according to claim 1, wherein R1, R2, R3, R5, R6, R9, and R10 is hydrogen; R4 is —NH2, —NHCH3, or —N(CH3)2; R7 is hydrogen, halogen, lower alkyl, or phenyl; R8 is hydrogen or —SO2R29 (R29 is mentioned before); R11 is hydrogen, halogen, lower alkyl, —CN, or —CONH2.

25. A pharmaceutical composition containing a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-24.

26. A therapeutic or prophylactic medicament against the serotonin receptors mediated diseases, comprising a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-24.

27. A therapeutic or prophylactic medicament according to claim 26, wherein the serotonine receptor is a 5-HT6 receptor.

28. A therapeutic or prophylactic medicament according to claim 26, wherein the disease is that of central nervous system.

29. A therapeutic or prophylactic medicament according to claim 28, wherein the disease of the central nervous system is schizophrenia, Alzheimer's disease, Parkinson's disease, depression, anxiety, pain, or migraine.

30. A method for treating or preventing the serotonin receptors mediated diseases, which comprises administrating to said mammals an effective amount of a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-24.

31. Use of a compound, prodrug, pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-24, in order to prepare a therapeutic or prophylactic medicament for the serotonin receptors mediated diseases.